

Customer No. 20350

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
(415) 576-0200

00/90/EO



OLD U.S. PTO

Attorney Docket No.

18512-000130US

"Express Mail" Label No. EL394877217

Date of Deposit: March 6, 2000

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231

By:

Sunil Dutt



## ASSISTANT COMMISSIONER FOR PATENTS

## BOX PATENT APPLICATION

Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the

- ☐ patent application of  
☐ continuation patent application of  
☒ divisional patent application of  
☐ continuation-in-part patent application of

Inventor(s)/Applicant Identifier: Salkoff et al

For: A pH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES

- ☒ This application claims priority from each of the following Application Nos./filing dates:  
 09/176,664 / 10/21/98, 60/063,138 / 10/22/97 and 60/076,172 / 2/27/98  
 the disclosure(s) of which is (are) incorporated by reference.
- ☒ Please amend this application by adding the following before the first sentence: "This application is a [ X ] divisional of application Serial No. 09/176,664, filed 10/21/98, the disclosure of which is incorporated by reference."

Enclosed are:

- ☒ Title Page  
☒ 69 page(s) of specification  
☒ 7 page(s) of claims  
☒ 6 pages of sequence listing  
☒ 1 page of Abstract  
☒ 5 sheet(s) of [ ] formal [ X ] informal drawing(s).  
☒ An assignment of the invention to The Washington University and ICAgen (copy from parent)  
☒ A [ X ] signed [ ] unsigned Declarations. (copies from parent)  
☒ A Power of Attorney by Assignee with Certificate Under 37 CFR Section 3.73(b). (copy from parent)  
☒ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 [ ] is enclosed [ X ] was filed in the prior application and small entity status is still proper and desired. (copy from parent)  
☒ Information Disclosure Statement under 37 CFR 1.97.  
☒ Statement under 37 CFR 1.821(e) (copy of Communication and Preliminary Amendment, and paper copy of sequence listing from parent)

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	44 - 20	= *24
INDEP. CLAIMS	11 - 3	= *8
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED		

\* If the difference in Col. 1 is less than 0, enter "0" in Col. 2.

## SMALL ENTITY

RATE	FEE
	\$345.00
x \$9.00 =	\$216.00
x \$39.00 =	\$312.00
+ \$130.00 =	
TOTAL	\$873.00

## OTHER THAN SMALL ENTITY

RATE	FEE
	\$690.00
x \$18.00 =	
x \$78.00 =	
+ \$260.00 =	
TOTAL	

Please charge Deposit Account No. 20-1430 as follows:

- ☒ Filing fee \$ 873.00  
☒ Any additional fees associated with this paper or during the pendency of this application.  
☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b)

- ☐ A check for \$\_\_\_\_\_ is enclosed.  
 2 extra copies of this sheet are enclosed.

Telephone:  
(415) 576-0200Facsimile:  
(415) 576-0300Respectfully submitted,  
TOWNSEND and TOWNSEND and CREW LLP

Annette S. Parent  
 Reg No.: 42,058  
 Attorneys for Applicant

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(d)) - NONPROFIT ORGANIZATION)**

Applicant or Patentee: Salkoff et al.  
 Application or Patent No.: 09/176,664  
 Filed or Issued: October 21, 1998  
 Title: A PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Nonprofit Organization: The Washington University  
 Address of Nonprofit Organization: One Brookings Drive  
St. Louis, Missouri 63130

Type of Nonprofit Organization:

- ☐ University or other institution of higher education.  
☐ Tax exempt under Internal Revenue Service Code [26 USC 501(a) and 501(c)(3)].  
☐ Nonprofit scientific or educational under statute of state or the United States of America  
 (Name of State \_\_\_\_\_).  
☐ Would qualify as tax exempt under Internal Revenue Service Code [26 USC 501(a) and 501(c)(3) if located in the United States of America.  
☐ Would qualify as nonprofit scientific or educational under statute of state of the United States of America if located in the United States of America  
 (Name of State \_\_\_\_\_)  
 (Citation of statute \_\_\_\_\_).

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention, entitled A PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES by inventor(s) described in:

- ☐ the specification filed herewith;  
☒ Application No. 09/176,664, filed October 21, 1998;  
☐ Patent No. \_\_\_\_\_, issued \_\_\_\_\_.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

**Andrew Neighbour, Ph.D.**

**Associate Vice Chancellor  
For Technology Management**

Name of Person Signing: \_\_\_\_\_  
 Title in Organization of Person Signing: \_\_\_\_\_  
 Address of Person Signing: \_\_\_\_\_

Signature Andrew Neighbour

Date 12/31/98

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) & 1.27(c)) - SMALL BUSINESS CONCERN**

Applicant or Patentee: Salkoff et al.Application or Patent No.: 09/176,664Filed or Issued: October 21, 1998Title: PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES

I hereby declare that I am:

☐  
☒

the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: ICAgen, IncorporatedAddress of Small Business Concern: 4222 Emperor Boulevard, Suite 460, Durham, North Carolina 27703

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES by inventor(s) Lawrence Salkoff, Matthew Schreiber and Chris Silvia described in:

☐  
☒  
☐

the specification filed herewith.

Application No. 09/176,664, filed 10/21/98.

Patent No. \_\_\_\_\_, issued \_\_\_\_\_.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name  
Address
☐ Individual    ☐ Small Business Concern    ☐ Nonprofit Organization
Name  
Address
☐ Individual    ☐ Small Business Concern    ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: PKay WagonerTitle of Person if Other than Owner: CEOAddress of Person Signing: Suite 460 4222 Emperor Blvd  
Durham NC 27703Signature [Signature]

Date

12/29/98

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 018512-000120US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On March 4, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Harder

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Salkoff *et al.*

Application No.: 09/176,664

Filed: October 21, 1998

For: A pH SENSITIVE POTSSIUM  
CHANNEL IN SPERMATOCYTES

Examiner: Not yet assigned

Art Unit: 1643

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Application mailed November 10, 1998, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 7, line 8, insert --(SEQ ID NO:20)-- after "mSlo3".

On page 7, line 9, insert --(SEQ ID NO:21)-- after "mSlo1 (mouse)".

On page 7, line 9, insert --(SEQ ID NO:22)-- after "dSlo1 (*Drosophila*)".



On page 14, line 8, replace "SEQ ID NO:1, 3, 18, or 18" with  
--SEQ ID NO:1, 3, 16, or 18--.

On page 14, line 25, replace "SEQ ID NOS:9 and 9, 10 and 11, 12 and 13 or 14  
and 15" with --SEQ ID NOS:8 and 9, 10 and 11, 12 and 13 or 14 and 15--.

On page 55, line 19, insert --(SEQ ID NO:23)-- after "(sense)".

On page 55, line 19, insert --(SEQ ID NO:24)-- after "(antisense)".

On page 57, line 10, insert --(SEQ ID NO:25)-- after "(sense)".

On page 55, line 10, insert --(SEQ ID NO:26)-- after "(antisense)".

On page 57, line 11, insert --(SEQ ID NO:27)-- after "(sense)".

On page 57, line 12, insert --(SEQ ID NO:28)-- after "(antisense)".

On page 57, line 13, insert --(SEQ ID NO:29)-- after "(sense)".

On page 57, line 14, insert --(SEQ ID NO:30)-- after "(antisense)".

On page 57, line 15, insert --(SEQ ID NO:31)-- after "(sense)".

On page 57, line 16, insert --(SEQ ID NO:32)-- after "(antisense)".

On page 57, line 25, insert --(SEQ ID NO:33)-- after "(sense)".

On page 57, line 26, insert --(SEQ ID NO:34)-- after "(antisense)".

On page 62, line 5, insert --(SEQ ID NO:35)-- after the first occurrence of "3"  
in that line.

On page 62, line 5, insert --(SEQ ID NO:36)-- after the second occurrence of  
"- 3'" in that line.

On page 63, line 33, insert --(SEQ ID NO:5)-- after "MLDS".

On page 64, line 2, insert --(SEQ ID NOS:37 and 38)-- after "LTEL 870".

On page 64, line 3, insert --(SEQ ID NOS:39 and 40)-- after "ITEL 885".

On page 64, line 4, insert --(SEQ ID NOS:41 and 42)-- after "GAVF 906".

On page 64, line 5, insert --(SEQ ID NOS:43 and 44)-- after "GTAF 918".

On page 64, line 6, insert --(SEQ ID NO:45)-- after "GAAF".

On page 64, line 7, insert --(SEQ ID NOS:46 and 47)-- after "SEME 941".

On page 64, line 8, insert --(SEQ ID NOS:48 and 49)-- after "PELE 963".

On page 64, line 9, insert --(SEQ ID NOS:50 and 51)-- after "HLLP 1034".

On page 64, line 9, insert --(SEQ ID NOS:52 and 53)-- after "ELVP 1048".

Please cancel the present informal "SEQUENCE LISTING", pages 77-82, and insert therefor the accompanying paper copy of the Sequence Listing, page numbers 1 to 39, at the end of the application. Cancel the page number of the Abstract and renumber it, accordingly, page 77.

REMARKS

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOs:1-53, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
ASP:dmw

**PATENT APPLICATION**

**A PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES**

**Inventor(s):**

Lawrence Salkoff, a citizen of the United States of America, residing at  
6327 Alamo Ave, Clayton, MO 63105

Matthew Schreiber, a citizen of the United States of America, residing at  
7561 York Dr., Apt. 2N, Clayton, MO 63105

Chris Silvia, a citizen of the United States of America, residing at 3105  
Broomsedge Way, Durham, NC 27712

**Assignee:**

The Washington University

ICAgen, Inc.

Townsend and Townsend and Crew LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94107  
(415)576-0200

## A PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES

### CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of USSN 60/063,138, filed October 22, 1997, and USSN 60/076,172, filed February 27, 1998, both of which are incorporated by reference.

### STATEMENT AS TO FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with Government support under Grant No. RO1-NS24785, awarded by the National Institutes of Health. The Government has certain rights in this invention.

### FIELD OF THE INVENTION

The invention provides isolated nucleotide and amino acid sequences of Slo3, a pH sensitive potassium channel expressed in sperm; antibodies to Slo3; methods of screening for Slo3 inhibitors and activators; and methods of identifying Slo3 homologs.

### BACKGROUND OF THE INVENTION

Potassium channels are found in a wide variety of animal cells such as nervous, muscular, glandular, immune or epithelial tissue. The channels regulating these currents open and allow the escape of potassium under certain conditions. The outward flow of potassium ions upon opening of these channels makes the interior of the cell more negative, counteracting depolarizing voltages applied to the cell. These channels are regulated, e.g., by calcium sensitivity, voltage-gating, and ATP-sensitivity.

The *Drosophila* Slo1 gene encodes a calcium-activated potassium channel present in both neurons and muscle (Elkins *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 83:8415 (1986); Atkinson *et al.*, *Science* 253:551 (1991); and Adelman *et al.*, *Neuron* 9:209 (1992)). Mammalian homologs of dSlo1 were cloned and found to be "Maxi" or BK (large conductance) channel types, as the single channel conductance was 272 pS with

symmetrical potassium concentrations. Slo1 channels cloned from mouse and human show strong conservation of sequence and functional properties (Butler *et al.*, *Science* 261:221-224 (1993); Dworetzky *et al.*, *Brain Res. Mol. Brain Res.* 27:189-193 (1994); Tseng-Crank *et al.*, *Neuron* 13:1315-1330 (1994); McCobb *et al.*, *Am. J. Physiol.* 269:H767-H777 (1995); and Wallner *et al.*, *Rec. Chan.* 3:185-199 (1995)). One proposed role of the Slo1 channel is to provide negative feedback for the entry of calcium into cells via voltage-dependent calcium channels. Perhaps because of the versatility of this mechanism, Slo1 channels are expressed in many tissues, including brain, skeletal and smooth muscle, auditory hair cells, pancreas, and adrenal gland (Marty, *Nature* 291:497-500 (1981); Pallotta *et al.*, *Nature* 293:471-474 (1981); Petersen & Mauryama, *Nature* 307:693-696 (1984); Tabcharani & Misler, *Biochim. Biophys. Acta.* 982:62-72 (1990); Neely & Lingle, *J. Physiol.* 453:97-131 (1992)). In these tissues, Slo1 channels are involved in diverse functions such as regulating arteriolar smooth muscle tone (Brayden & Nelson, *Science* 256:532-535 (1992)), tuning of hair cell frequency (Fuchs, *Curr. Op. Neurobiol.* 2:457-461 (1992); Wu *et al.*, *Prog. Biophys. Mol. Bio.* 63:131-158 (1996)), and modulation of transmitter release at nerve terminals (Robitaille & Charlton, *J. Neurosci.* 12:297-305 (1995); Knaus *et al.*, *J. Neurosci.* 16:955-963 (1996)), all situations in which both membrane potential and intracellular calcium are critical factors. While numerous family members of every type of voltage-gated K<sup>+</sup> channel have been found, to date the Slo1 channel has remained the sole functionally characterized representative of the Slo family (Wei *et al.*, *Neuropharmacology* 35:805-829 (1996)).

Spermatocytes require proteins tailored to fulfill roles unique to the process of germ cell development and fertilization. Cellular signaling in spermatogenic cells is tightly regulated to prevent inappropriate activation of the irreversible steps that prepare the sperm to fertilize the oocyte. Many of these steps are triggered and coordinated by changes in membrane potential and intracellular Ca<sup>2+</sup> concentration and pH. Between mating and fertilization, sperm undergo capacitation, a process which later enables them to fertilize the oocyte. Capacitation involves an increase in cytosolic pH (pHi), which promotes metabolic and swimming activity (Babcock *et al.*, *Proc. Natl. Acad. Sci. USA* 80:1327-1331 (1983); Babcock & Pfeiffer, *J. Biol. Chem.* 262:15041-15047 (1987); Vredenburg-Wilberg & Parrish, *Mol. Reprod. Dev.* 40:490-502 (1995)). This increase in pHi is accompanied by changes in membrane potential and a rise in cytoplasmic Ca<sup>2+</sup>, which trigger the acrosome reaction upon contact with the oocyte (Arnoult *et al.*, *J. Cell Biol.* 134:637-645 (1996); Florman, *Dev. Biol.* 165:152-164

(1994)). Because of the central importance of these events in development, many efforts have been made to identify the specific proteins, including ion channels, which regulate spermatogenic function. In particular, there have been reports of channels present in spermatocytes and spermatids that have been proposed to play central roles in these reactions (Cook & Babcock, *J. Biol. Chem.* 268:22402-22407 (1993), including voltage dependent calcium channels (Florman *et al.*, *Dev. Biol.* 152:304-214 (1992); Arnoult *et al.*, *Proc. Natl. Acad. Sci. USA* 93:13004-13009 (1996); Lievano *et al.*, *FEBS Lett.* 388:150-154 (1996); Santi *et al.*, *Am. J. Physiol.* 271:C1583-C1593 (1996)). Apart from a cyclic nucleotide gated channel, however, few of these channels have been directly cloned from testis (Weyand *et al.*, *Nature* 368:859-863 (1994)).

## SUMMARY OF THE INVENTION

Potassium channels have evolved to play specialized roles in many inexcitable tissues. The present invention provides for the first time isolated nucleotide and amino acid sequences of Slo3, a potassium channel with novel functional properties, abundantly expressed in spermatocytes. The physiological reactions that sperm undergo to achieve fertilization include changes in both pH<sub>i</sub> and membrane potential. Although Slo3 is a member of the Slo family, to which the large-conductance, calcium-activated Slo1 potassium channel belongs, Slo3 channels are not gated by calcium. Slo3 channels, however, are activated by changes in intracellular pH and membrane potential. Slo3 channels also exhibit markedly lower selectivity for K<sup>+</sup> over Na<sup>+</sup> than most voltage-gated K<sup>+</sup> channels.

In one aspect, the invention provides an isolated nucleic acid encoding a polypeptide monomer of a pH sensitive potassium channel. The monomer (i) has a calculated molecular weight of between 120-156 kDa; (ii) has a unit conductance of approximately 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; (iii) has increased activity above approximately intracellular pH of 7.1; and (iv) specifically binds to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16 or SEQ ID NO:18.

In one embodiment, the nucleic acid encodes mSlo3 or hSlo3. In another embodiment, the nucleic acid encodes SEQ ID NO:1, SEQ ID NO:16, or SEQ ID NO:18. In one embodiment, the nucleic acid selectively hybridizes under moderate stringency hybridization conditions to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17, or SEQ ID

NO:19. In one embodiment, the nucleic acid has a nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17, or SEQ ID NO:19.

In one embodiment, the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions to the same sequence as the primer sets selected from the group consisting of:

CTCGAACTCCCTAAAATCTTACAGAT (SEQ ID NO:8) and  
TTCCGTTGAGCCAGGGGTCACCAGAATT (SEQ ID NO:9);  
TCTGCTTTGTGAAGCTAAATCT (SEQ ID NO:10) and  
TTTCAAAGCCTCTTTAGCGGTAA (SEQ ID NO:11); and  
TTATGCCTGGATCTGCACTCTACATG (SEQ ID NO:12) and  
ATAGTTTCCGTCTACTACCGAAA (SEQ ID NO:13).

In another embodiment, the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions to the same sequence as the primer sets selected from the group consisting of:

GGCAGCGCTCATTCTTTCCTCCTT (SEQ ID NO:14) and  
TGCCCCAAAACCTCAACCCAAAATA (SEQ ID NO:15).

In another aspect, the invention provides an isolated nucleic acid encoding at least 15 contiguous amino acids from a pH sensitive potassium channel polypeptide monomer, said monomer having an amino acid sequence of SEQ ID NO:1, SEQ ID NO:16, or SEQ ID NO:18 and conservatively modified variants thereof.

In one embodiment, the nucleic acid encodes a pH sensitive potassium channel polypeptide monomer having: (i) a unit conductance of 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; (ii) a molecular weight of between 120-156 kDa; and (iii) increased activity above an intracellular pH of 7.1; and where the nucleic acid either: (i) selectively hybridizes under moderate stringency hybridization conditions to a nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17 or SEQ ID NO:19; or (ii) encodes a protein which could be encoded by a nucleic acid that selectively hybridizes under moderate stringency hybridization conditions to a nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17 or SEQ ID NO:19.

In another aspect, the invention provides an isolated nucleic acid encoding a polypeptide monomer of a pH sensitive potassium channel, the sequence: (i) encoding a monomer having a core domain that has greater than 60% amino acid sequence identity to amino acids 35-641 of an mSlo3 core domain as measured using a sequence comparison

algorithm; and (ii) specifically binding to polyclonal antibodies raised against the core domain of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18.

In another aspect, the invention provides an isolated polypeptide monomer of a pH sensitive potassium channel, the monomer: (i) having a calculated molecular weight of between 120-156 kDa; (ii) having a unit conductance of approximately 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; (iii) having increased activity above approximately intracellular pH of 7.1; and (iv) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18.

In another aspect, the invention provides an antibody that selectively binds to mSlo3 or hSlo3.

In another aspect, the invention provides an expression vector comprising a nucleic acid encoding a polypeptide monomer of a pH sensitive potassium channel, the monomer: (i) having a calculated molecular weight of between 120-156 kDa; (ii) having a unit conductance of approximately 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; (iii) having increased activity above approximately intracellular pH of 7.1; and (iv) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18.

In another aspect, the invention provides a host cell comprising the expression vector.

In another aspect, the invention provides a method for identifying a compound that increases or decreases ion flux through a pH sensitive potassium channel, the method comprising the steps of: (i) contacting the compound with a eukaryotic host cell or cell membrane in which has been expressed a pH sensitive potassium channel monomer polypeptide: (a) having a calculated molecular weight of between 120-156 kDa; (b) having a unit conductance of approximately 80-120 pS when the monomer is in the functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; and (c) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18; and (ii) determining the functional effect of the compound upon the cell or cell membrane expressing the pH sensitive potassium channel.



In one embodiment, the increased or decreased flux of ions is determined by measuring whole cell conductance. In one embodiment, the pH sensitive potassium channel monomer polypeptide is recombinant.

In another aspect, the invention provides method of detecting the presence of Slo3 in mammalian tissue, the method comprising the steps of: (i) isolating a biological sample from a patient; (ii) contacting the biological sample with a Slo3-specific reagent that selectively binds to Slo3; and, (iii) detecting the level of Slo3-specific reagent that selectively associates with the sample.

In one embodiment, the Slo3 specific reagent is selected from the group consisting of: Slo3 specific antibodies, Slo3 specific oligonucleotide primers, and Slo3 nucleic acid probes. In one embodiment, the sample is from a human.

In another aspect, the invention provides in a computer system, a method of screening for mutations of Slo3 genes, the method comprising the steps of: (i) receiving input of a first nucleic acid sequence encoding a pH sensitive potassium channel protein having a nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17, SEQ ID NO:19 and conservatively modified versions thereof; (ii) comparing the first nucleic acid sequence with a second nucleic acid sequence having substantial identity to the first nucleic acid sequence; and (iii) identifying nucleotide differences between the first and second nucleic acid sequences.

In one embodiment, the second nucleic acid sequence is associated with a disease state.

In another aspect, the invention provides in a computer system, a method for identifying a three-dimensional structure of Slo3 proteins, the method comprising the steps of: (i) receiving input of at least about 10 amino acids of an amino acid sequence of a pH sensitive potassium channel monomer or at least about 30 nucleotides of a nucleic acid encoding the protein, the protein having an amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18, and conservatively modified versions thereof; and (ii) generating a three-dimensional structure of the protein encoded by the amino acid sequence.

In one embodiment, the amino acid sequence is a primary structure and said generating step includes the steps of: (i) forming a secondary structure from said primary structure using energy terms encoded by the primary structure; and (ii) forming a tertiary structure from said secondary structure using energy terms encoded by said secondary structure. In one embodiment, the generating step includes the step of forming

a quaternary structure from said tertiary structure using anisotropy terms encoded by the tertiary structure. In one embodiment, the method further comprises the step of identifying regions of the three-dimensional structure of the protein that bind to ligands and using the regions to identify ligands that bind to the protein.

5

## BRIEF DESCRIPTION OF THE DRAWINGS

### Figure 1A-B: Primary sequence of mSlo3

Figure 1A: Alignment of primary sequence of mSlo3 with BK  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  channels mSlo1 (mouse) and dSlo1 (*Drosophila*). Hydrophobic segments are designated S0 through S10. Segments S1-S6 represent the transmembrane segments that surround pore of the channel. The region designated "Calcium Bowl" has been implicated in the regulation of mSlo1 by calcium. The core and tail domain structure of Slo1 has been conserved (Wei *et al.*, *Neuron* 13:671-681 (1994)). mSlo3 residues 35 through 641 encompass S0 through S8, the core domain, and share 56% and 50% identity with mSlo1 and dSlo1 while interspecies homologs mSlo1 and dSlo1 exhibit 62% identity in this region. mSlo3 residues 686-1136 encompassing S9 and S10, the tail, share 39% identity with mSlo1 and dSlo1 while the interspecies homologs mSlo1 and dSlo1 share 68% identity in this region. A region having no significant homology between mSlo1 and mSlo3 is found between S8 and S9. An arrowhead indicates a phenylalanine residue (F) in a region critical for ion selectivity.

Figure 1B: Kyte-Doolittle hydrophilicity plots of mSlo3 and mSlo1. The mbr5 mSlo1 (Butler *et al.*, 1992) and splice variant A2C2E2G5I0 dSlo1 (Atkinson *et al.*, *Science* 253:551-553 (1991); Adelman *et al.*, *Neuron* 9:209-216 (1992)) sequences are shown. Slo2 is a more distantly related sequence present in the nematode database (Wei *et al.*, *Neuropharmacology* 35:805-829 (1996)).

### Figure 2A-D: Expression of mSlo3 transcripts is largely restricted to the testis

Figure 2A: RT-PCR of mouse brain, heart, skeletal muscle, kidney, testis, lung and liver with mSlo3-specific primers, with (+) and without (-) addition of reverse transcriptase. An expected 156 bp product is detected only with testis RNA. Similar results were obtained with two additional mSlo3 primer pairs specific to S8 to S9 and S9 to S10 regions.

Figure 2B: Control RT-PCR assays with  $\beta$ -actin specific primers produce an expected 537 bp product from all tissues. Additional negative controls with genomic DNA (10 ng) or primers alone are also shown.

Figure 2C: Northern blot analysis of total RNA (20 mg) from mouse brain, heart, skeletal muscle, kidney, testis, lung and liver reveals an abundant mSlo3 transcript only in testis, with an approximate size of 4 kb.

Figure 2D: Northern blot analysis of polyadenylated RNA (2 mg) from human tissues (spleen, thymus, prostate, testis, uterus, small intestine, colon, and leukocytes) with mSlo3, reveals a cross-hybridizing mRNA species only in testis, with an approximate size of 4 kb. For controls, the same blots were hybridized with a human  $\beta$ -actin probe and results are shown below.

#### **Figure 3A-D: mSlo3 channel sensitivity to voltage and pH from individual inside-out patches**

Figure 3A: Currents at constant voltage (+80 mV). Activity increases at higher pH. The cytoplasmic surface was exposed to recording solution at indicated pH;  $N_{po}$  at pH 7.1, 7.3, 7.6, and 8.0 was 0.000, 0.014, 0.031, and 0.258, respectively, based on the presence of a minimum of five channels.

Figure 3B: Reversibility of pH effect. Activity in a single patch is shown sequentially from top to bottom at indicated pH.

Figure 3C: Currents at constant pH 7.6. Activity increases at positive potentials.

Figure 3D: Macroscopic current traces and corresponding current-voltage relations. The diminished current at pH 7.1 was restored when the same patch was exposed to pH 8. The slight decrease in current amplitude between the conditions at pH 8 was likely due to current rundown. Holding potential was -40; on-line leak subtraction was employed.

#### **Figure 4A-D: mSlo3 whole cell currents from *Xenopus* oocytes**

Figure 4A: Manipulation of intracellular pH alters current amplitude. (Left) Control currents at start of experiment. (Middle) Diminished current amplitude after intracellular acidification (12.5 minute perfusion with NaHCO<sub>3</sub> replacing NaCl in nd96). (Right) Recovery during alkalization (10 minute perfusion with nd96).

supplemented with 30 mM NH<sub>4</sub>Cl). Voltage families are from -80 to +60 mV in 10 mV increments.

Figure 4B: Representative tail currents in 10 mM K<sup>+</sup>, 88 mM Na<sup>+</sup> at 11°C.

Figure 4C: Tail current amplitude versus voltage for the currents shown in

5 Figure 4B. Instantaneous currents at the time of the voltage jump were calculated from exponential fits of tail currents extrapolated back to time zero. Currents are plotted versus test potential (large filled squares). A Goldman-Hodgkin-Katz (GHK) current equation was fitted to the tail current-voltage relation (solid line) with Na<sup>+</sup>/K<sup>+</sup> permeability ratio, P = 0.15; calculated underlying K<sup>+</sup> (small triangles) and Na<sup>+</sup> (small  
10 squares) currents are also shown.

Figure 4D: mSlo3 exhibits relatively low selectivity for K<sup>+</sup> over Na<sup>+</sup>. Reversal potential was determined by measuring tail currents in varying external [K<sup>+</sup>]; [Na<sup>+</sup>] was also varied so that the total monovalent concentration ([K<sup>+</sup>] + [Na<sup>+</sup>]) was 98 mM. Points were fitted with a GHK equation where the Na<sup>+</sup>/K<sup>+</sup> permeability ratio, P,  
15 was allowed to vary freely. *Drosophila* Shab reversal potentials were determined as a control (Wei *et al.*, 1990). For mSlo3 reversal potential at 2, 5, 10, 50, and 98 [K<sup>+</sup>], n = 6, 3, 5, 6, 7, respectively; for dShab at 2, 10, 50, and 98, n = 3, 1, 3, 3.

## DETAILED DESCRIPTION OF THE INVENTION

### 20 I. Introduction

The present invention provides for the first time isolated nucleotide and amino acid sequences for Slo3 and demonstrates that Slo3 is a pH sensitive potassium, voltage-gated channel. Functionally, Slo3 is expressed in spermatocytes, is voltage-gated, and is pH sensitive. Furthermore, Slo3 exhibits markedly lower selectivity for K<sup>+</sup>  
25 over Na<sup>+</sup> than most voltage-gated potassium channels. Among a wide panel of tissues, both mSlo3 (mouse Slo3) and hSlo3 (human Slo3) mRNA were detected in testis, where the mRNA was abundantly expressed in developing spermatocytes. This expression pattern and sensitivity to both pH and voltage, indicate that Slo3 is involved in sperm capacitation and/or the acrosome reaction, essential steps in fertilization.

30 When mSlo3 protein (mouse Slo3) is recombinantly expressed in *Xenopus* oocytes, the homotetramer channel protein has a unitary conductance of between 80 and 120 pS (as measured with symmetrical potassium concentrations); and for example, at a concentration of 160 mM potassium, the channel has a conductance of 106 pS. Unitary conductance may be conveniently determined using single channel or macroscopic

channel inside-out or outside-out patch clamp configurations or whole cell recordings (see Wei *et al.*, 1994, *supra*). Patch clamp and whole cell recording methods are well known in the art (see, e.g., Franciolini, *Experientia*, 42:589-594 (1986); and Sakmann *et al.*, *Annual Review of Physiology*, 46:455-472 (1984)).

5           The isolated Slo3 proteins within the scope of the present invention include those which when expressed in a cell from a quiet line, define a functionality and pharmacology indicative of a Slo3 channel. A quiet line is a cell line that in its native state (e.g., not expressing Slo3 channels) has low or uninteresting electric activity, e.g., a CHO cell line. For example, a control cell (without expression of a Slo3 channel of the present invention) and an experimental cell (expressing a Slo3 channel) are maintained under conditions standard for measurement of electrophysiological parameters as provided in the working examples disclosed herein.

10           For example, a cell expressing a Slo3 channel of the present invention can have a conductance of between 80-120 pS, can comprise an Slo3 channel protein monomer of about 120 to 156 kD, can exhibit pH sensitivity (e.g., increased activity at above approximately pH 7.1) and voltage-gating, can exhibit amino acid identity of at least 60%, and more preferably at least 70%, 80%, 90% or 95% in an alignment with the core domain of the exemplary mouse and human Slo3 channel sequences disclosed herein, and can be specifically reactive, under immunologically reactive conditions, with an antibody raised to an exemplary Slo3 sequence disclosed herein (e.g., SEQ ID NO:1, 3, 16 and 18). Such standard methods aid in the identification of Slo3 proteins of the present invention.

20           Structurally, the full length nucleotide sequence of mSlo3 (SEQ ID NO:2) encodes a protein of 1113 amino acids (SEQ ID NO:1) with a predicted molecular mass of 126 kDa. hSlo3 encodes a protein of a similar size and expression pattern (see Example II). Slo3 is a member of the Slo of potassium channel protein family as evidenced by sequence homology to the BK calcium-activated potassium channel (Slo1; see Figure 1A). The hydrophilicity profiles of Slo1 and Slo3 sequences indicate 11 hydrophobic segments, S0 through S10, which can be divided into "core" and "tail" domains (Figure 1B). Within the core domain (hydrophobic regions S0-S8 of Slo3 proteins) mSlo3 and the sequenced region of hSlo3 share at least 61.5% amino acid identity, while mSlo1 and mSlo3 share 51% identity in this region. Homology in the core domain is much higher than in the tail domain, which is involved in calcium sensing (Wei *et al.*, *Neuron* 13:671-681 (1994)).

Two notable differences suggest possible functional distinctions between mSlo1 and mSlo3. First, the "Calcium Bowl," a hyperconserved aspartate-rich region involved in calcium sensing, is absent in Slo3 (Schreiber & Salkoff, *Biophys. J.* 73:1355-1363 (1997)). Second, mSlo3 contains GFG rather than GYG in the conserved pore signature sequence involved in K<sup>+</sup> ion selectivity (Yool & Schwarz, *Nature* 349:700-704 (1991); Hartmann *et al.*, *Science* 251:942-944 (1991); Heginbotham & MacKinnon, *Biophys. J.* 66:1061-1067 (1994)). This difference shows that ionic selectivity differs between the two channels.

Specific regions of the Slo3 nucleotide and amino acid sequence may be used to identify polymorphic variants, interspecies homologs, and alleles of Slo3. This identification can be made *in vitro*, e.g., under stringent hybridization conditions and sequencing, or by using the sequence information in a computer system for comparison with other nucleotide sequences. Typically, identification of polymorphic variants and alleles of Slo3 is made by comparing the amino acid sequence of the core domain (amino acids 35-641 of mSlo3, S0 through S8 of Slo3). This domain is also useful for identifying members of the Slo family,. For example, potassium channel proteins that share at least 60% or greater amino acid identity in the core domain are Slo3 proteins, while those that share approximately 50% or less homology are members of the Slo family. Another useful region for identifying homologs of Slo3 is the region between S8 and S9. This region is not highly conserved between mSlo1 and mSlo3, and so can be used to identify interspecies homologs of Slo3. Antibodies that bind specifically to the core domain of Slo3 can also be used to identify alleles, interspecies homologs, and polymorphic variants.

Polymorphic variants, interspecies homologs, and alleles of Slo3 are confirmed by expressing the putative Slo3 polypeptide monomer and examining functional characteristics, such as voltage-gating and pH sensitivity. This assay is used to demonstrate that a protein having about 60% or greater, preferably 75-80% or greater amino acid identity to the core domain of Slo3 shares the same functional characteristics as Slo3 and is therefore a species of Slo3. Typically, Slo3 having the amino acid sequence of SEQ ID NO:1 or 3 is used as a positive control in comparison to the putative Slo3 protein to demonstrate the identification of a polymorphic variant, allele, or interspecies homologue of Slo3.

For example, measurements of the cell expression the putative Slo3 are taken to detect induction of ion flux (e.g., by radiotracer), or a change in ionic

conductance of the cell (e.g., by patch clamp), or a change in voltage (e.g., by fluorescent dye). If the presence of an ion channel is indicated by a pH induced or voltage-gated change, subsequent tests are used to characterize the channel as a Slo3 channel of the present invention. For example, pH sensitivity can be determined as described above, using inside out patches in saline of different pH. Whole cell recordings in sodium bicarbonate or ammonium chloride can also be used. Compounds such as rotenone and FCCP can be used to acidify the cell, and protonofors can also be used to determine pH sensitivity. Preferably, at least two characteristics are determined, more preferably at least 3, or 4 are determined. Characteristics of Slo3 channels of the present invention are disclosed more fully herein.

The present invention also provide polymorphic variants of the mSlo3 depicted in SEQ ID NO:1: variant #1, in which a valine residue is substituted for an isoleucine residue at amino acid position 21; variant #2, in which an isoleucine residue is substituted for a leucine residue at amino acid position 5; and variant #3, in which a serine residue is substituted for an alanine residue at amino acid position 25.

The present invention also provide polymorphic variants of the hSlo3 depicted in SEQ ID NO:16: variant #1, in which a valine residue is substituted for an isoleucine residue at amino acid position 23; variant #2, in which an isoleucine residue is substituted for a leucine residue at amino acid position 6; and variant #3, in which a serine residue is substituted for an alanine residue at amino acid position 25.

The isolation of Slo3 protein for the first time provides a means for assaying for compounds that increase or decrease the ion channel activity of this pH sensitive potassium channel, which is involved in sperm physiology. Slo3 nucleic acids and proteins are useful for testing inhibitors or activators of Slo3 using *in vitro* or *in vivo* assays, e.g., expressing Slo3 in cells or cell membranes and then measuring flux of ions through the channel. Such inhibitors or activators identified using Slo3 can be used therapeutically to treat infertility conditions related to sperm physiology, or as contraceptives. Slo3 expression also provides a convenient diagnostic marker for spermatocytes. Spermatocytes lacking Slo3 expression may be indicative of sperm that lack the capability of undergoing capacitation or acrosome reactions, which are essential for fertilization. Antibodies or other probes for Slo3 can be also used *in vitro* as diagnostic tools to examine Slo3 expression. Slo3 can also be used to study sperm physiology *in vitro*, e.g., the capacitation and acrosome reactions that are essential for sperm activity.

Portions of the Slo3 nucleotide sequence may be used to identify homologs of the channel, as well as variants or mutations of the channel that may be associated with disease. This identification can be made *in vitro* or by using the sequence information in a computer system for comparison with other nucleotide sequences.

5 Similarly, these portions of Slo3 nucleotide sequence may be used to determine the presence of a Slo3 channel mRNA or channel protein in a particular tissue of interest. Information derived from the Slo3 nucleotide sequence may also be used to identify the chromosomal localization of the Slo3 gene or genes using chromosomal panels, radiation hybrid screening, fluorescent *in situ* hybridization methods (FISH), or by comparison of  
10 the sequence with computer nucleic acid databases. The Slo3 channel or fragments thereof may also be used to treat diseases using gene therapy. A Slo3 nucleotide sequence information may also be used to construct models of the ion channel protein in a computer system, these models subsequently being used to identify compounds that can modulate channel function.

15 Furthermore, the invention provides assays for Slo3 activity where Slo3 acts as a direct or indirect reporter molecule, e.g., as part of a chimera with another channel protein such as Slo1. Such uses of Slo3 as a reporter molecule in assay and detection systems have broad applications, e.g., Slo3 can be used as a reporter molecule to measure changes in potassium concentration, membrane potential, current flow, ion  
20 flux, transcription, signal transduction, receptor-ligand interactions, second messenger concentrations, *in vitro*, *in vivo*, and *ex vivo*. In one embodiment, Slo3 can be used as an indicator of current flow in a particular direction (e.g., outward or inward potassium flow), and in another embodiment, Slo3 can be used as an indirect reporter via attachment to a second reporter molecule such as green fluorescent protein.

## 25 II. Definitions

Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. Numeric ranges are inclusive of the numbers defining the range. The terms  
30 defined below are more fully defined by reference to the specification as a whole.

By "pH sensitive potassium channel" or "Slo3 channel" is meant a membrane channel which is voltage-gated, pH sensitive (e.g., with increased activity as measured by increased current amplitude above about pH 7.1), and has a unitary conductance of from about 80-120 pS when measured under a symmetrical potassium



concentration of 160 mM in a *Xenopus* oocyte using the conditions specified in Example IV. An Slo3 channel comprises multiple Slo3 channel proteins as subunits, typically four Slo3 channel proteins (e.g., full length or substantially full length Slo3 channel proteins).

5 A "Slo3 core domain" refers to the amino acids corresponding to the S0-S8 region of a Slo3 polypeptide, e.g., amino acids 35-641 of mSlo3 (SEQ ID NO:1).

10 By "pH sensitive potassium channel subunit" or "Slo3 channel protein" is meant a polypeptide of a molecular weight of between about 120-156 kDa having a core domain with at least about 60% identity to the core domain of SEQ ID NO:1, 3, 18, or 18, and having the characteristic of pH sensitivity and/or voltage gating. These proteins serve as monomers of the Slo3 channel. Thus, a Slo3 channel protein can have the functional characteristics to form a heteromeric or homomeric protein with the functional characteristics of an Slo3 channel, or be a peptide fragment thereof. This term refers both to recombinant and naturally occurring forms of Slo3. Both recombinant and naturally occurring Slo3 can be used in the methods of the invention described herein, e.g., in  
15 assays to identify inhibitors or activators of Slo3.

The term Slo3 therefore refers to polymorphic variants, alleles, mutants, and interspecies variants of Slo3 that: (1) have greater than 60% amino acid sequence identity to a Slo3 core domain; or (2) bind to antibodies raised against an immunogen comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18 and conservatively modified variants thereof; or (3) specifically hybridize under stringent hybridization conditions to a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:17, SEQ ID NO:19 and conservatively modified variants thereof; or (4) are amplified by primers that specifically hybridize under stringent hybridization conditions to the same sequence as a  
20 primer set consisting of SEQ ID NOS:9 and 9, 10 and 11, 12 and 13 or 14 and 15.

25 "pH sensitive" refers to a characteristic of Slo3 channels, where the channels have increased current amplitude in response to changes in intracellular pH (pHi). Typically, pH sensitive channels show increased current amplitude above approximately pHi 7.1. For example, mSlo3 at a pHi of 6.8 did not show increased activity, while activity was substantially increased at pHi 7.8. pH sensitivity can be  
30 measure using a number of assays. For example, single channel recordings are made from inside out patches that have been perfused with saline of different pHs and the open probability of the channel vs. the pH is plotted to determine pH sensitivity. In another example, macroscopic current is examined with an inside out patch perfused with saline

of varying pHs, and the amplitude of the current is measured. In another example, a whole cell recording is made with a two electrode voltage clamp, where the cell is in sodium bicarbonate solution (lowers intracellular pH) or ammonium chloride solution (raises intracellular pH).

5                   The phrase “voltage-gated” activity or “voltage-gating” refers a characteristic of a potassium channel composed of individual polypeptide monomers or subunits. Generally, the probability of a voltage-gated potassium channel opening increases as a cell is depolarized. Voltage-gated potassium channels primarily allow efflux of potassium because they have greater probabilities of being open at membrane potentials more positive than the equilibrium potential for potassium ( $E_K$ ) in typical cells.  $E_K$  is the combination of the voltage potential and  $[K^+]$  potential at which there is no net flow of potassium ion. This value, also known as the “reversal potential” or the “Nernst” potential for potassium, depends on the relative concentrations of potassium found inside and outside the membrane, and is typically between -60 and -100 mV for mammalian cells. Some voltage-gated potassium channels undergo inactivation, which can reduce potassium efflux at higher membrane potentials. These channels can also allow potassium influx in certain instances when they remain open at membrane potentials negative to  $E_K$  (see, e.g., Adams & Nonner, in *Potassium Channels*, pp. 40-60 (Cook, ed., 1990)).

20                   Typically, the channel is composed of four subunits and the channel can be heteromeric or homomeric. “Homomeric” refers to a potassium channel composed of the same type of subunit, while “heteromeric” refers to a potassium channel composed of two or more different types of subunits. Voltage-gated potassium channels composed of Slo are typically homomeric, having four Slo subunits. The characteristic of voltage gating can be measured by a variety of techniques for measuring changes in current flow and ion flux through a channel, e.g., by changing the  $[K^+]$  of the external solution and measuring the activation potential of the channel current (see, e.g., U.S. Patent No. 5,670,335), by measuring current with patch clamp techniques or voltage clamp under different conditions, and by measuring ion flux with radiolabeled tracers or voltage-sensitive dyes under different conditions.

30                   The terms “isolated” “purified” or “biologically pure” refer to material that is substantially or essentially free from components which normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high

performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. In particular, an isolated Slo3 nucleic acid is separated from open reading frames which flank the Slo3 gene and encode proteins other than Slo3. The term "purified" denotes that a nucleic acid or protein gives rise to  
5 essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

The term "subsequence" in the context of a referenced nucleic acid sequence includes reference to a contiguous sequence from the nucleic acid having fewer  
10 nucleotides in length than the referenced nucleic acid. In the context of a referenced protein, polypeptide, or peptide sequence, "subsequence" refers to a contiguous sequence from the referenced protein having fewer amino acids than the referenced protein.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences which are not  
15 found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses  
20 nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-  
25 methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions, as described below) and complementary sequences, as well as the sequence explicitly indicated. The term nucleic acid is used interchangeably with gene, cDNA,  
30 mRNA, oligonucleotide, and polynucleotide.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a

corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,  $\gamma$ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an  $\alpha$  carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence

herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule.

- 5 Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

- 15 The following groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
- 2) Serine (S), Threonine (T);
- 3) Aspartic acid (D), Glutamic acid (E);
- 20 4) Asparagine (N), Glutamine (Q);
- 5) Cysteine (C), Methionine (M);
- 6) Arginine (R), Lysine (K), Histidine (H);
- 7) Isoleucine (I), Leucine (L), Valine (V); and
- 8) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

- 25 (*see, e.g.,* Creighton, *Proteins* (1984)).

A "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include <sup>32</sup>P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available (e.g., the peptide of SEQ ID NO:1 can be made detectable, e.g., by incorporating a radio-label into the peptide, and used to detect antibodies specifically reactive with the peptide).

As used herein a "probe or primer" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of

chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly  
5 labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound,  
10 either covalently, through a linker, or through ionic, van der Waals or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe.

"Amplification" primers are oligonucleotides comprising either natural or analog nucleotides that can serve as the basis for the amplification of a select nucleic acid  
15 sequence. They include, e.g., polymerase chain reaction primers and ligase chain reaction oligonucleotides. Amplification primers are used to "amplify" a target nucleic acid sequence.

The term "recombinant" when used with reference to a cell, or protein, nucleic acid, or vector, includes reference to a cell, protein, or nucleic acid, or vector, that  
20 has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes and proteins that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

An "expression vector" is a nucleic acid construct, generated  
25 recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The terms "identical" or percent "identity," in the context of two or more  
30 nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison

algorithms or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence, which has a designated percent sequence or subsequence complementarity when the test sequence has a designated or substantial identity to a reference sequence. Preferably, the amino acid or nucleotide sequence identity is at least about 60%, more preferably at least about 75-80%, more preferably about 90-95%. For example, a designated amino acid percent identity of 60% refers to sequences or subsequences that have at least about 60% amino acid identity when aligned for maximum correspondence over a comparison window as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Preferably, the percent identity exists over a region of the sequence that is at least about 25 amino acids in length, more preferably over a region that is 50-100 amino acids in length.

When percentage of sequence identity is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated according to, e.g., the algorithm of Meyers & Miller, *Computer Applic. Biol. Sci.* 4:11-17 (1988) e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA)..

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence

identity for the test sequence(s) relative to the reference sequence, based on the designated or default program parameters.

5 A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 25 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g.,* Ausubel *et al., supra*).

20 One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained



from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux *et al.*, *Nuc. Acids Res.* 12:387-395 (1984)).

Another example of algorithm that is suitable for determining percent sequence identity (i.e., substantial similarity or identity) is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues, always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as default parameters a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.*, Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is

less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

An indication that two nucleic acid sequences or polypeptides are substantially identical, i.e., they have a designated percent identity, is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. A further indication that two polynucleotides are substantially identical is if the reference sequence, amplified by a pair of oligonucleotide primers or a pool of degenerate primers that encode a conserved amino acid sequence, can then be used as a probe under stringent hybridization conditions to isolate the test sequence from a cDNA or genomic library, or to identify the test sequence in, e.g., a northern or Southern blot. Alternatively, another indication that the sequences are substantially identical is if the same set of PCR primers can be used to amplify both sequences.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA), wherein the particular nucleotide sequence is detected at least at twice background, preferably 10 times background.

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are

occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 time background hybridization. Exemplary "highly stringent" hybridization conditions include hybridization in a buffer comprising 50% formamide, 5x SSC, and 1% SDS at 42°C, or hybridization in a buffer comprising 5x SSC and 1% SDS at 65°C, both with a wash of 0.2x SSC and 0.1% SDS at 65°C.

Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, and 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Nucleic acids which do not hybridize to each other under moderately stringent or stringent hybridization conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

The phrase "encodes a protein which could be encoded by a nucleic acid that selectively hybridizes under moderate stringency hybridization conditions to a sequence" in the context of nucleic acids refers to those nucleic acids encoding naturally occurring proteins or derivatives of natural proteins, but which are deliberately modified or engineered to no longer hybridize to the protein of natural origin under the stated conditions.

The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab, F(ab)<sub>2</sub>). The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or

epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

Antibodies exist e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'<sub>2</sub>, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'<sub>2</sub> may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'<sub>2</sub> dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (*see, e.g., Fundamental Immunology* (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments such as single chain Fv, chimeric antibodies (i.e., comprising constant and variable regions from different species), humanized antibodies (i.e., comprising a complementarity determining region (CDR) from a non-human source) and heteroconjugate antibodies (e.g., bispecific antibodies).

An "anti-Slo3" antibody is an antibody or antibody fragment that specifically binds a polypeptide encoded by a Slo3 gene, cDNA, or a subsequence thereof. The antibody can be either a monoclonal or polyclonal antibody.

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

The term “immunoassay” is an assay that uses an antibody to specifically bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

The phrase “specifically (or selectively) binds to an antibody” or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein.

For example, antibodies raised to mSlo3 or hSlo3 with the amino acid sequence encoded in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, and SEQ ID NO:18 respectively, can be selected to obtain polyclonal antibodies specifically immunoreactive with that protein and not with other proteins, except for polymorphic variants and alleles. This selection may be achieved by subtracting out antibodies that cross-react with Slo3 molecules from other species. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (*see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual* (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

The phrase “selectively associates with” refers to the ability of a nucleic acid to “selectively hybridize” with another as defined above, or the ability of an antibody to “selectively (or specifically) bind to a protein, as defined above.

The phrase “functional effects” in the context of assays for testing compounds affecting the channel includes the determination of any parameter that is indirectly or directly under the influence of the channel. It includes changes in ion flux, membrane potential, voltage gating, and pH sensitivity and also includes other physiologic effects such increases or decreases of transcription or hormone release.

By “determining the functional effect” is meant examining the effect of a compound that increases or decreases ion flux on a cell or cell membrane in terms of cell

and cell membrane function. The ion flux can be any ion that passes through the channel and analogs thereof, e.g., potassium, rubidium, sodium, and radioisotopes thereof. Preferably, the term refers to the functional effect of the compound on Slo3 channel activity, e.g., changes in ion flux, current amplitude, voltage gating, pH sensitivity, and the like. Such functional effects can be measured by any means known to those skilled in the art, e.g., patch clamping, whole cell currents, pH and voltage sensitive dyes, radioisotope efflux, inducible markers, and the like.

"Inhibitors," "activators," and "modulators" of Slo3 refer to inhibitory or activating molecules identified using *in vitro* assays for Slo3 function. Inhibitors are compounds that decrease, block, prevent, delay activation, inactivate, desensitize, or down regulate the channel. Activators are compounds that increase, open, activate, facilitate, enhance activation, sensitize or up regulate channel activity. Such assays for inhibitors and activators include e.g., expressing Slo in cells or cell membranes and then measuring flux of ions through the channel and determining changes in polarization (i.e., electrical potential). Methods of measuring changes of cell membrane polarization and ion flux include voltage-clamp techniques, determination of whole cell currents, radiolabeled rubidium flux assays, and fluorescence assays using voltage-sensitive dyes. Samples or assays that are treated with a potential Slo3 activator or inhibitor are compared to control samples without the inhibitor, to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative Slo3 activity value of 100. Inhibition of Slo3 is achieved when the Slo3 activity value relative to the control is about 90%, preferably 50%, more preferably 25%. Activation of Slo3 is achieved when the Slo3 activity value relative to the control is 110%, more preferably 150%, more preferable 200% higher.

By "host cell" is meant a cell which contains an expression vector and supports the replication or expression of the expression vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, e.g., *Xenopus*, or mammalian cells such as CHO, HeLa and the like. The Slo3 channel can also be expressed in a cell membrane derived from such a cell.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains a Slo3 channel protein or nucleic acid encoding the corresponding Slo3 channel protein. Such samples include, but are not limited to, seminal fluid containing sperm, sperm cells, testis tissue, and brain tissue. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. A biological

sample is typically obtained from a eukaryotic organism, preferably a multicellular eukaryotes such as insect, protozoa, birds, fish, reptiles, and preferably a mammal such as rat, mice, cow, dog, guinea pig, or rabbit, and most preferably a primate such as macaques, chimpanzees, or humans.

5 By "conductance" is meant electrical conductance. Electrical conductance is conveniently measured in Siemens (1/ohm = mho). Unitary conductance is determined by measuring single channel currents using a patch clamp protocol under conditions set forth in Examples III and IV (i.e., in a *Xenopus* oocyte) using a symmetrical potassium ion concentration of 160 mM (see generally, Hille, *Ionic Channels of Excitable*  
10 *Membranes* (2d ed.) In the context of the present invention, "conductance" refers to the unitary electrical conductance of a single homomeric protein of the referenced Slo3 channel protein.

"Functional tetrameric form" refers to expression of a Slo3 protein or monomer in which a plurality of the Slo3 proteins are assembled to form, by themselves  
15 or in conjunction with other endogenous *Xenopus* oocyte molecules, an Slo3 potassium channel. Expression within a *Xenopus* oocyte is disclosed in the Examples provided herein, e.g., Example III. Typically the Slo3 channel is a homotetramer formed of four Slo3 monomer proteins.

By "contiguous amino acids from" in the context of a specified number of  
20 amino acid residues from a specified sequence, is meant a sequence of amino acids of the specified number from within the specified reference sequence which has the identical order of amino acids each of which is directly adjacent to the same amino acids as in the reference sequence.

### 25 III. Nucleic acids encoding Slo3

The present invention provides isolated nucleic acids of RNA, DNA, or chimeras thereof, which encode Slo3 channel proteins. Nucleic acids of the present invention can be used as probes, for example, in detecting deficiencies in the level of mRNA, mutations in the gene (e.g., substitutions, deletions, or additions), for monitoring  
30 up regulation of Slo3 channels in drug screening assays, or for recombinant expression of Slo3 channel proteins for use as immunogens in the preparation of antibodies or for *in vitro* or *in vivo* expression assays.

#### A. General Recombinant DNA Methods

This invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)).

For nucleic acids, sizes are given in either kilobases (kb) or base pairs (bp). These are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. For proteins, sizes are given in kilodaltons (kDa) or amino acid residue numbers. Proteins sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.

Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, *Tetrahedron Letts.* 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter *et. al.*, *Nucleic Acids Res.* 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson & Reanier, *J. Chrom.* 255:137-149 (1983).

The sequence of the cloned genes and synthetic oligonucleotides can be verified after cloning using, e.g., the chain termination method for sequencing double-stranded templates of Wallace *et al.*, *Gene* 16:21-26 (1981).

#### B. Cloning methods for the isolation of nucleotide sequences encoding Slo3

In general, the nucleic acid sequences encoding Slo3 and related nucleic acid sequence homologs are cloned from cDNA and genomic DNA libraries or isolated using amplification techniques with oligonucleotide primers. For example, Slo3 sequences are typically isolated from human nucleic acid (genomic or cDNA) libraries by hybridizing with a nucleic acid probe, the sequence of which can be derived from SEQ ID NO:2, 4, 17, or 19, preferably from the core domain. A suitable tissue from which Slo3 RNA and cDNA can be isolated is testis.

Amplification techniques using primers can also be used to amplify and isolate Slo3 from DNA or RNA. For example, nucleic acids encoding a mSlo3 channel



protein of SEQ ID NO:1 may be obtained by amplification of a mouse testis cDNA library or reverse transcribed from mouse testis RNA using isolated nucleic acid primer pairs having the sequence:

CTCGAACTCCCTAAAATCTTACAGAT (SEQ ID NO:8) and

5 TTCCGTTGAGCCAGGGGTCACCAGAATT (SEQ ID NO:9);

TCTGCTTTGTGAAGCTAAATCT (SEQ ID NO:10) and

TTTCAAAGCCTCTTTAGCGGTAA (SEQ ID NO:11); or

TTATGCCTGGATCTGCACTCTACATG (SEQ ID NO:12) and

ATAGTTTCCGTCTACTACCGAAA (SEQ ID NO:13).

10 Nucleic acids encoding an hSlo3 channel protein may also be obtained by amplification of a human testis cDNA library or reverse transcribed human testis RNA, using the following primers:

GGCAGCGCTCATTCTTTCCTCCTT (SEQ ID NO:14) and

TGCCCAAACCTCAACCCAAAATA (SEQ ID NO:15).

15 These primers can be used, e.g., to amplify either the full length sequence or a probe of one to several hundred nucleotides, which is then used to screen a human library for full-length Slo3. Nucleic acids encoding Slo3 can also be isolated from expression libraries using antibodies as probes. Such polyclonal or monoclonal antibodies can be raised using the sequence of SEQ ID NO:1, 3, 16, or 18.

20 Slo3 polymorphic variants, alleles, and interspecies homologs that are substantially identical to the core domain of Slo3 can be isolated using Slo3 nucleic acid probes and oligonucleotides under stringent hybridization conditions, by screening libraries. Alternatively, expression libraries can be used to clone Slo3 polymorphic variants, alleles, and interspecies homologs, by detecting expressed homologs  
25 immunologically with antisera or purified antibodies made against the core domain of Slo3, which also recognize and selectively bind to the Slo3 homolog.

To make a cDNA library, one should choose a source that is rich in Slo3 mRNA, e.g., testis tissue. The mRNA is then made into cDNA using reverse transcriptase, ligated into a recombinant vector, and transfected into a recombinant host  
30 for propagation, screening and cloning. Methods for making and screening cDNA libraries are well known (*see, e.g., Gubler & Hoffman, Gene 25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra*).

For a genomic library, the DNA is extracted from the tissue and either mechanically sheared or enzymatically digested to yield fragments of about 12-20 kb.

The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are packaged *in vitro*. Recombinant phage are analyzed by plaque hybridization as described in Benton & Davis, *Science* 196:180-182 (1977). Colony hybridization is carried out as generally  
5 described in Grunstein *et al.*, *Proc. Natl. Acad. Sci. USA.*, 72:3961-3965 (1975).

An alternative method of isolating Slo3 nucleic acid and its homologs combines the use of synthetic oligonucleotide primers and amplification of an RNA or DNA template (see U.S. Patents 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis *et al.*, eds, 1990)). Methods such as polymerase chain  
10 reaction (PCR) and ligase chain reaction (LCR) can be used to amplify nucleic acid sequences of Slo3 directly from mRNA, from cDNA, from genomic libraries or cDNA libraries. Degenerate oligonucleotides can be designed to amplify Slo3 homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers. Polymerase chain reaction or other *in vitro* amplification methods may also  
15 be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of Slo3 encoding mRNA in physiological samples, for nucleic acid sequencing, or for other purposes. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.

Gene expression of Slo3 can also be analyzed by techniques known in the  
20 art, e.g., reverse transcription and amplification of mRNA, isolation of total RNA or poly A+ RNA, northern blotting, dot blotting, *in situ* hybridization, RNase protection, probing DNA microchip arrays, and the like.

Synthetic oligonucleotides can be used to construct recombinant Slo3  
25 genes for use as probes or for expression of protein. This method is performed using a series of overlapping oligonucleotides usually 40-120 bp in length, representing both the sense and non-sense strands of the gene. These DNA fragments are then annealed, ligated and cloned. Alternatively, amplification techniques can be used with precise primers to amplify a specific subsequence of the Slo3 gene. The specific subsequence is  
30 then ligated into an expression vector. As described below in Example VI, Slo3 chimeras can be made, which combine, e.g., either the core or the tail domain of Slo3 with another domain of a heterologous potassium channel protein to create a chimeric, functional potassium channel subunit.

The gene for Slo3 is typically cloned into intermediate vectors before transformation into prokaryotic or eukaryotic cells for replication and/or expression. These intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors. Isolated nucleic acids encoding Slo3 channel proteins comprise a nucleic acid sequence encoding a Slo3 channel protein selected from the group consisting of SEQ ID NO:1, 3, 16, and 18 and subsequences, interspecies homologs, alleles and polymorphic variants thereof. In preferred embodiments, the isolated nucleic acid encoding a Slo3 channel protein is selected from the group consisting of: SEQ ID NO:2, 4, 17, and 19, and subsequences thereof.

### C. Expression in prokaryotes and eukaryotes

To obtain high level expression of a cloned gene, such as those cDNAs encoding Slo3, one typically subclones Slo3 into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.* and Ausubel *et al.* Bacterial expression systems for expressing the Slo3 protein are available in, e.g., *E. coli*, *Bacillus* sp., and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.

The promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the Slo3 encoding nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding Slo3 and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. The nucleic acid sequence encoding Slo3 may typically be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell. Such signal peptides would include, among others, the

signal peptides from tissue plasminogen activator, insulin, and neuron growth factor, and juvenile hormone esterase of *Heliothis virescens*. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

5 In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

10 The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as GST and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., c-myc.

15 Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A+, pMTO10/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40  
20 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Some expression systems have markers that provide gene amplification such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase.  
25 Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a Slo3 encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

The elements that are typically included in expression vectors also include a replicon that functions in *E. coli*, a gene encoding antibiotic resistance to permit  
30 selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. The prokaryotic sequences are preferably chosen

such that they do not interfere with the replication of the DNA in eukaryotic cells, if necessary.

Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of Slo3 protein, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.* 264:17619-17622 (1989); *Guide to Protein Purification, in Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g., Morrison, J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983).

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g., Sambrook et al., supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing Slo3.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of Slo3, which is recovered from the culture using standard techniques identified below.

#### IV. Purification of Slo3

Either naturally occurring or recombinant Slo3 can be purified for use in functional assays. Naturally occurring Slo3 is purified, *e.g.,* from tissue such as testis tissue, and any other source of a Slo3 homolog. Recombinant Slo3 is purified from any suitable expression system.

Slo3 may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (*see, e.g., Scopes, Protein Purification: Principles and Practice* (1982); U.S. Patent No. 4,673,641; Ausubel *et al., supra*; and Sambrook *et al., supra*).

A number of procedures can be employed when recombinant Slo3 is being purified. For example, proteins having established molecular adhesion properties can be

reversible fused to Slo3. With the appropriate ligand, Slo3 can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. Finally Slo3 could be purified using immunoaffinity columns.

5

#### *A. Purification of Slo3 from recombinant bacteria*

Recombinant proteins are expressed by transformed bacteria in large amounts, typically after promoter induction; but expression can be constitutive. Promoter induction with IPTG is a one example of an inducible promoter system. Bacteria are  
10 grown according to standard procedures in the art. Fresh or frozen bacteria cells are used for isolation of protein.

Proteins expressed in bacteria may form insoluble aggregates ("inclusion bodies"). Several protocols are suitable for purification of Slo3 inclusion bodies. For example, purification of inclusion bodies typically involves the extraction, separation  
15 and/or purification of inclusion bodies by disruption of bacterial cells, e.g., by incubation in a buffer of 50 mM TRIS/HCL pH 7.5, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 1 mM DTT, 0.1 mM ATP, and 1 mM PMSF. The cell suspension can be lysed using 2-3 passages through a French Press, homogenized using a Polytron (Brinkman Instruments) or sonicated on ice. Alternate methods of lysing bacteria are apparent to those of skill in the  
20 art (*see, e.g., Sambrook et al., supra; Ausubel et al., supra*).

If necessary, the inclusion bodies are solubilized, and the lysed cell suspension is typically centrifuged to remove unwanted insoluble matter. Proteins that formed the inclusion bodies may be renatured by dilution or dialysis with a compatible buffer. Suitable solvents include, but are not limited to urea (from about 4 M to about 8  
25 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to about 8 M). Some solvents which are capable of solubilizing aggregate-forming proteins, for example SDS (sodium dodecyl sulfate), 70% formic acid, are inappropriate for use in this procedure due to the possibility of irreversible denaturation of the proteins, accompanied by a lack of immunogenicity and/or activity.  
30 Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of immunologically and/or biologically active protein. Other suitable buffers are known to those skilled in the art. Slo3 is

separated from other bacterial proteins by standard separation techniques, e.g., with Ni-NTA agarose resin.

Alternatively, it is possible to purify Slo3 from bacteria periplasm. After lysis of the bacteria, when Slo3 is exported into the periplasm of the bacteria, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to skill in the art. To isolate recombinant proteins from the periplasm, the bacterial cells are centrifuged to form a pellet. The pellet is resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria are centrifuged and the pellet is resuspended in ice-cold 5 mM MgSO<sub>4</sub> and kept in an ice bath for approximately 10 minutes. The cell suspension is centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well known to those of skill in the art.

#### *B. Standard Protein Separation Techniques For Purifying Slo3*

##### Solubility Fractionation

Often as an initial step, particularly if the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. The preferred salt is ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

##### Size Differential Filtration

The molecular weight of Slo3 can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for

example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.

### Column Chromatography

Slo3 can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).

Alternatively, Slo3 protein can be expressed transiently in a cell by introducing into a cell an RNA encoding the Slo3 protein. The RNA is transcribed *in vitro* according to standard procedures and then introduced into a cell by means such as injection or electroporation. The RNA then expresses the Slo3 protein. Such systems are useful for measuring single channel and whole cell conductance of a Slo3 channel protein, e.g., when the RNA is transiently expressed in cells such as *Xenopus* oocytes, CHO, and HeLa cells.

### **V. Immunological detection of Slo3**

In addition to the detection of Slo3 genes and gene expression using nucleic acid hybridization technology, one can also use immunoassays to detect Slo3. Immunoassays can be used to qualitatively or quantitatively analyze Slo3. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).

#### *A. Antibodies to Slo3*

Methods of producing polyclonal and monoclonal antibodies that react specifically with Slo3 are known to those of skill in the art (see, e.g., Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *supra*; Goding, *Monoclonal*



Antibodies: Principles and Practice (2d ed. 1986); and Kohler & Milstein, *Nature*, 256:495-497 (1975). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (see, e.g., Huse *et al.*, *Science* 246:1275-1281 (1989); Ward *et al.*, *Nature* 341:544-546 (1989)).

A number of Slo3 comprising immunogens may be used to produce antibodies specifically reactive with Slo3., for example, recombinant Slo3 or a antigenic fragment thereof such as the core or tail domain, is isolated as described herein.

Recombinant protein can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen. Naturally occurring protein may also be used either in pure or impure form. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those of skill in the art. An inbred strain of mice or rabbits is immunized with the protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to Slo3. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (see Harlow & Lane, *supra*).

Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see Kohler & Milstein, *Eur. J. Immunol.* 6:511-519 (1976)). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host.

Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science* 246:1275-1281 (1989).

Monoclonal antibodies and polyclonal sera are collected and titrated  
5 against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of  $10^4$  or greater are selected and tested for their cross reactivity against non-Slo3 proteins or even other homologous proteins from other organisms, using a competitive binding immunoassay. Specific polyclonal antisera and monoclonal  
10 antibodies will usually bind with a KD of at least about 0.1 mM, more usually at least about 1  $\mu$ M, preferably at least about 0.1  $\mu$ M or better, and most preferably, 0.01  $\mu$ M or better.

Once Slo3 specific antibodies are available, Slo3 can be detected by a variety of immunoassay methods. For a review of immunological and immunoassay  
15 procedures, see *Basic and Clinical Immunology* (Stites & Terr eds., 7th ed. 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

#### 20 B. Immunological binding assays

As explained above, Slo3 expression is associated with sperm physiology, e.g., capacitation and acrosome reactions. Thus, Slo3 provides a marker with which to examine these reactions in sperm. In a preferred embodiment, Slo3 is detected and/or quantified using any of a number of well recognized immunological binding assays (see,  
25 e.g., U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology* Volume 37: *Antibodies in Cell Biology* (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed. 1991).

Immunoassays also often utilize a labeling agent to specifically bind to and  
30 label the binding complex formed by the antigen and antibody. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent may be a labeled Slo3 polypeptide or a labeled anti-Slo3 antibody. Alternatively, the labeling agent may be another antibody, which specifically binds to the antibody/Slo3 complex. In a one embodiment, the labeling agent is a second Slo3 polypeptide bearing a

label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second antibody can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin. Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G, may also be used.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

#### Non-Competitive assay formats

Immunoassays for detecting Slo3 in samples may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of antigen (in this case the protein) is directly measured. In one preferred "sandwich" assay, for example, the anti-Slo3 antibodies can be bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture Slo3 present in the test sample. Slo3 is thus immobilized is then bound by a labeling agent.

#### Competitive assay formats

In competitive assays, the amount of Slo3 present in the sample is measured indirectly by measuring the amount of an added (exogenous) antigen (i.e., the Slo3) displaced (or competed away) from the anti-Slo3 antibody by the antigen present in the sample. In one competitive assay, a known amount of, in this case, the Slo3 is added to the sample and the sample is then contacted with an antibody that specifically binds to the Slo3. The amount of Slo3 bound to the antibody is inversely proportional to the concentration of Slo3 present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of the Slo3 bound to the antibody may be determined either by measuring the amount of Slo3 present in a Slo3/antibody complex, or alternatively by measuring the amount of remaining

uncomplexed protein. The amount of Slo3 may be detected by providing a labeled Slo3 molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay Slo3 is immobilized on a solid substrate. A known amount of anti-Slo3 antibody is added to the sample, and the sample is then contacted with the immobilized Slo3. The amount of anti-Slo3 antibody bound to the immobilized Slo3 is inversely proportional to the amount of Slo3 present in the sample. Again, the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

Immunoassays in the competitive binding format can be used for crossreactivity determinations. For example, a protein partially encoded by SEQ ID NO:1, 3, 16, or 18 can be immobilized to a solid support. Proteins are added to the assay that compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to Slo3 encoded by SEQ ID NO:1, 3, 16, or 18. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the considered proteins, e.g., distantly related homologs.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps the protein of this invention, to the immunogen protein (i.e., Slo3 comprising SEQ ID NO:1, 3, 16, or 18). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the protein partially encoded by SEQ ID NO:1, 3, 16, or 18 that is required to inhibit 50% of binding, then the second protein is said to specifically bind to the polyclonal antibodies generated to a Slo3 immunogen.

### Other assay formats

Western blot (immunoblot) analysis is used to detect and quantify the presence of Slo3 in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the Slo3. The anti-Slo3 antibodies specifically bind to the Slo3 on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-Slo3 antibodies.

Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (see Monroe *et al.*, *Amer. Clin. Prod. Rev.* 5:34-41 (1986)).

### Reduction of non-specific binding

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

### Labels

The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads

(e.g., Dynabeads™), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>32</sup>P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (e.g., polystyrene, polypropylene, latex, etc.). The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to an anti-ligand (e.g., streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used in conjunction with the labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

The molecules can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidotases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, e.g., luminol. For a review of various labeling or signal producing systems which may be used, see U.S. Patent No. 4,391,904.

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally simple colorimetric labels may be

detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

## VI. Assays for compounds that increase or decrease ion flux

Slo3 and its alleles, polymorphic variants, and interspecies homologs are subunits of pH sensitive, voltage-gated channels. The activity of such a channel comprising a Slo3 subunit can be assessed using a variety of *in vitro* and *in vivo* assays, e.g., measuring current, measuring membrane potential, measuring ion flux, e.g., potassium or rubidium, measuring potassium concentration, measuring second messengers and transcription levels, and using e.g., voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology. Furthermore, such assays can be used to test for inhibitors and activators of channels comprising Slo3. Such modulators of voltage-gated channel activity are useful for investigating and regulating sperm capacitation and the acrosome reaction, as well as for treating disorders related to sperm physiology.

Modulators of Slo3 activity are tested using biologically active Slo3, either recombinant or naturally occurring. The protein can be isolated, expressed in a cell, or expressed in a membrane derived from a cell. Modulation is tested using one of the *in vitro* or *in vivo* assays described herein. Samples or assays that are treated with a potential Slo3 inhibitor or activator are compared to control samples without the test compound, to examine the extent of modulation. Compounds that increase the flux of ions will cause a detectable increase in the ion current density by increasing the probability of a channel comprising Slo3 being open, by decreasing the probability of it being closed, increasing conductance through the channel, and allowing the passage of ions.

Increased or decreased flux of ions may be assessed by determining changes in polarization (i.e., electrical potential) of the cell or membrane expressing the Slo3 channel. A preferred means to determine changes in cellular polarization is by measuring changes in current (thereby measuring changes in polarization) with voltage

clamp and patch-clamp techniques, e.g., the "cell-attached" mode, the "inside-out" mode, and the "whole cell" mode (see, e.g., Ackerman *et al.*, *New Engl. J. Med.* 336:1575-1595 (1997)). Whole cell currents are conveniently determined using the standard methodology (see, e.g., Hamil *et al.*, *Pflugers. Archiv.* 391:85 (1981). Whole cell  
5 currents are also conveniently determined using the conditions set forth in Example IV. Other known assays include: radiolabeled rubidium flux assays and fluorescence assays using voltage-sensitive dyes (see, e.g., Vestergaard-Bogind *et al.*, *J. Membrane Biol.* 88:67-75 (1988); Daniel *et al.*, *J. Pharmacol. Meth.* 25:185-193 (1991); Holevinsky *et al.*, *J. Membrane Biology* 137:59-70 (1994)).

10 The effects of the test compounds upon the function of the channels can also be measured by changes in the electrical currents or ionic flux or by the consequences of changes in currents and flux. Changes in electrical current or ionic flux are measured by either increases or decreases in flux of cations such as potassium or rubidium ions. The cations can be measured in a variety of standard ways. They can be  
15 measured directly by concentration changes of the ions or indirectly by membrane potential or by radiolabeling of the ions. Consequences of the test compound on ion flux can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test compound on the channels of this invention. The effects of a test compound can be measured by a toxin binding assay. When the functional consequences  
20 are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release (e.g., dopamine), hormone release (e.g., insulin), transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), cell volume changes (e.g., in red blood cells), immuno-responses (e.g., T cell activation), changes in cell metabolism such as cell growth or pH changes, changes in  
25 intracellular second messengers such as  $\text{Ca}^{2+}$  or IP<sub>3</sub>, and changes in the sperm capacitation or acrosome reactions.

Assays for compounds capable of inhibiting or increasing potassium flux through the channel proteins comprising Slo3 can be performed by application of the compounds to a bath solution in contact with and comprising cells having an channel of  
30 the present invention (see, e.g., Blatz *et al.*, *Nature* 323:718-720 (1986); Park, *J. Physiol.* 481:555-570 (1994)). Generally, the compounds to be tested are present in the range from 1 pM to 100 mM.

Preferably, the Slo3 channel of the assay will be selected from a channel protein of SEQ ID NO:1, 16, or 18 conservatively modified variant thereof.



Alternatively, the Slo3 channel of the assay will be derived from a eukaryote and include an amino acid subsequence having sequence similarity to the core domain (S0-S8 of Slo3) of mSlo3 and hSlo3 channel proteins. Generally, the functional Slo3 channel protein will be at least 100, 200, 300, or 400-500 amino acids in length. Generally, the sequence similarity will be at least 60%, typically at least 70%, generally at least 75%, preferably at least 80%, more preferably at least 85%, most preferably at least 90%, and often at least 95%. Thus, Slo3 channel homologs will hybridize, under at least moderate hybridization conditions, to a nucleic acid of at least about 100 nucleotides in length from the core domain of an mSlo3 or hSlo3 nucleic acid and complementary sequences thereof.

The Slo3 channel homologs will generally have substantially similar conductance characteristics (e.g., 80-120 pS) and pH sensitivity characteristics, as described above. Chimeras formed by expression of at least two of mSlo3 and hSlo3 also be used, as well as chimera formed by fusing Slo3 or a Slo3 subsequence to another Slo molecule such as Slo1 or another potassium channel subunit. In a preferred embodiment, the cell placed in contact with a compound which is assayed for increasing or decreasing ion flux is a eukaryotic cell, e.g., an oocyte of *Xenopus* (e.g., *Xenopus laevis*) or a mammalian cell such as a CHO or HeLa cell.

As described in Example VI, chimeric Slo3 molecules can be made, which combine a subsequence such as either the pore or the tail region of Slo3 with a portion of another molecule, e.g., the pore or tail of another potassium channel subunit such as Slo1, or the pore region from a bacterial channel such as KcsA (McKinnon *et al.*, *Science* 280:106-109 (1998)). Such chimeras provide opportunities to screen and identify modulators of a specific Slo3 region, such as the pore or the tail.

Yet another assay for compounds that increase or decrease potassium flux in pH sensitive potassium channels involves computer assisted drug design, in which a computer system is used to generate a three-dimensional structure of Slo3 proteins based on the structural information encoded by the amino acid sequence. The amino acid sequence interacts directly and actively with a preestablished algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the protein. The models of the protein structure are then examined to identify regions of the structure that have the ability to bind to ligands. These regions are then used to identify ligands that bind to the protein or regions in which Slo3 interacts with other subunits.

The three-dimensional structural model of the protein is generated by entering channel protein amino acid sequences of at least 10 amino acid residues or

corresponding nucleic acid sequences encoding a channel protein into the computer system. The amino acid sequence of the channel protein is selected from the group consisting of: SEQ ID NOS:1, 3, 16, and 18 and conservatively modified versions thereof. The amino acid sequence represents the primary sequence of the protein, which  
5 encodes the structural information of the protein. At least 10 residues are entered into the computer system from computer keyboards or computer readable substrates that include, but are not limited to, electronic storage media (e.g., magnetic diskettes, tapes, cartridges, and chips), optical media (e.g., CD ROM), information distributed by internet sites, and RAM. The three-dimensional structural model of the channel protein is then generated by  
10 the interaction of the amino acid sequence and the computer system. The software is known to those skilled in the art.

The amino acid sequence represents a primary structure that encodes the information necessary to form the secondary, tertiary and quaternary structure of the monomer protein and channel. The software looks at certain parameters encoded by the  
15 primary sequence to generate the structural model. These parameters are referred to as "energy terms," and primarily include electrostatic potentials, hydrophobic potentials, solvent accessible surfaces, and hydrogen bonding. Secondary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms  
20 encoded by the primary structure or amino acid sequence to create the secondary structural model.

The tertiary structure of the protein encoded by the secondary structure is then formed on the basis of the energy terms of the secondary structure. The user at this point can enter additional variables such as whether the protein is membrane bound or  
25 soluble, its location in the body, and its cellular location, e.g., cytoplasmic, surface, or nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure. In modeling the tertiary structure, the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.

30 Finally, quaternary structure of multi-subunit proteins can be modeled in a similar fashion, using anisotropy terms. These terms interface different protein subunits to energetically minimize the interaction of the subunits. In the case of channel proteins, typically four identical subunits make up the quaternary structure of the channel.

Once the structure has been generated, potential ligand binding regions are identified by the computer system. Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above. The three-dimensional structure of the potential ligand is then compared to that of the channel protein to identify ligands that bind to the channel protein. Binding affinity between the protein and ligands is determined using energy terms to determine which ligands have an enhanced probability of binding to the protein.

Computer systems are also used to screen for mutations of Slo3 genes. Such mutations can be associated with disease states. Once the mutations are identified, diagnostic assays can be used to identify patients having such mutated genes associated with disease states. Identification of the mutated Slo3 genes involves receiving input of a first nucleic acid sequence encoding a pH sensitive potassium channel protein having an amino acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 16, 18 and conservatively modified versions thereof. The sequence is entered into the computer system as described above. The first nucleic acid sequence is then compared to a second nucleic acid sequence that has substantial identity to the first nucleic acid sequence. The second nucleic acid sequence is entered into the computer system in the manner described above. Once the first and second sequences are compared, nucleotide differences between the sequences are identified. Such sequences can represent allelic differences in Slo3 genes, and mutations associated with disease states.

## VII. Cellular transfection and gene therapy

The present invention provides packageable Slo3 channel protein nucleic acids (cDNAs), supra, for the transfection of cells *in vitro* and *in vivo*. These packageable nucleic acids can be inserted into any of a number of well known vectors for the transfection of target cells and organisms as described below. The nucleic acids are transfected into cells, *ex vivo* or *in vivo*, through the interaction of the vector and the target cell. The Slo3 channel protein nucleic acid, under the control of a promoter, then expresses the pH sensitive potassium channel protein of the present invention thereby mitigating the effects of absent, partial inactivation, or abnormal expression of the Slo3 channel protein gene. For example, the Slo3 gene may be used to treat infertility conditions due to its involvement in sperm physiology, e.g., capacitation and acrosome reactions.

Such gene therapy procedures have been used to correct acquired and inherited genetic defects, cancer, and viral infection in a number of contexts. The ability to express artificial genes in humans facilitates the prevention and/or cure of many important human diseases, including many diseases which are not amenable to treatment by other therapies. As an example, *in vivo* expression of cholesterol-regulating genes, genes which selectively block the replication of HIV, and tumor-suppressing genes in human patients dramatically improves the treatment of heart disease, AIDS, and cancer, respectively. For a review of gene therapy procedures, see Anderson, *Science* 256:808-813 (1992); Nabel & Felgner, *TIBTECH* 11:211-217 (1993); Mitani & Caskey, *TIBTECH* 11:162-166 (1993); Dillon, *TIBTECH* 11:167-175 (1993); Miller, *Nature* 357:455-460 (1992); Van Brunt, *Biotechnology* 6(10):1149-1154 (1988); Vigne, *Restorative Neurology and Neuroscience* 8:35-36 (1995); Kremer & Perricaudet, *British Medical Bulletin* 51(1):31-44 (1995); Haddada *et al.*, in *Current Topics in Microbiology and Immunology*, (Doerfler & Böhm eds., 1995); and Yu *et al.*, *Gene Therapy*, 1:13-26 (1994).

Delivery of the gene or genetic material into the cell is the first critical step in gene therapy treatment of disease. A large number of delivery methods are well known to those of skill in the art. Such methods include, for example liposome-based gene delivery (Mannino & Gould-Fogerite, *BioTechniques* 6:682-691 (1988); U.S. Pat No. 5,279,833; WO 91/06309; and Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413-7414 (1987)), and replication-defective retroviral vectors harboring a therapeutic polynucleotide sequence as part of the retroviral genome (*see, e.g.*, Miller *et al.*, *Mol. Cell. Biol.* 10:4239 (1990); Kolberg, *J. NIH Res.* 4:43 (1992); and Cornetta *et al.* *Hum. Gene Ther.* 2:215 (1991)). Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof (*see, e.g.*, Buchscher *et al.*, *J. Virol.* 66:2731-2739 (1992); Johann *et al.*, *J. Virol.* 66:1635-1640 (1992); Sommerfelt *et al.*, *Virol.* 176:58-59 (1990); Wilson *et al.*, *J. Virol.* 63:2374-2378 (1989); Miller *et al.*, *J. Virol.* 65:2220-2224 (1991); PCT/US94/05700.

AAV-based vectors are also used to transduce cells with target nucleic acids, e.g., in the *in vitro* production of nucleic acids and peptides, and for *in vivo* and *ex vivo* gene therapy procedures (*see, e.g.*, West *et al.*, *Virology* 160:38-47 (1987); U.S. Patent No. 4,797,368; WO 93/24641; Kotin, *Human Gene Therapy* 5:793-801 (1994); Muzyczka, *J. Clin. Invest.* 94:1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin *et*

al., *Mol. Cell. Biol.* 5:3251-3260 (1985); Tratschin *et al.*, *Mol. Cell. Biol.* 4:2072-2081 (1984); Hermonat & Muzyczka, *Proc. Natl. Acad. Sci. USA* 81:6466-6470 (1984); and Samulski *et al.*, *J. Virol.* 63:03822-3828 (1989). Cell lines that can be transfected by rAAV include those described in Lebkowski *et al.*, *Mol. Cell. Biol.* 8:3988-3996 (1988).

5

#### *A. Ex vivo transfection of cells*

*Ex vivo* cell transfection for diagnostics, research, or for gene therapy (e.g., via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art. In a preferred embodiment, cells are isolated from the subject organism, transfected with an Slo3 channel protein nucleic acid (gene or cDNA), and re-infused back into the subject organism (e.g., patient). Various cell types suitable for *ex vivo* transfection are well known to those of skill in the art (*see, e.g.*, Freshney *et al.*, *Culture of Animal Cells, a Manual of Basic Technique* (3d ed. 1994)).

10

15

As indicated above, in a preferred embodiment, the packageable nucleic acid which encodes an Slo3 channel protein is under the control of an activated or constitutive promoter. The transfected cell(s) express a functional Slo3 channel protein, which mitigates the effects of deficient or abnormal Slo3 channel protein gene expression.

20

#### *B. In vivo transfection*

Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containing therapeutic nucleic acids can be administered directly to the organism for transduction of cells *in vivo*. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. The packaged nucleic acids are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such packaged nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

25

30

Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.

The packaged nucleic acids, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

5 Formulations suitable for parenteral administration, such as, for example, by intravenous, intramuscular, intradermal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include  
10 suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. The formulations of packaged nucleic acid can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

15 Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by the packaged nucleic acid as described above in the context of *ex vivo* therapy can also be administered intravenously or parenterally as described above.

The dose administered to a patient, in the context of the present invention  
20 should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose will be determined by the efficacy of the particular vector employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or  
25 transduced cell type in a particular patient.

In determining the effective amount of the vector to be administered in the treatment or prophylaxis of conditions owing to diminished or aberrant expression of Slo3 channel protein, the physician evaluates circulating plasma levels of the vector, vector toxicities, progression of the disease, and the production of anti-vector antibodies. In  
30 general, the dose equivalent of a naked nucleic acid from a vector is from about 1  $\mu$ g to 100  $\mu$ g for a typical 70 kilogram patient, and doses of vectors which include a retroviral particle are calculated to yield an equivalent amount of therapeutic nucleic acid.

For administration, inhibitors and transduced cells of the present invention can be administered at a rate determined by the LD-50 of the inhibitor, vector, or

transduced cell type, and the side-effects of the inhibitor, vector or cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

Transduced cells are prepared for reinfusion according to established methods (see, e.g., Abrahamsen *et al.*, *J. Clin. Apheresis* 6:48--53 (1991); Carter *et al.*, *J. Clin. Apheresis*, 4:113-117 (1988); Aebbersold *et al.*, *J. Immunol. Meth.* 112:1-7 (1988); Muul *et al.*, *J. Immunol. Methods* 101:171-181 (1987); and Carter *et al.*, *Transfusion* 27:362-365 (1987)). After a period of about 2-4 weeks in culture, the cells should number between  $1 \times 10^8$  and  $1 \times 10^{12}$ . In this regard, the growth characteristics of cells vary from patient to patient and from cell type to cell type. About 72 hours prior to reinfusion of the transduced cells, an aliquot is taken for analysis of phenotype, and percentage of cells expressing the therapeutic agent.

#### VIII. Chromosomal assignment of the hSlo3 gene

To identify the chromosomal location of hSlo3, the cDNA sequences encoding hSlo3 and the 5' and 3' untranslated DNA sequence, as well as DNA sequence derived from genomic DNA may be used to map the hSlo3 gene to a site on a number of different types of genetic maps. This may be accomplished by mapping methods which are well known in molecular genetics, including somatic cell hybrid mapping, radiation hybrid (RH) mapping, and chromosome mapping using fluorescent *in situ* hybridization (FISH).

An example of one of these methods which is commonly used to map a DNA sequence is the method of radiation hybrid mapping. This procedure allows one to establish with high resolution the position of a DNA sequence within the RH map by comparison of the experimental results with those obtained with known DNA markers, and evaluating the statistical probability that such a map assignment is non-random (see, e.g., Cox *et al.*, *Science* 250:245-250 (1990)).

Typically, a human/hamster somatic cell hybrid panel is used for this purpose. These panels are commercially available, an example of which is the commonly used Stanford G3 panel, available from Research Genetics Inc. The panel is composed of genomic DNA from each of 83 different clonal human/hamster cell hybrid cell lines. Each cell line contains fragments of human genomic DNA in addition to the genomic host DNA of the hamster cell line from which they were derived. Since the human genomic DNA is distributed unevenly among the 83 clonal lines, PCR amplification of a specific

human DNA fragment using genomic DNA from each of the clonal lines results in an amplified product in only those clonal lines containing the fragment of the corresponding human genomic DNA. Identification of the lines which produce a positive signal and which do not give a pattern that may be deconvoluted to a map position is determined by comparison of the pattern with patterns derived from other markers in a database, for example the RH server database at the Stanford Human Genome Center. Localization of the RH mapped DNA sequence to a site on a human chromosome may then be established using physical map information derived from nearby known RH markers that have already been assigned a locus on the physical map. This assignment may be accomplished using publicly available databases such as the Genome Database.

The chromosomal localization of Slo3 may be used to determine whether a disease or genetic defect is attributable to changes in the genomic DNA containing the Slo3 gene. Examples of such changes are well known in the literature and include point mutations, insertions, and deletions. Examples of human diseases attributable to changes in genomic DNA sequence include cystic fibrosis and long Q-T syndrome. Association of a disease with changes in the gene coding for a Slo3 may be accomplished by examination of the genetics literature to find diseases for which the chromosomal assignment is already known but for which a specific mutation has not been determined. This can also be accomplished by examining genomic DNA sequence of an individual or group of individuals directly to determine if a mutation has occurred using established methods or a combination of both. Examples of such methods include but are not limited to PCR, single strand conformational polymorphism (SSCP) analysis, and direct sequencing of genomic DNA.

Alternatively, a disease may be mapped to a chromosomal location or a specific gene without prior knowledge of its identity by positional cloning or other methods known to those of skill. The identification of the gene may then be established by comparing the chromosomal location or actual DNA sequence with those derived from the literature or from databases containing known sequence data such as Genbank

## IX. Kits

Slo3 and its homologs are a useful tool for examining expression and regulation of pH sensitive, voltage-gated potassium channels, particularly in developing sperm. Slo3 specific reagents that specifically hybridize to Slo3 nucleic acid, such as



Slo3 probes and primers, and Slo3 specific reagents that specifically bind to the Slo3 protein, e.g., Slo3 antibodies are used to examine expression and regulation.

Nucleic acid assays for the presence of Slo3 DNA and RNA in a sample include numerous techniques are known to those skilled in the art, such as Southern analysis, northern analysis, dot blots, RNase protection, S1 analysis, amplification techniques such as PCR and LCR, and *in situ* hybridization. In *in situ* hybridization, for example, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the art of *in situ* hybridization: Singer *et al.*, *Biotechniques* 4:230-250 (1986); Haase *et al.*, *Methods in Virology*, vol. VII, pp. 189-226 (1984); and *Nucleic Acid Hybridization: A Practical Approach* (Hames *et al.*, eds. 1987). In addition, Slo3 protein can be detected with the various immunoassay techniques described above, e.g., ELISA, western blots, etc.. The test sample is typically compared to both a positive control (e.g., a sample expressing recombinant Slo3) and a negative control.

The present invention also provides for kits for screening for modulators of Slo3. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise any one or more of the following materials: biologically active Slo3, reaction tubes, and instructions for testing Slo3 activity. Preferably, the kit contains biologically active Slo3. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. For example, the kit can be tailored for *in vitro* or *in vivo* assays for measuring the activity of a homomeric voltage-gated potassium channel comprising an Slo3 subunit.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

## EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

### Example I: Cloning mSlo3, a pH sensitive potassium channel

The nucleotide sequence for mSlo3 was cloned by searching a database for EST sequences with homology to mSlo1, generating a probe based on the EST sequence using PCR, and screening a library with the EST probe.

#### *A. Methods*

By tBlastn (NCBI), an EST (GenBank accession No. AA072586) was identified by homology to the C-terminal "tail" of mSlo1. The EST derived from a mouse promyelocytic WEHI-3 cell line cDNA library. A 32P-labeled 1254 bp PCR product generated from the EST-pBluescript plasmid (Genome Systems) was employed to isolate cDNA clones from a WEHI-3 library (Stratagene) by hybridization. The oligonucleotides used to generate the probe were 5' GTGGA-TGATACC-GACATGC-TGGAC 3' (sense) and 5' GAGACCACCTCTC TCCCGTGTCGT 3' (antisense). mSlo3 expression in the WEHI-3 cell line is apparently anomalous; all isolated cDNAs were inappropriately spliced or truncated, and PCR analysis of the WEHI-3 cDNA bank using combinations of primers homologous to mSlo3 and vector sequence indicated that complete cDNAs were not represented.

Subsequent screening of a mouse testis cDNA library (Dr. Graeme Mardon) yielded cDNAs that extended to the putative initiator methionine, as shown in Figure 1. The reading frame was closed upstream from the indicated methionine. A full length cDNA was constructed from two overlapping cDNAs and the presence of full length transcripts in testis corresponding to this cDNA was verified by RT-PCR from total testis RNA. The entire cDNA was sequenced in both directions.

For expression in *Xenopus* oocytes, a Kozak initiator sequence was introduced by PCR and the entire open reading frame was subcloned into the pOocyte-Xpress vector, containing *Xenopus* 5' and 3'  $\beta$ -globin UTRs. The 5' end generated by PCR was checked for errors by sequencing in both directions.

## B. Results

mSlo3 cDNA was isolated from a testis cDNA library based on its homology to the large-conductance calcium-activated (BK) potassium channel, mSlo1 (Butler *et al.*, *Science* 261:221-224 (1993)). The probe was generated from an expressed sequence tag identified in the GenBank database. The new channel was termed mSlo3 ("m" denoting derivation from mouse). Figure 1A illustrates that the 1113 amino acid mSlo3 is similar to the 1196 amino acid mSlo1 protein (Butler *et al.*, 1993, *supra*) as well as *Drosophila* Slo1 (Atkinson *et al.*, *Science* 253:551-553 (1991); Adelman *et al.*, 1992, *supra*). The hydrophilicity profiles of both sequences indicate 11 hydrophobic segments, S0 through S10 (Figure 1B). As with mSlo1, these can be divided into "core" and "tail" domains. Homology of mSlo3 to mSlo1 in the core domain (S0-S8) (51%), which is generally conserved in the voltage-gated superfamily of K<sup>+</sup> channels, is much higher than in the tail domain, which is involved in calcium sensing (Wei *et al.*, *Neuron* 13:671-681 (1994)).

Two notable differences between mSlo3 and mSlo1 demonstrate their functional distinctions. First, the "Calcium Bowl," a hyperconserved aspartate-rich region involved in calcium sensing, is absent in mSlo3 (Schreiber & Salkoff, *Biophys. J.* 73:1355-1363 (1997)). This absence showed that mSlo3 is gated by factors other than calcium. Second, mSlo3 contained GFG rather than GYG in the conserved pore signature sequence involved in K<sup>+</sup> ion selectivity (Yool & Schwarz, *Nature* 349:700-704 (1991); Hartmann *et al.*, *Science* 251:942-944 (1991); Heginbotham & MacKinnon, *Biophys. J.* 66:1061-1067 (1994)). Most K<sup>+</sup> selective channels contain GYG. This difference demonstrated that ionic selectivity differs between the two channels: mSlo3 has greater permeability to Na<sup>+</sup> than Slo1 channels. A block of conservation containing arginine at regular intervals in the beginning of the S4 region may underlie the fact that, in addition to other factors, both mSlo3 and Slo1 channels are gated by voltage. mSlo3 core residues 35 through 641 share 51% identity with mSlo1. Overall, mSlo3 shares less than 30% amino acid identity with mSlo1.

### Example II: mRNA expression of mSlo3

*In situ* hybridization, northern analysis, RT-PCR, and cDNA cloning were used to investigate mSlo3 expression in a variety of tissues. These experiments demonstrated that mSlo3 is abundant in spermatocytes.

### A. Methods

For each tissue tested with RT-PCR, MMLV reverse transcriptase (GIBCO) was used on 5 mg total RNA primed with 25 mM random hexanucleotides (Boehringer Mannheim) and 200 mM dNTPs at 42°C, for 1 hr. 0.1% of each first strand synthesis was assayed by PCR, using 1.0 mM oligonucleotide primers, 200 mM dNTPs and 0.0075 units KlenTaq, cycling 30 times. Reaction products were electrophoresed on 1.5% and 3.0% agarose gels, using standard Tris-borate (TBE) buffer, and visualized by staining with ethidium bromide. PCR primer pairs used were:

mSlo3 (S4 to S5). 5' CTCGAAGTCCCTAAAATCTTACAGAT 3' (sense) and 5' TTCCGTTGAGCCAGGGGTCACCAGAATT 3' (antisense) to generate a 156 bp product; mSlo3 (S8 to S9). 5' TCTGCTTTGTGAAGCTAAATCT 3' (sense) and 5' TTTCAAAGCCTCTTTAGCGGTAA 3' (antisense) to generate a 690 bp product; mSlo3 (S9 to S10); 5' TTATGCCTGGATCTGCACTCTACATG 3' (sense) and 5' ATAGTTTCCGTCTACTACCGAAA 3' (antisense) to generate a 221 bp product. As a control, Human  $\beta$ -actin. 5' GATGATATCGCCGCGCTCGTCGTCGAC 3' (sense) and 5' TCGGTCCAGGTCTGCGTCCTACCGTAC 3' (antisense) to generate a 535 bp product.

For northern blot analysis, total RNA or poly A+ RNA was isolated from freshly dissected mouse and human tissue using Trizol (GIBCO). The mouse tissues were brain, heart, skeletal muscle, kidney, lung, liver and testis, the human tissues were spleen, thymus, prostate, testis, uterus, small intestine, colon, and leukocytes. 20 mg total RNA or 2 mg poly A+ RNA from each tissue was electrophoresed on a 1% agarose denaturing gel, using MOPS-formaldehyde buffer, then transferred to nitrocellulose. The human tissue blot was obtained commercially (Clontech). A PCR product generated using primers 5' CGGAAACGTCATGTACAATCGAAATCCA 3' (sense) and 5' TTCC-GTTG-AGCC-AGGG-GTCACCAGAATT 3' (antisense) was labeled using random hexanucleotides (Boehringer-Mannheim). Blots were hybridized and washed under standard high stringency conditions and exposed to X-ray film for 16 hours. After hybridization with mSlo3 probes, blots were rehybridized with a human  $\beta$ -actin probe to verify RNA loading. For examination of human tissues, 2 mg of poly A+ RNA from the tissues described above were electrophoresed as described. The probe was the mSlo3 probe described above.

For *in situ* hybridization, testes from white mice >30 days old were dissected, frozen, sectioned immediately with a cryostat, collected on slides, and stored at

009029 9/20/95 16:50

-20°C. A partial mSlo3 cDNA (approximately 1 kb, corresponding to coding sequence for residues 170-510) was subcloned into pBluescript II KS+ (Stratagene). T3 and T7 RNA polymerase (Stratagene) were used to synthesize 32P-UTP-labeled antisense and sense probes, respectively, from linearized plasmid. Slides were hybridized overnight at 55°C. After washing, slides were dipped in NTB-2 liquid emulsion (Kodak), air dried, and placed in light protected boxes at 4°C for 10 days.

### B. Results

For RT-PCR and northern analysis, mouse brain, skeletal muscle, lung, liver, kidney, and heart tissue were examined; only testis produced a positive signal (Figure 3). Total RNA blots from the same tissues showed a transcript size of approximately 4 kb, also restricted to testis. Using the mouse Slo3 probe, in human tissues, poly A+ RNA on a northern blot again showed a transcript size of approximately 4 kb, again only in testis.

For *in situ* hybridization experiments, testes from white mice >30 days old were dissected, frozen, and sectioned immediately with a cryostat, collected on slides, and stored at -20°C. A partial cDNA (approximately 1 kb) for the potassium channel mSlo3 was cloned into the Bluescript expression vector (Stratagene). Both sense and antisense RNA probes were labeled with uridine 5'-[ $\alpha$ -<sup>32</sup>P]-triphosphate (10  $\mu$ Ci/ $\mu$ l). Slides were coverslipped and allowed to hybridized overnight at 55°C. Following washing, slides were dehydrated, air dried and dipped in Kodak NTB-2 liquid emulsion, then placed in air tight light boxes at 4°C for 10 days.

Labeling was observed in annular rings corresponding to the positions of spermatocytes in seminiferous tubules. Positive hybridization signals appeared as white dots on darkfield micrographs. Dense circular patterns of hybridization signals corresponded to the annular clusters of spermatocytes. The annular structure shows the cross-section of a single seminiferous tubule, composed largely of developing spermatocytes. Stem cells and primary spermatocytes were at the outer edges, while more mature spermatocytes were found near the lumen. Supporting Sertoli cells and Leydig cells, difficult to distinguish at this resolution, were present in lower numbers. Hybridization signals at the inner margins of the circular patterns of seminiferous tubules corresponded to the positions of secondary spermatocytes and possibly even spermatids. Dark-field microscopy of the same view shows intense hybridization of antisense probe with mSlo3 mRNA in developing spermatocytes. The outer edges and interstices

between tubules are unstained, suggesting that primary and secondary spermatocytes are the predominant cell type expressing the message, rather than spermatogonia (spermatic stem cells). Staining of the innermost regions of the tubule suggests that even early spermatids may be expressing the message. The high density of labeling demonstrates a high degree of mSlo3 expression in spermatocytes.

In addition to the dense patterns of staining in testis *in situ*, two additional experiments indicated that mSlo3 is abundantly expressed in testis. Northern analysis of total RNA isolated from testis gives a positive signal after only 10 hrs. of exposure. In addition, cDNAs encoding mSlo3 were abundant in a cDNA library constructed from adult testis derived RNA (unique cDNAs encoding mSlo3 represented approximately 0.01% of total cDNAs in the library). In contrast to its abundance in testes, mSlo3 was absent or expressed at much lower levels in other tissues, such as brain, skeletal muscle, and heart.

### Example III: *Xenopus* oocyte expression of mSlo3

mSlo3 clones were expressed in *Xenopus* oocytes, in order to analyze potassium channel function.

#### A. Methods

As described above in Example I, the entire open reading frame of mSlo3 was assembled in a modified Bluescript II KS+ vector (Stratagene) containing *Xenopus* 5' and 3'  $\beta$ -globin UTRs. For expression, cRNA was generated from template linearized at a unique vector Not1 site and transcribed using the mMessage mMachine T3 kit (Ambion).

#### B. Results

A full-length mSlo3 cDNA was cloned into pBSC-MXT, a Bluescript-derived plasmid (Stratagene) containing *Xenopus*  $\beta$ -globin 5' and 3' untranslated sequences. cDNA expression constructs were linearized at a unique Not-I site, and capped cRNA was synthesized using the mMessage mMachine (Ambion). Reactions were precipitated with LiCl to remove the DNA template and resuspended in nuclease-free water at a final concentration of approximately 1 mg/ml. Oocytes were prepared for injection as previously described (Wei *et al.*, *Science* 248:599-603 (1990)), except for the use of a Drummond nanojector. Approximately 50 nl of RNA in nuclease-free water was

injected into each oocyte. Oocytes were incubated in ND96 medium (Wei *et al.*, 1994, *supra*) and analyzed 1-8 days after injection.

#### Example IV: Electrophysiology

mSlo3 clones expressed in *Xenopus* oocytes, as described above in Example III, were analyzed for electrophysiological characteristics.

##### A. Methods

cRNA (40 nl at approximately 1 mg/ $\mu$ l) was injected into mature *Xenopus* oocytes; recordings were made 1-8 days later. For whole cell-recording, medium nd96 (concentrations in mM; 96 NaCl, 2 KCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 5 HEPES, pH 7.5) supplemented with 1 mM DIDS (to block endogenous chloride currents) employed as bath solution, or modified as noted in figure legends. Patches were perfused with either 0 Ca<sup>2+</sup> EGTA solutions (160 K gluconate, 34 KOH, 10 HEPES, and 10 EGTA) or Ca<sup>2+</sup>-containing (184 K gluconate, 10 KOH, 10 HEPES, 200 mM hemicalcium gluconate) solutions. HCl was used to adjust pH. Pipet solution contained 0.5 K gluconate, 0.5 KCl, 1.1 KOH, 10 HEPES, 159 Na gluconate, and 2 hemiMg gluconate, pH 7.1. Recording. Two-electrode voltage clamp was carried out with a TEV-200 amplifier (Dagan). Patch currents were recorded on either an Axopatch 1B or 200A amplifier (Axon), and digitized at either 3.4, 5 or 10 kHz. Data acquisition and analysis programs were CCURRENT and CQUANT (Dr. Keith Baker) or pClamp6 (Axon). Recordings were made at room temperature except tail currents which were recorded at 11°C using a Peltier device (Cambion).

##### B. Results

When expressed in the *Xenopus* oocyte expression system, mSlo3 cRNA produced currents that were sensitive to pH and voltage. Since pHi regulation is critical in spermatid function, mSlo3 activity was tested over a range of pHi in detached, perfused patches (Figure 3). mSlo3 currents were small or absent at a pHi of 7.1 or lower, while raising pHi resulted in sharp increases in channel activity. Whole-cell mSlo3 currents were also sensitive to manipulations of intracellular pH (Figure 4). Acidification of the oocyte using bicarbonate-based bath solution strongly attenuated currents, while alkalization by ammonium chloride reversed this decrease (Fakler *et al.*, *EMBO J.* 15:4093-4099 (1996); Sasaki *et al.*, *Biochim. et Biophys. Acta* 1137:45-51 (1992)). These

results are consistent with those obtained with perfused patches. Despite channel rundown, which occurred rapidly over the course of minutes, macroscopic currents could be elicited from large-diameter patch electrodes (Figure 3D). These currents revealed that although mSlo3 is similar in primary structure to the high conductance  $\text{Ca}^{2+}$ -activated potassium channel mSlo1, mSlo3 activation is not sensitive to  $\text{Ca}^{2+}$  (Figure 3D). Channel activity was robust even in the presence of 10 mM EGTA (0 M  $\text{Ca}^{2+}$  conditions in Figure 3D, and all experiments in Figure 3A-C).

Several other mSlo3 properties were distinct from its closest homolog, mSlo1. mSlo3 single-channel conductance was lower than mSlo1 (approximately 100 pS vs. 270 pS in symmetric  $\text{K}^+$  as derived from the slope of the unit current amplitude versus voltage relation; Butler *et al.*, 1992, *supra*). Unlike Slo1, Slo3 was relatively insensitive to TEA (EC<sub>50</sub> approximately 100 mM versus less than 0.2 mM for mSlo1), consistent with a Y to V change at residue 283 near the  $\text{K}^+$  selective pore (Butler *et al.*, 1992, *supra*; Kavanaugh *et al.*, *J. Biol. Chem.* 266:7583-7587 (1991)). The highly selective mSlo1 channel toxin blockers charybdotoxin (50 nM) and iberiotoxin (20 nM) did not affect mSlo3 currents (Miller *et al.*, *Nature*, 313:316-318 (1985); Galvez *et al.*, *J. Biol. Chem.* 265:11083-11090 (1990)). Of particular note, tail current analysis revealed that mSlo3 is less selective for  $\text{K}^+$  over  $\text{Na}^+$  than Slo1, having a PK/PNa of approximately 5 versus >50 for mSlo1 (Figure 4C, D; Tseng-Crank *et al.*, 1994, *supra*).

These experiments demonstrated that mSlo3 has the following electrophysiological characteristics when expressed in *Xenopus* oocytes:

1. mSlo3 is sensitive to pH, being very active above pH 7.1. mSlo3 is outwardly rectifying.
2. Although mSlo3 is structurally related to the Maxi K calcium-activated channel, mSlo1, mSlo3 is insensitive to calcium.
3. In *Xenopus* oocytes with the symmetric  $\text{K}^+$  concentrations used above (160 mM KCL), mSlo3 has a single channel conductance of approximately 100 pS.
4. mSlo3 has a relatively high conductivity to  $\text{Na}^+$  for a  $\text{K}^+$  channel; the PNa/PK ratio is about 0.25.

#### Example V: Cloning hSlo3, a human homolog of the mSlo3 channel

Sequence of hSlo3 was obtained by PCR and human testis cDNA library screening, using the mSlo3 sequence as a probe.



### A. Methods

The nucleotide sequence of mSlo3 was examined in the core domain, and PCR primers were synthesized to amplify the corresponding segment from a human testis cDNA library (Clontech). The primers were 5' GGCAGCGCTCATTCTTTCCTCCTT - 3' and 5' TGCCCAAAACCTCAACCCAAAATA - 3'. PCR was performed at an annealing temperature of 50°C for 30 seconds and an extension time of 30 seconds at 72°C for 40 cycles. PCR fragments were subcloned into pCR II (Invitrogen) and sequenced.

The cDNA library (2 x 10<sup>6</sup> pfu) was subsequently screened with a mSlo3 probe. A 2.6 kb BamHI fragment of mSlo3 was labeled with 32P by random primer extension, and bacteriophage lambda plaque filter lifts were hybridized in 30% formamide, 1X Denhardt's, Tris-HCl 20 mM (pH 7.4), 4X SSC, 0.1% SDS, denatured sheared salmon sperm DNA 20 µg/ml, yeast tRNA 20 µg/ml at 42°C overnight. Filters were washed in 2X SSC/0.1% SDS at 42°C for 15 minutes x 2, then in 0.2X SSC/0.1% SDS at 42°C for 30 minutes. Filters were exposed to x-ray film overnight at -80°C and developed. Bacteriophage plaques that showed corresponding labeling on the autoradiograms were purified to homogeneity, the phage DNA prepared and cDNA inserts excised with EcoRI and subcloned into pBluescript II SK (Stratagene) for sequencing. Sequencing was performed on an ABI automated sequencer.

### B. Results

DNA fragments generated by PCR of a human testis cDNA library were sequenced, and the nucleotide sequence obtained (SEQ ID NO:4) was highly homologous with mSlo3, showing approximately 70% sequence identity on the nucleotide level. The translated amino acid sequence (SEQ ID NO:3) was 61.5% identical to mSlo3 on the amino acid level over the sequence region, with 94% identity in the S1 region. PCR of human cDNA libraries derived from brain, pancreas, heart, retina, and leukemia cell line (Jurkat) failed to produce the expected band.

Screening of a human testis cDNA library at moderate stringency produced 6 clones, all of which were identified as being hSlo3 by PCR using specific internal primers. One clone was partially sequenced, producing a nucleotide sequence which was identical to the DNA fragments derived from the PCR of the library. Although the clones have not been sequenced in their entirety, the high sequence identity

in conjunction with the localization of the channel mRNA to human testis by northern blot (Example II) and PCR establishes the identity of the human Slo3 channel.

### Example VI: Slo3/Slo1 Chimeras

5 In this experiment, a Slo1 core-Slo3 tail chimera has been made, to demonstrate that two distinct regions of the Slo1 tail are involved in calcium sensing. These regions were demonstrated by re-introducing small regions of the Slo1 tail into a calcium-insensitive BK channel constructed from two Slo family members, Slo1 and Slo3 (Schreiber *et al.*, *J. Biol. Chem.* 273:3509-3516 (1998)). Although these regions are  
10 adjacent, it is possible that they contribute independently to calcium sensitivity. This independence is supported by the fact that one of the regions that we describe, the Calcium Bowl (Schreiber *et al.*, *Biophys. J.* 73:1355-1363 (1997)) has been modified in another family member, mSlo2, to be a site of chloride regulation, while the channel retains regulation by calcium at a second site.

#### 15 A. Methods

Wild-type channel constructs. mSlo1 constructs were based on the mbr5 cDNA construct described previously Butler *et al.*, *Science* 261:221-224 (1993)); the mSlo1 and tail were as described in Wei *et al.*, *Neuron* 13:671-681 (1994). Briefly, the  
20 mSlo1 core begins at the initiator methionine and terminates after S8 in the unconserved linker region. The mSlo1 tail construct begins at a native internal methionine before the S9 hydrophobic domain. The mSlo3 tail construct is derived from the mSlo3 cDNA (GenBank accession number AF039213; Schreiber. *et al.*, *J. Biol. Chem.* 273:3509-3516 (1998)).

25 Chimeric mSlo1-mSlo3 tail constructs: mSlo3 and chimeric tail constructs were cloned into pOocyte-Xpress, a Bluescript-derived plasmid (Stratagene) containing *Xenopus*  $\beta$ -globin 5' and 3' untranslated sequences (Melton *et al.*, *Nucl. Acids Res.* 12:7035-7056 (1984)). Chimeric constructs were generated by standard overlap PCR techniques (Horton *et al.*, *Gene* 77:61-68 (1989)). Oligonucleotides were synthesized at  
30 the Washington University Protein and Nucleic Acid Laboratory. The mSlo3 tail construct consisted of the C-terminal region of mSlo3 corresponding to that included in the mSlo1 tail, starting with methionine number 687 in mSlo3 (so that N-terminal residues were MLDS). The initiator methionine was placed into a Kozak consensus sequence (Kozak, *Mol. Biol.* 196:947-950 (1987)). To generate chimeras, the tail domain

was divided into segments A through D. First and last residues of each segment are as follows: Region A: replaces mSlo3 792 IAVN ... LTEL 870 with mSlo1 793 RAVN ... ITEL 885. This region begins after S9 and runs to a point just N-terminal to the Calcium Bowl. Region B: replaces mSlo3 871 KNPS ... GAVF 906 with mSlo1 886 VNDT ... GTAF 918, except that the C-terminal end of this fragment is a hybrid of the mSlo1 and mSlo3 sequences reading GAAF. Chimera B tail includes the entire Calcium Bowl region. Region C: replaces mSlo3 899 STSF ... SEME 941 with mSlo1 909 TQPF ... PELE 963. This region includes S10 and 20 residues following S10. Region D: replace mSlo3 939 EMEH ... HLLP 1034 with mSlo1 951 ELEA ... ELVP 1048. Region D is a large segment near the C-terminal of the protein. Larger pieces were also generated and denoted by their composition, e.g. BC was a chimeric beginning at the N-terminal end of B through the C-terminal end of C. Reciprocal experiments, the coexpression of mSlo1 tail with mSlo3 core, failed to produce functional channels.

*Xenopus* oocyte expression: mSlo3 and chimeric tail constructs were linearized at a unique Not1 site, and capped cRNA was synthesized using the T3 mMessage mMachine kit (Ambion). Reactions were precipitated with LiCl and resuspended in nuclease-free distilled water at a final concentration of approximately 1.0 mg/ml. Oocytes were prepared for injection as previously described (Wei *et al.*, *Science* 248:599-603 (1990)) except for the use of a Drummond nanojector. Approximately 50 nl was injected into each oocyte. Oocytes were incubated in ND96 medium (Wei *et al.*, *Neuron* 13:671-681 (1994)) and analyzed 1-8 days after injection.

Electrophysiology: Before patch recording, vitelline membranes were removed from oocytes in hypertonic stripping solution (200 mM potassium aspartate, 20 mM KCl, 1 mM MgCl<sub>2</sub>, 10 mM EGTA, 10 mM HEPES). Inside-out patch recordings were made using buffered calcium perfusion solutions as described previously (Wei. *et al.*, *Neuron* 13:671-681 (1994)). Methanesulfonate-based perfusion and pipet (extracellular) solutions contained symmetric K<sup>+</sup> (160mM), pH 7.0. mSlo1 core + mSlo3 channels were not sensitive to pH in terms of either changes in V50 or Gmax when tested with solutions at pH 7 or 8 containing 184 K gluconate, 10 KOH, 10 HEPES, and 200  $\mu$ M hemiCa gluconate, pH adjusted with HCl; the pH 7 solution was used in the pipet to provide symmetric [K<sup>+</sup>]. From pH 7 to pH 8,  $\Delta V_{50} = 8.1 \pm 2.1$  mV; n = 6 patches. The ratio of maximal conductances for at pH 8 to that at pH 7 was  $0.89 \pm .12$ ; n=6 patches. Similar results (no effect of pH) were obtained with pH 7 and pH 8 solutions containing nominally zero calcium (10 mM EGTA). Macroscopic currents were measured with an

Axopatch 1B amplifier (Axon Instruments), digitized at 10 kHz, and filtered at 5 kHz. Analysis was carried out using pClamp (Axon Instruments). For characterization, each patch was subjected to a family of voltage clamp step pulses in 10 mV increments. Conductance-voltage relations were plotted and fitted with Boltzmann functions.

5 Conductance was then normalized to the maximal conductance of the Boltzmann fit.

### B. Results

Considering the role of calcium in Slo1 channel activation, it was surprising to find a closely related channel, Slo3, which was lacking in calcium sensitivity (Schreiber *et al.*, *J. Biol. Chem.* 273:3509-3516 (1998)). Like mSlo1, mSlo3 is a large-conductance, voltage-gated potassium channel with corresponding core and tail domains. However, despite their overall homology, mSlo3 is insensitive to calcium. This lack of calcium sensitivity has allowed production of a chimeric channel with properties similar to the Slo1 core, but lacking calcium sensitivity. This was accomplished by fusing the mSlo3 tail with the mSlo1 core. The Slo1 core construct included the N-terminal two-thirds of mouse Slo1, ending downstream of the S8 hydrophobic segment, in the "linker" region; the Slo3 tail began at a native internal methionine upstream from S9. Remarkably, the Slo3 tail + Slo1 core hybrid channels produced robust expression. The ability of the Slo3 tail to form functional channels with the Slo1 core indicates that the Slo3 tail can supply a function necessary for channel assembly, similar to that of a chaperone, in lieu of the Slo1 tail. This function is likely to be encoded by regions that are conserved between the mSlo1 and mSlo3 tails.

Hybrid channels consisting of Slo3 tail and Slo1 core exhibit voltage sensitivity (as reflected in the slope of the Boltzmann fit to the G-V curve) characteristic of the Slo1 core. This is to be expected if the core determines voltage sensitivity. Most importantly, the chimeric channels were calcium insensitive, which is a characteristic of Slo3 channels. Thus, changing  $[Ca^{2+}]$  did not alter the voltage range of activation or the activation kinetics of the chimeric channels, two gating parameters strongly altered by  $Ca^{2+}$  in wild-type Slo1 channels (DiChiara *et al.*, *J. Physiol.* 489:403-418 (1995); Cui *et al.*, *J. Gen. Physiol.* 109:647-673 (1997); Cox *et al.*, *J. Gen. Physiol.* 109:633-646 (1997)). These experiments are further evidence for the importance of the Slo1 tail in calcium sensing. This chimeric calcium-insensitive BK channel has been used to identify specific regions of the Slo1 tail involved in calcium sensing.

Chimera ABCD tail produces wild-type Slo1 calcium sensitivity: To map the regions involved in calcium sensitivity, the Slo1 tail was divided into four segments, A through D. To verify that all calcium sensing regions were included, regions A, B, C, and D, when transplanted as a unit (chimera ABCD) were shown to completely restore wild-type calcium sensing to the mSlo3 tail. This indicates that the structures essential to Slo1 calcium sensing are contained within ABCD, a region comprising approximately 56% of the total length of the tail domain. These four regions are contiguous or slightly overlapping and encompass 269 amino acid residues out of a total of 480 Slo tail residues. The hydrophobic region S9 is not included in ABCD. In addition, this result suggests that the remaining N- and C-terminal-most regions of the Slo1 tail that were not transplanted, including the S9 hydrophobic segment and the C-terminal ~120 amino acids, are unlikely to make any direct contribution to calcium sensing. However, the regions outside of ABCD may be involved in other roles of the tail that are conserved between Slo1 and Slo3. As mentioned above, one possible function of these regions might be to promote proper channel assembly or targeting to the plasma membrane. Each region (A, B, C, or D) was then tested for its ability to restore calcium sensitivity by adding it back to the Slo3 tail, and testing its calcium sensitivity in Slo3 tail chimera +Slo1 core channels.

The Calcium Bowl (Region B) restores a portion of wild-type calcium sensitivity: In a previous paper a series of mutations in the Calcium Bowl region of the tail was created to show its involvement in the calcium-sensing process (Schreiber *et al.*, *Biophys. J.* 73:1355-1363 (1997)). Further evidence showing the involvement of this region in  $\text{Ca}^{2+}$  sensing would be provided by adding this region back to the  $\text{Ca}^{2+}$  - insensitive channel and restoring  $\text{Ca}^{2+}$  sensitivity. Thus, this small region was added (Region B) into the calcium-insensitive Slo3 tail; and then assayed for the calcium-sensitivity of the channels formed from this Slo3 modified tail coexpressed with Slo1 core (chimera B tail + Slo1 core). The results of this experiment show that the Calcium Bowl does, in fact, restore significant calcium sensitivity to the channel. In this experiment, 34 residues encompassing the Calcium Bowl from mSlo1 replaced 37 residues of the mSlo3 tail. Within this region, 12 amino acids were identical; of the 22 additional Slo1 residues added back, 8 represented conservative changes. Overall similarity between the sequences included conservative changes was 59%. The 12 amino acids in conserved positions allowed an accurate alignment through this region. Of the 22 amino acids that differ between the two constructs, seven are negatively charged amino

acids present in Slo1 but absent in Slo3; negatively charged amino acids are favored to coordinate calcium (Marsden, *Biochem. Cell. Biol.* 68:587-601 (1990)).

The qualitative effect on  $\text{Ca}^{2+}$  on channels formed from chimera B tail + Slo1 core was similar to that observed for wild-type mSlo1 (or mSlo1 tail + mSlo1 core) channels; as  $[\text{Ca}^{2+}]$  was raised, the G-V curve shifted to more negative voltages. Thus, higher  $[\text{Ca}^{2+}]$  permits the channel to activate at more negative voltages. As with wild-type Slo1,  $[\text{Ca}^{2+}]$  had little or no effect on the voltage sensitivity of the current, as reflected in the slope of the G-V curve. Although the response to  $\text{Ca}^{2+}$  was significant in channels formed from chimera B tail + Slo1 core, the magnitude of the  $\text{Ca}^{2+}$ -induced voltage shifts were not equal to that of wild-type channels; The  $\Delta V_{50}$  from 4 to 300  $\mu\text{M}$   $\text{Ca}^{2+}$  was approximately -58  $\mu\text{V}$  for chimera B tail + Slo1 core, compared with -84 mV for wild-type Slo1 tail + Slo1 core. The fact that the magnitude of change in the position of the G-V curve,  $\Delta V_{50}/\Delta[\text{Ca}^{2+}]$ , is less than that with the complete Slo1 tail could be due to several factors, but it is also consistent with previous observations that there is likely to be more than one calcium sensing site per subunit in mSlo1 (Schreiber *et al.*, *Biophys. J.* 73:1355-1363 (1997)). One possibility is that the Calcium Bowl is an autonomous region that is sufficient to confer  $\text{Ca}^{2+}$  sensing, and an additional region also contributes to the calcium-sensing function.

A region downstream from the Calcium Bowl also contributes to calcium sensing: The region downstream from the Calcium Bowl, which includes the S10 hydrophobic segment (region C), also produced calcium-sensitive channels when incorporated into the Slo3 tail and coexpressed with the Slo1 core (chimera C tail + Slo1 core channels. However, increasing  $\text{Ca}^{2+}$  had a proportionally smaller effect on chimera C tail + Slo1 core channels than on chimera B tail + Slo1 core channels, as reflected in the slope of the  $V_{50}$  versus  $[\text{Ca}^{2+}]$  relation. As with chimera B tail + Slo1 core channels, the magnitude of the  $\Delta V_{50}/\Delta[\text{Ca}^{2+}]$  was less than that for mSlo1 tail, suggesting neither region B nor C can separately account for Slo1 calcium sensitivity.

B and C make additive contributions to calcium sensitivity: To assay the effect of combining regions B and C, the chimeric tail construct BC was created. Regions B and C together produce channels with higher calcium than either B or C alone. This shows simple additivity. Over the range of calcium from 0 to 300  $\mu\text{M}$  the difference between the  $V_{50}$  for the control mSlo3 tail alone and each chimera was -77 mV for chimera B tail and -27 mV for chimera C tail. For chimera BC tail, the difference was -100 mV. This is remarkably close to the -104 mV obtained by adding the values for

chimera B and C tails. Thus, these regions appear to make independent contributions to the channel's calcium sensitivity.

Other regions of the tail do not confer calcium sensitivity: In addition to testing regions B and C, the remaining segments of the Slo1 tail were tested. Neither region A nor D produced calcium sensitive channels when incorporated in to the Slo3 tail. Thus, only two limited regions of the tail, B and C, confer calcium sensing properties. Both chimera A tail and D tail shift the starting position of the G-V curve along the voltage axis, but calcium ion has very little effect on the magnitude of the shift. this indicates that in addition to conferring calcium sensitivity, distinct regions of the tail play a role in determining the voltage range of activation of the channel, perhaps by transducing an allosteric interaction of tail and core.

Chimera A, a 93 aa region of mSlo1 tail between S9 and S10 N-terminal to the Calcium Bowl, was also considerably larger than either of the regions that conferred calcium sensitivity. Channels with this tail construct showed no significant response to calcium. However, the voltage range of activation of channels with the chimera tail regions, with a V50 in zero calcium 40 mV more positive than that obtained with the Slo3 tail. In addition chimera A tail showed a slightly reduced G-V slope, quite similar to the decrease in slope seen in 0  $\mu$ M calcium with wild-type mSlo1 tail (Stefani *et al.*, *Proc. Natl. Acad.Sci (USA)* 94:5427-5431 (1997); Cui *et al.*, *J.Gen.Physiol.* 109:647-673 (1997)). A similar effect of region A in shifting the voltage operating range can be seen in comparing channels formed with chimera ABCD tail versus chimera BCD tail: the V50 of chimera ABCD tail + Slo1 core is shifted approximately +60 to +80 mV versus chimera BCD tail at all  $[Ca^{2+}]$ . Viewed simply as a voltage-dependent channel in the absence of calcium ion, these results suggest region A could be an inhibitory domain responsible for setting the voltage range of activation to very positive values in Wild-type Slo1 channels.

Chimera D, a 98 residue region C-terminal to S10 was the largest single domain transplanted. Like chimera A, channels formed with chimera D tail + Slo1 core also showed no sensitivity to calcium ion. However, the voltage range of activation was repositioned approximately -40 mV relative to that of the Slo3 tail - Slo1 core channels. Although this shift is in the opposite direction of that conferred by chimera A tail, the net effect of having both regions, A and B, is apparently inhibitory, because including both regions (in chimera ABCD tail) produced channels with a very positively shifted current/voltage relation. It is inferred than both region A and B may include, or

allosterically influence, the transduction interface between core and tail. In contrast, regions B and C may influence the transduction interface only in a calcium-dependent allosteric manner.

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding a polypeptide monomer of a pH sensitive potassium channel, the monomer:

5 (i) having a calculated molecular weight of between 120-156 kDa;  
(ii) having a unit conductance of approximately 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte;

10 (iii) having increased activity above approximately intracellular pH of 7.1; and

(iv) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18.

15 2. An isolated nucleic acid of claim 1, wherein the nucleic acid encodes mSlo3.

3. An isolated nucleic acid of claim 1, wherein the nucleic acid encodes hSlo3.

20 4. An isolated nucleic acid of claim 1, wherein the nucleic acid encodes SEQ ID NO:1.

25 5. An isolated nucleic acid of claim 1, wherein the nucleic acid encodes SEQ ID NO:16 or 18.

6. An isolated nucleic acid of claim 1, wherein the nucleic acid selectively hybridizes under moderate stringency hybridization conditions to SEQ ID NO:2.

30 7. An isolated nucleic acid of claim 1, wherein the nucleic acid selectively hybridizes under moderate stringency hybridization conditions to SEQ ID NO:4, SEQ ID NO:17, or SEQ ID NO:19.

8. An isolated nucleic acid sequence of claim 1, wherein the nucleic acid has a nucleotide sequence of SEQ ID NO:2.

9. An isolated nucleic acid sequence of claim 1, wherein the nucleic acid has a nucleotide sequence of SEQ ID NO:4, SEQ ID NO:17, or SEQ ID NO:19.

10. An isolated nucleic acid of claim 1, wherein the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions to the same sequence as the primer sets selected from the group consisting of:

CTCGAACTCCCTAAAATCTTACAGAT (SEQ ID NO:8) and  
TTCCGTTGAGCCAGGGGTCACCAGAATT (SEQ ID NO:9);  
TCTGCTTTGTGAAGCTAAATCT (SEQ ID NO:10) and  
TTTCAAAGCCTCTTTAGCGGTAA (SEQ ID NO:11); and  
TTATGCCTGGATCTGCACTCTACATG (SEQ ID NO:12) and  
ATAGTTTCCGTCTACTACCGAAA (SEQ ID NO:13).

11. An isolated nucleic acid of claim 1, wherein the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions to the same sequence as the primer sets selected from the group consisting of:

GGCAGCGCTCATTCTTTCCTCCTT (SEQ ID NO:14) and  
TGCCCAAACCTCAACCCAAAATA (SEQ ID NO:15).

12. An isolated nucleic acid encoding at least 15 contiguous amino acids from a pH sensitive potassium channel polypeptide monomer, said monomer having an amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, SEQ ID NO:18 and conservatively modified variants thereof.

13. The isolated nucleic acid of claim 12,  
wherein said nucleic acid encodes a pH sensitive potassium channel polypeptide monomer having:

(i) a unit conductance of 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; and

(ii) a molecular weight of between 120-156 kDa; and

(iii) increased activity above an intracellular pH of 7.1;

wherein said nucleic acid either:

(i) selectively hybridizes under moderate stringency hybridization conditions to a nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17,

5 SEQ ID NO:19; or

(ii) encodes a protein which could be encoded by a nucleic acid that selectively hybridizes under moderate stringency hybridization conditions to a nucleotide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17, SEQ ID NO:19.

10 14. An isolated nucleic acid encoding a polypeptide monomer of a pH sensitive potassium channel, the sequence:

(i) encoding a monomer having a core domain that has greater than 60% amino acid sequence identity to amino acids 35-641 of a Slo3 core domain as measured using a sequence comparison algorithm; and

15 (ii) specifically binding to polyclonal antibodies raised against the core domain of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18.

15 15. An isolated nucleic acid of claim 14, wherein the Slo3 has a sequence of SEQ ID NO:1.

20

16. An isolated nucleic acid of claim 14, wherein the Slo3 has a sequence of SEQ ID NO:16 or SEQ ID NO:18.

25 17. An isolated polypeptide monomer of a pH sensitive potassium channel, the monomer:

(i) having a calculated molecular weight of between 120-156 kDa;

(ii) having a unit conductance of approximately 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte;

30 (iii) having increased activity above approximately intracellular pH of 7.1; and

(iv) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16 OR SEQ ID NO:18.

18. An isolated monomer of claim 17, wherein the monomer has an amino acid sequence of mSlo3.

19. An isolated monomer of claim 17, wherein the monomer has an amino acid sequence of hSlo3.

20. An isolated monomer of claim 17, wherein the monomer has an amino acid sequence of SEQ ID NO:1.

21. An isolated monomer of claim 17, wherein the monomer has an amino acid sequence of SEQ ID NO:16 or SEQ ID NO:18.

22. An antibody that selectively binds to mSlo3.

23. An antibody of claim 22, wherein the mSlo3 has an amino acid sequence of SEQ ID NO:1.

24. An antibody that selectively binds to hSlo3.

25. An antibody of claim 24, wherein the hSlo3 has an amino acid sequence of SEQ ID NO:16 or SEQ ID NO:18.

26. An expression vector comprising a nucleic acid encoding a polypeptide monomer of a pH sensitive potassium channel, the monomer:

(i) having a calculated molecular weight of between 120-156 kDa;  
(ii) having a unit conductance of approximately 80-120 pS when the monomer is in a functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte;

(iii) having increased activity above approximately intracellular pH of 7.1; and

(iv) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, or SEQ ID NO:18.

27. A host cell transfected with the vector of claim 26.

28. A method for identifying a compound that increases or decreases ion flux through a pH sensitive potassium channel, the method comprising the steps of:

(i) contacting the compound with a eukaryotic host cell or cell membrane in which has been expressed a pH sensitive potassium channel monomer polypeptide:

(a) having a calculated molecular weight of between 120-156 kDa;

(b) having a unit conductance of approximately 80-120 pS when the monomer is in the functional tetrameric form of a potassium channel and is expressed in a *Xenopus* oocyte; and

(c) specifically binding to polyclonal antibodies generated against SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16 or SEQ ID NO:18; and

(ii) determining the functional effect of the compound upon the cell or cell membrane expressing the pH sensitive potassium channel.

29. A method of claim 28, wherein the increased or decreased flux of ions is determined by measuring whole cell conductance.

30. A method of claim 28, wherein the pH sensitive potassium channel monomer polypeptide is recombinant.

31. A method of claim 28, wherein the pH sensitive potassium channel monomer polypeptide is mSlo3.

32. A method of claim 28, wherein the pH sensitive potassium channel monomer polypeptide is hSlo3.

33. A method of claim 28, wherein the pH sensitive potassium channel monomer polypeptide has an amino acid sequence of SEQ ID NO:1.

34. A method of claim 28, wherein the pH sensitive potassium channel monomer polypeptide has an amino acid sequence of SEQ ID NO:16 or SEQ ID NO:18.

35. A method of detecting the presence of Slo3 in mammalian tissue, the method comprising the steps of:

- (i) isolating a biological sample;
- (ii) contacting the biological sample with a Slo3-specific reagent
- 5 that selectively binds to Slo3; and,
- (iii) detecting the level of Slo3-specific reagent that selectively associates with the sample.

36. A method of claim 35, wherein the Slo3 specific reagent is selected  
10 from the group consisting of: Slo3 specific antibodies, Slo3 specific oligonucleotide primers, and Slo3 nucleic acid probes.

37. A method of claim 35, wherein the sample is from a human.

38. In a computer system, a method of screening for mutations of Slo3  
15 genes, the method comprising the steps of:

- (i) receiving input of at least about 30 nucleotides of first nucleic acid sequence encoding a pH sensitive potassium channel protein having a nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:17, or SEQ ID NO:19 and  
20 conservatively modified versions thereof;
- (ii) comparing the first nucleic acid sequence with a second nucleic acid sequence having substantial identity to the first nucleic acid sequence; and
- (iii) identifying nucleotide differences between the first and second nucleic acid sequences.

39. The method of claim 38, wherein the second nucleic acid sequence  
25 is associated with a disease state.

40. In a computer system, a method for identifying a three-dimensional  
30 structure of Slo3 proteins, the method comprising the steps of:

- (i) receiving input of at least about 10 amino acids of an amino acid sequence of a pH sensitive potassium channel monomer or at least about 30 nucleotides of a nucleotide sequence of a gene encoding the protein, the protein having an

amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, SEQ ID NO:18,  
and conservatively modified versions thereof; and

(ii) generating a three-dimensional structure of the protein  
encoded by the amino acid sequence.

5

41. The method of claim 40, wherein said amino acid sequence is a  
primary structure and wherein said generating step includes the steps of:

(i) forming a secondary structure from said primary structure using  
energy terms encoded by the primary structure; and

10

(ii) forming a tertiary structure from said secondary structure using  
energy terms encoded by said secondary structure.

15

42. The method of claim 40, wherein said generating step includes the  
step of forming a quaternary structure from said tertiary structure using anisotropy terms  
encoded by the tertiary structure.

20

43. The method of claim 41, wherein said generating step further  
includes the step of forming a quaternary structure from said tertiary structure using  
anisotropy terms encoded by the tertiary structure.

44. The method of claim 40, further comprising the step of identifying  
regions of the three-dimensional structure of the protein that bind to ligands and using the  
regions to identify ligands that bind to the protein.

## SEQUENCE LISTING

### mSlo3 amino acid sequence (SEQ ID NO:1):

MSQTLDSLNLQKELTETSTCTIEIQAAFILSSLATFFGGGLIILFLFRIALKSSRSWKYVKGPRGLLELFSSRR  
 5 IEANPLRKLYFHGVFRQRIEMLLSAQTVVGQVLVILVFVLSIGSLVIYFINSMDPVRRCSSYEDKIVHGDLS  
 FNAFFSFYFGLRFWAAEDKIKFWLEMNSIVDIFTIPPTFISYYLKSNNWLGLRFLRALRLELPKILQILQVI  
 KTSNSVKLSKLLSIVISTWFTAAGFLHLVENSQDPWLNGRNSQTMSYFESIYLVTTATMSTVGFQDVVAKTSL  
 GRIFIVFFTLGSLILFANYIPEMVELFSTRKKYTKPYEAVKGKKFIVVCGNITVDSVTAFLRNFLHWKSGEI  
 NIEIVFLGETLPCLELETLLKCHTSCTNFVCGTALKFEDLKRVAVERSEACLILANHFCSLDHEDNSNIMR  
 10 VLSIKNYYPQTRVIIQILQSQNKVFLSKIPNWDWSAGDNILCFABELKLGFIAGQCLVPGLCTFLTTLFIEQN  
 QKVFPKHPWQKHFLNGLKNKILTQRLSNDFVGMTFPQVSRLCFVKLNLMLIAIQHKPFFHSCCTLILNPSSQ  
 VRLNKDTLGFFIADSSKAVKRAFFYCSNCHSDVCNPELIGKCNCKIKSRQQLIAPTIMVMKSSSLDFTTSSH  
 IHASMSTEIHTCFSREQPSLITITITNRPTTNDTVDTDMLDSSGMFHWCRAMPLDKVVLKRSEKAKHEFQNH  
 IVVCVFGDAQCTLVGLRNFMPLRASNYTRQELKDIVFIGSLEYFQREWRFLRNFPKIHIMPGSALYMGDLI  
 15 AVNVEQCSMCVILATPYKALSSQILVDTEAIMATLNIQSLRITSPTPGSSKSEVKPSSAFDSKERKQRYKQI  
 PILTELKNPSNIHFIEQMGGLDGMKGTSLSLSTSFSTGAVFSDTFLDSLATSFYNYHVVELLQMLVTGGI  
 SSEMEHYLVKEKPYKTTDDYEAIKSGRTRCKLGLSLDQTVLSGINPRKTFGQLFCGSLDNFGILCVGLYRM  
 IDEEESQEHKRFVITRPSNECHLLPSDLVFCAIPFNTTCGKSDSSPFNFRLLKTTLQTRRRHWPRGRISSIR  
 TMPTSPTIFTQSTTRERGGSLSTTTPESILWTR  
 20

### mSlo3 nucleotide sequence (SEQ ID NO:2):

ATGTCTCAAACATTGCTAGACAGTTTAAATCAGAAGGAGTTGACGGAACGTCATGTACAATCGAAATCCAG  
 GCAGCGTTCATTCTTCTCCTTGGCGACTTTCTTCGGGGGACTCATCATCTTATTCCTTTTCAGAATAGCC  
 TTGAAAAGCTCAAGAAGTTGGAATACGTCAAGGGCCAAGAGGACTCTTGGAACATTTCTCATCACGTAGA  
 25 ATCGAGGCTAATCCTTTGAGGAACTTTACTTTTCATGGAGTATTTTCGTCAGCGCATCGAAATGCTGCTTTCT  
 GCACAGACCGTCGTGGGGCAAGTGTGGTGATCCTTGTCTTTGTACTAAGCATCGGGTCTCTTGTGATCTAT  
 TTCATCAATTCAATGGATCCTGTTTCAAGGTGTTCTTCATATGAAGACAAAATTGTCCATGGGGATTGAGT  
 TTCAACGCTTTCTTTAGCTTCTATTTTGGGTTGAGGTTTTGGGCAGCTGAAGACAAGATCAAGTTCTGGTTG  
 GAGATGAATTCATTTGTAGACATTTTTACCATCCCGCCAACCTTTATTTCTTATTATTTGAAGAGTAATTGG  
 30 CTAGGTTTGAGATTTCTAAGAGCTCTGCGGTTGCTCGAACTCCCTAAAAATCTTACAGATCCTACAAGTCATC  
 AAGACCAGCAATTCAGTGAAGCTTTCCAACTGTTGTCAATAGTTATCAGTACCTGGTTACGGGCAGCAGGA  
 TTCCTTCACCTGGTGAAAATTCTGGTGACCCCTGGCTCAACGGAAGAACTCACAGACTATGTCATACTTT  
 GAGTCTATTTATCTGGTGACAGCAACAATGTCAACTGTTGGCTTTGGGGACGTGGTGGCCAAGACATCCCTA  
 GGACGGATTTTCATTGTTTTCTTACCCTTGGGAGTTTGATACTATTTGCAAACTACATTCCAGAAATGGTG  
 35 GAGCTCTTTTCTACCAGGAAGAAATACACCAAGCCCTACGAAGCAGTCAAAGGAAAAAAGTTCATCGTGGTC  
 TGTGGAAACATCACAGTTGACAGTGTTACTGCTTTCCTGAGGAATTTTCTCCACTGGAAGTCCGGGGAAATC  
 AATATTGAGATCGTATTCCTTGGAGAGACTCTCCCTTGCTTGAAGTGGAGACCTTACTGAAGTGCCACACA  
 TCCTGTACCAACTTCGTATGCGGCACCGCACTGAAGTTCGAGGATCTGAAGCGAGTTGAGTGGAGAACTCG  
 GAGGCGTGCCGTGATTCTAGCCAACCATTTCTGTAGTGACTTACATGACGAAGACAACCTCAAACATTATGAGG  
 40 GTGCTCTCGATCAAGAACTATTATCCACAGACCAGAGTCATCATTAGATACTTCAGTCTCAAACAAGGTT



TTCTGTCAAAAATCCCCAACTGGGACTGGAGTGTGGAGACAATATCCTCTGCTTTGCAGAGCTAAAGCTC  
 GGATTTATCGCCCAAGGCTGCTTGGTGCCAGGGCTGTGCACCTTTCTCACGACTCTGTTTCATTGAACAAAAC  
 CAAAAGGTTTTTCTAAACATCCCTGGCAAAAACATTTCTTGAATGGCTTGAAGAACAAGATTCTGACACAG  
 CGCCTCTCTAACGACTTCGTGGGGATGACATTTCCCAGGTCTCCCGGCTCTGCTTTGTGAAGCTAAATCTC  
 5 ATGCTGATCGCCATCCAACACAAGCCCTTCTTTACAGTTGTTGCACTCTGATACTAAACCCATCATCCCAA  
 GTGAGGCTGAATAAGGACACCTTAGGGTTCTTCATTGCGGACTCCTCCAAAGCCGTCAAAAGGGCTTTCTTT  
 TACTGTTCCAACGTGTCACAGCGATGTGTGCAATCCTGAGCTAATTGGAAAGTGAAGTGTAAATCAAGAGC  
 CGACAACAACCTCATAGCACCGACCATCATGGTGATGAAAAGCAGCTTGACCGATTTACCACTTCTTCACAC  
 ATCCACGCTTCTATGTCAACAGAAATTCACACTTGTTTTTCAAGAGAACAGCCTAGTTTGATCACCATTACA  
 10 ACCAACAGACCAACGACAAACGACACAGTGGATGATACCGACATGCTGGACAGCAGTGGCATGTTTCACTGG  
 TGCAGAGCAATGCCCTTGGACAAGGTGGTTCTGAAACGAAGTGAGAAGGCAAAACACGAGTTTCAGAACCAC  
 ATTGTAGTATGCGTGTGTTGGAGATGCCCAATGTACCCTGGTGGGGCTTCGGAATTCGTGATGCCCTGAGA  
 GCCAGCAACTACCCCGGCGAGGAGCTGAAGGACATTGTTTTTATTGGGTCTCTGGAGTACTTCCAGAGAGAA  
 TGGCGATTTCTCCGAACTTTCCCAAGATACACATTATGCCTGGATCTGCACTCTACATGGGAGATCTGATT  
 15 GCAGTCAATGTAGAGCAGTGTCTATGTGCGTCATCTTAGCCACACCCTACAAGGCACTGAGCAGCCAGATT  
 CTGGTGGACACAGAGGCCATCATGGCCACCCTCAACATCCAGTCCCTGCGGATCACCAGTCTTACTCCAGGG  
 TCTTCAAAGTCAGAAGTAAAGCCATCATCTGCCTTTGATAGTAAAGAAAGGAAGCAAAGATACAAACAGATC  
 CCCATTCTCACTGAAGTGAAGTAAAGTCCCTCCAACATCCACTTTATTGAGCAGATGGGCGGACTGGATGGAATG  
 CTCAAAGGGACTAGCTTGATCTCAGCACTTCTTTCTCCACCGGTGCTGTCTTTTCAGACACCTTCTTGAT  
 20 TCTCTCCTGGCCACGTCTTCTACAATTACCATGTGCTGGAATTACTTCAGATGCTAGTGACTGGAGGCATA  
 AGCTCTGAGATGGAACACTATTTGGTTAAGGAGAAGCCCTATAAGACAACCTGACGACTATGAGGCAATCAAG  
 TCTGGGAGGACGCGGTGTAAGCTGGGACTCCTCTCTTTAGACCAAACCGTCTATCAGGCATTAATCCAAGA  
 AAAACCTTTGGACAGCTGTTCTGTGGCTCATTGGATAATTTCCGGATCCTATGTGTGCGCTTATACCGTATG  
 ATTGATGAAGAGGAACCCAGCCAAGAACACAAAAGGTTTGTGATCACCAGGCCATCCAATGAGTGCCACCTG  
 25 CTGCCCTCAGATCTCGTGTGTTTGTGCCATCCCTTTCAACACCACCTGTGGCAAATCAGACAGCAGTCCCTTC  
 AATTTACAGGCTCAAAACAACCTCTACAAACGCGACGACGCCATTGGCCCAGGGGTGGAATTTCTTCGATTGCG  
 ACCATGCCGACGAGTCCCACGATCTTTACCCAGTCGACGACACGGGAGAGAGGTGGTCTCAGCACCACTACT  
 CCCGAGTCTATCCTTTGGACACGTTAG

30 **hSlo3 amino acid sequence (SEQ ID NO:3):**

GLAALILSSFVTLFSLGLISLLIFRLIWRXVKKWQIIKGTGIILELFTSGTIARSHVRSLSLHFQGGQFRDHIEML  
 LSAQTFVGQVLVILVFVLSIGSLIIYFINSADPVGTLFII

**hSlo3 nucleotide sequence (SEQ ID NO:4):**

35 GGCTTGGCAGCGCTCATTCTTCTCCTTTGTGACCCTCTTCAGTGGACTCATCAGCCTGTTGATCTTCAGG  
 CTGATCTGGAGAYCTGTTAAAAATGGCAATCATCAAGGGAACAGGAATTATCTTGGAAGTGTTCACATCA  
 GGTACCATCGCTAGGAGCCATGTAAGAAGCCTCCACTTCCAGGGACAATTCGTGATCATATAGAAATGTTG  
 CTTTCAGCCCAGACCTTTGTGGGGCAAGTGTGGTGATCCTTGTCTTTGTACTAAGCATTGGGTCTCTTATA  
 ATCTATTTTCATCAATTCWGCTGACCCTGTTGGAACGCTGTTTCATCATATGAAGACAAAACCATTCCTATTGA  
 40 TTTGGTTTTCAATGCTTTCTTTAGTTTCTATTTGGGTTGAGGTTTGGCAAAGCC

**hSlo3-a amino acid sequence (SEQ ID NO:5)**

GLAAFILSSFVTLFSGLLIFRLIWRXVKKWQIIKGTGIILELFTSGTIARSHVRSLSHFQGGFRDHIEML  
LSAQTFVGQVLVILVFVLSIGSLIIYFINSADPVGTLFII

5

**hSlo3-b amino acid sequence (SEQ ID NO:6)**

GLAALILSSFVTLFTGLISLLIFRLIWRXVKKWQIIKGTGIILELFTSGTIARSHVRSLSHFQGGFRDHIEML  
LSAQTFVGQVLVILVFVLSIGSLIIYFINSADPVGTLFII

**hSlo3-c amino acid sequence (SEQ ID NO:7)**

GLAALILSSFVTLFSGLLIFRLIWRXVKKWQIIKGTGIILELFTSGTIARSHVRSLSHFQGGFRDHIEML  
LSAQTFVGQVLVILVFVLSIGSLIIYFINSMDPVGTLFII

**hSlo3-1 amino acid sequence (SEQ ID NO:16)**

15 MFQTKLRNETWEDLPKMSCTTEIQAAFILSSFVTFSSGLIILLIFRLIWRSVKKWQIIKGTGIILELFTSGT  
IARSHVRSLSHFQGGFRDHIEMLLSAQTFVGQVLVILVFVLSIGSLIIYFINSADPVGSCSSYEDKTIPIDLV  
FNAFFSFYFGLRFMAADDKIKFWLEMNSIVDIFTIPPTFISYYLKSNNWGLRFLRALRLLELPQILQILRAI  
KTSNSVKFSKLLSIILSTWFTAAGFIHLVENSGBPWLKGRNSQNI SYFESIYLMATTSTVGFQGDVVAKTSL  
GRTFIMFFTLGSLILFANYIPEMVELFANKRKYTSSYEALKGKKFIVVCGNITVDSVTAFLRNFLRDKSGEI  
20 NTEIVFLGETPPSLELETIFKCYLAYTTFISGSAMKWEDLRRVAVESAEACLI IANPLCSDSHAEDISNIMR  
VLSIKNYDSTTRIIIIQILQSHNKVYLPKIPSWNWDTGDNII CFAELKLGFI AQGCLVPGLCTFLTSLFVEQN  
KKVMPKQTWKKHFLNSMKNKILTQRLSDDFAGMSFPEVARLCFLKMYLLLLIAIEYKSLFTDGFGLILNPPP  
QVRIRKNTLGFFIAETPKDVRRALFYCSVCHDDVFPELITNCGCKSRSRQHITVPSVKRMKKCLKGISSRI  
SGQDSPPRVSASTSSISNFTTRTLQHDVEQDSDQLDSSGMFWCKPTSLDKVTLKRTGKSKYKFRNHIVACV  
25 FGDHSAAPMGLRNFVMPLRASNYTRKELKDIVFIGSLDYLQREWRFLRNFPQIYILPGCALYSGDLHAANIE  
QCSMCAVLSPPPQPSSNQTLDTEAIMATLTIGSLQIDSSSDPSPSVSEETPGYTNGHNEKSNCRKVPILTE  
LKNPSNIHFIEQLGGLEGSLQETNLHLSTAFSTGTVFSSSFLDLLATAFYNYHVLELLQMLVTGGVSSQLE  
QHLDKDKVYGVADSCSTLLSGRNRCKLGLLSLHETILSDVNPRNTFGQLFCGSLDLFGILCVGLYRIIDEEE  
LNPENKRFVITRPA NEFKLLPSDLVFCAPFSTACYKRNEEFSLQKSYEIVNKASQTTEDTFRHKLSSHPLI  
30 QLLRHCIHQSI L TSRELTPSLFLSK

**hSlo3-1 nucleotide sequence (SEQ ID NO:17)**

ATGTTTCAGACTAAGCTACGAAATGAACTTGGGAAGACTTGCCAAAAATGTCCTGCACAACTGAGATCCAA  
GCAGCATTCATTCTCTCTCTCTTGTGACCTTCTTCAGTGGACTCATCATCCTGTTGATCTTCAGGCTGATC  
35 TGGAGATCTGTTAAAAAATGGCAAATCATCAAGGGAACAGGAATTATCTTGGAAGTTCACATCAGGTACC  
ATCGCTAGGAGCCATGTAAGAAGCCTCCACTTCCAGGGACAATTTCTGTGATCATATAGAAATGTTGCTTTCA  
GCCCAGACCTTTGTGGGGCAAGTGTGGTGATCCTTGTCTTTGTACTAAGCATTGGGTCTCTTATAATCTAT  
TTCATCAATTCTGCTGACCCTGTTGGAAGCTGTTTCATCATATGAAGACAAAACCATTCCTATTGATTTGGTT  
TTCAATGCTTTCTTTAGTTTCTATTTTGGATTGAGGTTTATGGCAGCTGATGACAAGATCAAGTTCTGGCTG

GAGATGAATTCAATCGTAGACATCTTTACCATCCCACCAACCTTTATTTCTTATTATTTGAAGAGCAATTGG  
 CTAGGTTTAAAGGTTCCCTAAGAGCCTTGCGCCTGCTAGAACTCCCTCAAATCTTGCAAATTCTACGAGCCATC  
 AAGACCAGTAACTCAGTGAAGTTTTCCAACTGCTGTCAATAATTCTCAGTACCTGGTTCACAGCTGCGGGA  
 TTCATTACCTGGTGGAAAATTCTGGTGATCCCTGGCTCAAAGGTAGAAATTCACAGAATATATCATATTTT  
 5 GAGTCAATTTACCTGGTCATGGCAACAACGTCAACCGTTGGATTTGGAGATGTGGTAGCCAAGACATCCTTA  
 GGACGGACCTTCATCATGTTCTTCACACTGGGGAGTTTGATATTATTTGCGAACTATATACCTGAAATGGTG  
 GAACTGTTTGCTAACAAGAGGAAATACACCAGTTCMTATGAAGCACTCAAAGGAAAGAAGTTTATTGTGGTC  
 TGTGGAAACATCACTGTGGACAGTGTGACCGCTTTCCTGAGGAATTTCTCCGCGACAAGTCAGGAGAGATC  
 AACACTGAAATTGTTTTCTGGGAGAAACCCCTCCTTCTTTGGAACCTGAAACCATATTTAAATGCTACTTG  
 10 GCCTACACAACGTTTCAATTTCTGGATCTGCAATGAAGTGGGAGGATCTGAGGCGAGTTGCGGTGGAATCTGCA  
 GAGGCATGCCTGATTATAGCCAATCCTTTGTGCAGTGATTCCCATGCTGAAGATATTTCCAACATTATGAGG  
 GTGCTCTCTATCAAGAACTATGATTCTACCACCAGAATCATCATACAGATACTGCAATCCCATACAAGGTT  
 TATCTGCCAAAGATTCCCAGCTGGAACCTGGGACACCGGAGACAACATCATCTGCTTTGCTGAATTAACCTT  
 GGATTTATCGCCCAAGGCTGTTTGGTGCCAGGCTTGTGTACCTTCCTAACATCTCTATTTGTGGAGCAAAAC  
 15 AAAAAAGTTATGCCTAAACAGACCTGGAAGAAACACTTCTTGAATAGCATGAAAAACAAAATTCTGACCCAA  
 CGTCTCTCTGATGACTTTGCTGGAATGAGCTTTCCTGAAGTTGCCCGGCTCTGCTTTCTGAAGATGTACCTC  
 CTGTTGATAGCCATCGAATACAAGTCCCTCTTTACGGATGGTTTCTGTGGTCTGATACTAAATCCACCTCCA  
 CAAGTGAGGATACGTAAGAACACATTAGGGTTCTTTATTGCTGAAACTCCAAAGGACGTCAGAAGAGCCTTG  
 TTTTACTGTTTCAGTCTGTCTGATGATGTGTTTCTTCTGAGCTAATTACAAACTGTGGCTGCAAAAGCAGA  
 20 AGCCGGCAGCACATCACAGTGCCATCGGTAAAGAGAATGAAAAAATGTCTGAAGGGAATCTCCTCTCGTATA  
 TCAGGGCAGGATTCTCCGCCAAGGGTATCTGCAAGCACTTCGAGCATATCAAACCTTCACCACCAGGACTCTT  
 CAACATGATGTAGAACAAGATTCTGACCAGCTTGATAGCAGTGCGATGTTTCACTGGTGCAAAACCAACCTCT  
 TTGGACAAGGTGACTCTGAAACGAACTGGCAAGTCAAAGTATAAGTTTCGGAACCATATTGTAGCATGTGTA  
 TTTGGAGATGCCCCACTCAGCCCCGATGGGGCTTCGGAACCTTTGTAATGCCCTTGAGAGCCAGCAACTATACC  
 25 AGGAAGGAGCTGAAGGACATAGTGTTTCTTGGGTCTCTGGACTATCTACAGAGAGAATGGCGATTTCTCCGG  
 AATTTTCCCCAGATATACATTCTGCCTGGATGTGCACTTTATTCTGGAGACCTCCATGCGGCCAACATAGAG  
 CAATGCTCCATGTGTGCTGTCTTGTCCCCCCCCACCCAGCCATCAAGCAACCAGACTTTGGTAGACACAGAA  
 GCCATCATGGCAACCCTCACCATCGGATCCTTGCAAATTGACTCCTCCTCTGACCCGTCACCCTCAGTGTCA  
 GAGGAGACTCCAGGTTACACAAATGGACATAATGAGAAATCAAACCTGCCGAAAAGTCCCTATCCTTACTGAA  
 30 CTGAAAAATCCTTCCAACATTCACTTTATTGAACAGCTTGGTGGACTGGAAGGGTCCCTCCAAGAAACAAAT  
 CTGCATCTCAGCACTGCCTTTTCTACGGGCAGTGTTTTTTCCAGCAGCTTCTTGGATTCTCTGCTGGCCACG  
 GCCTTCTACAATTATCATGTCCTGGAATTGCTTCAGATGCTGGTGACAGGAGGAGTAAGTTCTCAGCTGGAA  
 CAACATTTAGATAAGGATAAAGTCTATGGTGTGGCAGATAGCTGCACGTCGCTCTTGTCTGGAAGAAACCGG  
 TGTAAAGCTGGGGCTTCTGTCCCTTACACGAAACATTTTATCAGACGTTAATCCAAGAAACACCTTTGGACAA  
 35 CTGTTCTGTGGCTCATTAGATCTTTTTGGAATCCTGTGTGTTGGCTTATACCGAATAATTGATGAAGAGGAG  
 CTCAACCCAGAAAACAAAAGTTTGTGATCACCCGGCCAGCCAATGAGTTCAAGCTGCTGCCTTCAGATCTT  
 GTGTTTTGTGCCATACCCCTTCAGCACTGCTTGTATAAAAGGAATGAAGAGTTCTCATTGCAAAAGTCATAT  
 GAAATTGTAAATAAAGCATCACAGACAACAGAGGACACATTTCAGACACAAATTGTCTCCACCCATTGATT  
 CAGTTACTGAGACATTGTATTACCAGTCTATTCTTACCAGCCGAGAACTAACTCCCTCTCTTTTCTTAAGC  
 40 AAATAGG

### hSlo3-2 amino acid sequence (SEQ ID NO:18)

MFQTKLRNETWEDLPKMSCTTEIQAAFILSSFVTFSSGLIILLIFRLIWRSVKKWQIIKGTGIIILELFTSGT  
IARSHVRSLSHFQGGFRDHIEMLLSAQTFVGQVLVILVFLVLSIGSLIIYFINSADPVGSCSSYEDKTIPIIDL  
FNAFFSFYFGLRFMAADDKIKFWLEMNSIVDIFTIPTTFISYYLKSNNWLGLRFLRALRLLELPQILQILRAI  
5 KTSNSVKFSKLLSIIILSTWFTAAGFIHLVENSGBPWLKGRNSQNI SYFESIYLMATTSTVGFQDVVAKTSL  
GRTFIMFFTLGSLILFANYIPEMVELFANKRKYTSSYEALKGKKFIVVCGNITVDSVTAFLRNFLRDKSGEI  
NTEIVFLGETPPSLELETIFKCYLAYTTFISGSAMKWEDLRRVAVESAEACLIIANPLCSDSHAEDISNIMR  
VLSIKNYDSTTRIIIIQILQSHNKVYLPKIPSWNWDTGDNIIICFAELKLGFI AQGCLVPGLCTFLTSLFVEQN  
KKVMPKQTWKKHFLNSMKNKILTQRLSDDFAGMSFPEVARGLILNPPPQVRIRKNTLGFFIAETPKDVRRAL  
10 FYCSVCHDDVFIPELITNCGCKSRSRQHITVPSVKRMKKCLKGISSRISGQDSPRVSASTSSISNFTTRTL  
QHDVEQDSDQLDSSGMFWCKPTSLDKVTLKRTGSKYKFRNHIVACVFGDAHSAPMGLRNFVMPLRASNYT  
RKELKDIVFIGSLDYLRQEWRFNRFPQIYILPGCALYSGDLHAANIEQCSMCAVLSPPPQPSNQTLVDTE  
AIMATLTIGSLQIDSSSDPSPSVSEETPGYTNGHNEKSNCRKVPILTELKNPSNIHFIEQLGGLEGSLQETN  
LHLSTAFSTGTVFSSSFLDLSLLATAFYNYHVLELLQMLVTGGVSSQLEQLDKDKVYGVADSDCTSLLSGRNR  
15 CKLGLLSLHETILSDVNPRNTFGQLFCGSLDLFGILCVGLYRIIDEEELNPENKRFVITRPA NEFKLLPSDL  
VFCAIPFSTACYKRNEEFSLQKSYEIVNKASQTTEDTFRHKLSSHPLIQLLRHCIHQSI L TSRELTPSLFLS  
K

### hSlo-3-2 nucleotide sequence (SEQ ID NO:19)

20 ATGTTTCAGACTAAGCTACGAAATGAACTTGGGAAGACTTGCCAAAAATGTCCTGCACAACTGAGATCCAA  
GCAGCATTCATTCTCTCTTCTTGTGACCTTCTTCAGTGGACTCATCATCCTGTTGATCTTCAGGCTGATC  
TGGAGATCTGTTAAAAAATGGCAAATCATCAAGGGAACAGGAATTATCTTGAACTGTTACATCAGGTACC  
ATCGCTAGGAGCCATGTAAGAAGCCTCCACTTCCAGGGACAATTTCTGTGATCATATAGAAATGTTGCTTTCA  
GCCCAGACCTTTGTGGGGCAAGTGTGGTGATCCTTGTCTTTGTACTAAGCATTGGGTCTCTTATAATCTAT  
25 TTCAATCAATTCTGCTGACCCTGTTGGAAGCTGTTTCATCATATGAAGACAAAACCATTCCTATTGATTTGGTT  
TTCAATGCTTTCTTTAGTTTCTATTTTGGATTGAGGTTTATGGCAGCTGATGACAAGATCAAGTTCTGGCTG  
GAGATGAATTCAATCGTAGACATCTTACCATCCCACCAACCTTTATTTCTTATTATTGAAGAGCAATTGG  
CTAGGTTTAAGGTTCTAAGAGCCTTGCGCCTGCTAGAACTCCCTCAAATCTTGCAAATCTACGAGCCATC  
AAGACCAGTAACTCAGTGAAGTTTTCCAAACTGCTGTCAATAATTCTCAGTACCTGGTTCACAGCTGCGGGA  
30 TTCATTACCTGGTGGAAAATTCTGGTGATCCCTGGCTCAAAGGTAGAAATTCACAGAATATATCATATTTT  
GAGTCAATTTACCTGGTCATGGCAACAACGTC AACCGTTGGATTGAGATGTGGTAGCCAAGACATCCTTA  
GGACGGACCTTCATCATGTTCTTCACACTGGGGAGTTTGATATTATTTGCGAACTATATACCTGAAATGGTG  
GAACTGTTTGCTAACAAGAGGAAATACACCAGTTTCTATGAAGCACTCAAAGGAAAGAGTTTATTGTGGTC  
TGTGGAACATCACTGTGGACAGTGTGACCGCTTTCCTGAGGAATTTCTCCGCGACAAGTCAGGAGAGATC  
35 AACACTGAAATGTTTTCTGGGAGAAACCCCTCCTTCTTTGGAACCTGAAACCATATTTAAATGCTACTTG  
GCCTACACAACGTTTCAATTTCTGGATCTGCAATGAAGTGGGAGGATCTGAGGCGAGTTGCGGTGGAATCTGCA  
GAGGCATGCCTGATTATAGCCAATCCTTTGTGCAGTGATTCCCATGCTGAAGATATTTCCAACATTATGAGG  
GTGCTCTCTATCAAGAAGTATGATTCTACCACCAGAATCATCATACAGATACTGCAATCCCATAAACAAGGTT  
TATCTGCCAAAGATTCCCAGCTGGAAGTGGGACACCGGAGACAACATCATCTGCTTTGCTGAATTTAAACTT  
40 GGATTTATCGCCCAAGGCTGTTTGGTGCCAGGCTGTGTACCTTCTTAACATCTCTATTTGTGGAGCAAAAC

AAAAAGGTTATGCCTAAACAGACCTGGGAAGAAAACACTTCTTGAATAGCATGAAAAACAAAATTCTGACCCAA  
CGTCTCTCTGATGACTTTGCTGGAATGAGCTTTCCTGAAGTTGCCCCGTGGTCTGATACTAAATCCACCTCCA  
CAAGTGAGGATACGTAAGAACACATTAGGGTCTTTATTGCTGAAACTCCAAAGGACGTGAGAAGAGCCTTG  
TTTTACTGTTTCAGTCTGTTCATGATGATGTGTTTCATTCTCTGAGCTAATTACAAACTGTGGCTGCAAAAGCAGA  
5 AGCCGGCAGCACATCACAGTGCCATCGGTAAAGAGAATGAAAAAATGTCTGAAGGGAATCTCCTCTCGTATA  
TCAGGGCAGGATTCTCCGCCAAGGGTATCTGCAAGCACTTCGAGCATATCAAACCTTCACCACCAGGACTCTT  
CAACATGATGTAGAACAAAGATTCTGACCAGCTTGATAGCAGTGGGATGTTTCACTGGTGCAAACCAACCTCT  
TTGGACAAGGTGACTCTGAAACGAACTGGCAAGTCAAAGTATAAGTTTCGGAACCATATTGTAGCATGTGTA  
TTTGGAGATGCCCACTCAGCCCCGATGGGGCTTCGGAACCTTTGTAATGCCCTTGAGAGCCAGCAACTATACC  
10 AGGAAGGAGCTGAAGGACATAGTGTTTCATTGGGTCTCTGGACTATCTACAGAGAGAATGGCGATTTCTCCGG  
AATTTTCCCCAGATATACATTCTGCCTGGATGTGCACTTTATTCTGGAGACCTCCATGCGGCCAACATAGAG  
CAATGCTCCATGTGTGCTGTCTTGTCCCCCCCCACCCAGCCATCAAGCAACCAGACTTTGGTAGACACAGAA  
GCCATCATGGCAACCCTCACCATCGGATCCTTGCAAATTGACTCCTCCTCTGACCCGTACCCCTCAGTGTCA  
GAGGAGACTCCAGGTTACACAAATGGACATAATGAGAAATCAAACCTGCCGAAAAGTCCCTATCCTTACTGAA  
15 CTGAAAAATCCTTCCAACATTCACTTTATTGAACAGCTTGGTGGACTGGAAGGGTCCCTCCAAGAAACAAAT  
CTGCATCTCAGCACTGCCTTTTCTACGGGCACCTGTTTTTTCCAGCAGCTTCTTGGATTCTCTGCTGGCCACG  
GCCTTCTACAATTATCATGTCCTGGAATTGCTTCAGATGCTGGTGACAGGAGGAGTAAGTTCTCAGCTGGAA  
CAACATTTAGATAAGGATAAAGTCTATGGTGTGGCAGATAGCTGCACGTCGCTCTTGTCTGGAAGAAACCGG  
TGTAAGCTGGGGCTTCTGTCTTACACGAAACCATTTTATCAGACGTTAATCCAAGAAACACCTTTGGACAA  
20 CTGTTCTGTGGCTCATTAGATCTTTTTGGAATCCTGTGTGTTGGCTTATACCGAATAATTGATGAAGAGGAG  
CTCAACCCAGAAAACAAAAGGTTTGTGATCACCCGGCCAGCCAATGAGTTCAAGCTGCTGCCTTCAGATCTT  
GTGTTTTGTGCCATACCCTTCAGCACTGCTTGTTATAAAAGGAATGAAGAGTTCTCATTGCAAAAGTCATAT  
GAAATTGTAATAAAGCATCACAGACAACAGAGGACACATTCAGACACAAATTGTCCTCCCACCCATTGATT  
CAGTTACTGAGACATTGTATTACACAGTCTATTCTTACCAGCCGAGAACTAACTCCCTCTCTTTTCCCTAAGC  
25 AAATAGT

## A PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES

### ABSTRACT OF THE DISCLOSURE


The invention provides isolated nucleic acid and amino acid sequences of  
5 Slo3, a pH sensitive potassium channel expressed in sperm; antibodies to Slo3; methods  
of screening for Slo3 inhibitors; and methods of screening for Slo3 homologs.

SF 171093 v1

# Figure 1A

mSkl	ISQTLLSLNQKETE..TSCTI.....EIQA...	35
mSkl	UDALLIPVTMEVP.....CDISRGQ.....	33
mSkl	MASGLIDTNFSSITANGMSGC...DQSTVEFLADDTDSFDFDADDCLKV...IKYVCE...	40
mSkl	IGGLIILFIFRI.....ALSSRSWYVKERGLLELFSSRIEANPLR...KLYT	83
mSkl	IGGLIFILFRTLKYLWTVCCHCGGNTNAQNIINSSVADGTLNPVDEEFVYAAEYVGW	93
mSkl	LAEELLVVLEWRAFAF...NSCR...NEFDLGPNDPKMKZQ...NASINNQIF...FGT	107
mSkl	HGVFRORIEMLLSAQIVYGOVLSILVLSIGSLVLSIN...NMDVARRHS...SVEHIXIVHG	141
mSkl	UISVNDWAGVMSAOTLIGRLVLSVLSAISIGALVLSID...SNPLISCONFAKIFILDA	151
mSkl	UIEAKDWAGEISCGDTTIGRLVLSVLSISIANLILVFDAS...ZEVEHCKKWSNNI...IQDI	167
mSkl	DISENAEFESFVEGLRFWAAE...DNIKFWLEMS...VDI...IPTPTI...YVLEKSN...WGLHFLRAI	201
mSkl	DMSENIFFELLVFGLRFIAAN...DKLWFWLFVSS...VDF...IVVYV...VLSV...WGLHFLRAI	212
mSkl	DISENIFFELLVFGLRFIAAN...DKLWFWLFVSS...VDF...IVVYV...VLSV...WGLHFLRAI	227
mSkl	RALELKLK...QI...QI...ISSSVLSK...LISIVISIVY...IAGGLLURESSGDFWL...NGR...SUTM	261
mSkl	RLIQFSEILQF...LISIVISIVY...IAGGLLURESSGDFWL...NGR...SUTM	272
mSkl	RIEMTVDF...LQF...LISIVISIVY...IAGGLLURESSGDFWL...NGR...SUTM	284
mSkl	TFESISIVYTAISIVYVGFVDDV...S...LGRIL...I...V...T...L...S...L...F...S...T...R...K...N...	331
mSkl	TFESISIVYTAISIVYVGFVDDV...S...LGRIL...I...V...T...L...S...L...F...S...T...R...K...N...	332
mSkl	TFESISIVYTAISIVYVGFVDDV...S...LGRIL...I...V...T...L...S...L...F...S...T...R...K...N...	346
mSkl	TKP...V...K...F...V...G...N...I...V...D...S...T...A...F...R...N...L...W...K...S...G...E...I...N...I...F...V...E...L...G...E...T...L...C...E...E...T...L...K...	381
mSkl	TKP...V...K...F...V...G...N...I...V...D...S...T...A...F...R...N...L...W...K...S...G...E...I...N...I...F...V...E...L...G...E...T...L...C...E...E...T...L...K...	392
mSkl	TKP...V...K...F...V...G...N...I...V...D...S...T...A...F...R...N...L...W...K...S...G...E...I...N...I...F...V...E...L...G...E...T...L...C...E...E...T...L...K...	406
mSkl	CTTSCTNFVCGFAIKYFDEKRVAVENSERCEGLASHF...S...LH...D...N...S...I...R...L...S...N...Y...P...	441
mSkl	CTTSCTNFVCGFAIKYFDEKRVAVENSERCEGLASHF...S...LH...D...N...S...I...R...L...S...N...Y...P...	452
mSkl	CTTSCTNFVCGFAIKYFDEKRVAVENSERCEGLASHF...S...LH...D...N...S...I...R...L...S...N...Y...P...	466
mSkl	QTRV...I...I...LOSQNVF...LSKIPNWDWSAGDNI...L...Z...V...L...A...L...G...S...A...Q...G...L...V...P...G...L...C...I...F...T...T...L...I...	501
mSkl	QTRV...I...I...LOSQNVF...LSKIPNWDWSAGDNI...L...Z...V...L...A...L...G...S...A...Q...G...L...V...P...G...L...C...I...F...T...T...L...I...	512
mSkl	QTRV...I...I...LOSQNVF...LSKIPNWDWSAGDNI...L...Z...V...L...A...L...G...S...A...Q...G...L...V...P...G...L...C...I...F...T...T...L...I...	526
mSkl	EON...QNVFPKHPWQH...H...F...N...L...K...N...K...I...L...I...Q...R...S...N...D...F...A...G...M...T...P...O...V...S...R...I...C...E...C...S...N...E...M...I...A...I...Q...H...	560
mSkl	EON...QNVFPKHPWQH...H...F...N...L...K...N...K...I...L...I...Q...R...S...N...D...F...A...G...M...T...P...O...V...S...R...I...C...E...C...S...N...E...M...I...A...I...Q...H...	571
mSkl	EON...QNVFPKHPWQH...H...F...N...L...K...N...K...I...L...I...Q...R...S...N...D...F...A...G...M...T...P...O...V...S...R...I...C...E...C...S...N...E...M...I...A...I...Q...H...	586
mSkl	FFHSC...CTLILN...SSQVRLNKD...L...G...F...E...I...A...D...S...N...A...V...R...A...P...E...L...S...N...C...H...S...D...C...N...D...E...L...I...G...K...N...	619
mSkl	FFHSC...CTLILN...SSQVRLNKD...L...G...F...E...I...A...D...S...N...A...V...R...A...P...E...L...S...N...C...H...S...D...C...N...D...E...L...I...G...K...N...	629
mSkl	FFHSC...CTLILN...SSQVRLNKD...L...G...F...E...I...A...D...S...N...A...V...R...A...P...E...L...S...N...C...H...S...D...C...N...D...E...L...I...G...K...N...	645
mSkl	ERR...I...Y...K...F...D...L...G...D...I...T...R...D...E...D...T...N...I...N...R...N...Y...R...P...F...G...T...G...N...G...T...G...H...H...M...N...S...T...R...A...A...A...A...A...	661
mSkl	ERR...I...Y...K...F...D...L...G...D...I...T...R...D...E...D...T...N...I...N...R...N...Y...R...P...F...G...T...G...N...G...T...G...H...H...M...N...S...T...R...A...A...A...A...A...	661
mSkl	ERR...I...Y...K...F...D...L...G...D...I...T...R...D...E...D...T...N...I...N...R...N...Y...R...P...F...G...T...G...N...G...T...G...H...H...M...N...S...T...R...A...A...A...A...A...	705
mSkl	...HEQVSLITITT...S...R...P...IT...ND...TVDD...D...S...R...S...S...G...T...G...I...Q...N...Q...N...G...V...S...L...F...A...G...I...A...D...D...Q...S...K...D...	686
mSkl	...HEQVSLITITT...S...R...P...IT...ND...TVDD...D...S...R...S...S...G...T...G...I...Q...N...Q...N...G...V...S...L...F...A...G...I...A...D...D...Q...S...K...D...	680
mSkl	...HEQVSLITITT...S...R...P...IT...ND...TVDD...D...S...R...S...S...G...T...G...I...Q...N...Q...N...G...V...S...L...F...A...G...I...A...D...D...Q...S...K...D...	765
mSkl	...MLDSS...M...H...R...M...P...L...D...V...L...K...R...S...E...K...K...H...E...F...Q...N...I...V...S...V...G...D...A...Q...C...T...L...V...G...L...S...	734
mSkl	...MLDSS...M...H...R...M...P...L...D...V...L...K...R...S...E...K...K...H...E...F...Q...N...I...V...S...V...G...D...A...Q...C...T...L...V...G...L...S...	739
mSkl	...MLDSS...M...H...R...M...P...L...D...V...L...K...R...S...E...K...K...H...E...F...Q...N...I...V...S...V...G...D...A...Q...C...T...L...V...G...L...S...	825
mSkl	F...M...P...L...R...A...S...Y...T...R...O...L...D...I...G...S...L...E...F...Q...R...E...W...R...F...R...N...E...A...H...M...V...G...S...A...I...Y...M...G...H...I...A...V...S...E...Q...	798
mSkl	F...M...P...L...R...A...S...Y...T...R...O...L...D...I...G...S...L...E...F...Q...R...E...W...R...F...R...N...E...A...H...M...V...G...S...A...I...Y...M...G...H...I...A...V...S...E...Q...	799
mSkl	F...M...P...L...R...A...S...Y...T...R...O...L...D...I...G...S...L...E...F...Q...R...E...W...R...F...R...N...E...A...H...M...V...G...S...A...I...Y...M...G...H...I...A...V...S...E...Q...	885
mSkl	CSNCCV...ATPYKALSSQI...LVDT...E...I...M...T...S...I...O...N...L...R...I...T...S...F...S...S...K...S...E...V...K...	847
mSkl	CSNCCV...ATPYKALSSQI...LVDT...E...I...M...T...S...I...O...N...L...R...I...T...S...F...S...S...K...S...E...V...K...	859
mSkl	CSNCCV...ATPYKALSSQI...LVDT...E...I...M...T...S...I...O...N...L...R...I...T...S...F...S...S...K...S...E...V...K...	941
mSkl	FS...AFDSKE...KQRYK...Q...I...L...L...L...K...N...F...S...N...I...H...F...I...E...U...M...G...G...L...D...C...M...L...K...G...S...H...S...T...S...F...S...T...A...	904
mSkl	FS...AFDSKE...KQRYK...Q...I...L...L...L...K...N...F...S...N...I...H...F...I...E...U...M...G...G...L...D...C...M...L...K...G...S...H...S...T...S...F...S...T...A...	916
mSkl	FS...AFDSKE...KQRYK...Q...I...L...L...L...K...N...F...S...N...I...H...F...I...E...U...M...G...G...L...D...C...M...L...K...G...S...H...S...T...S...F...S...T...A...	996
mSkl	V...SDTF...L...S...L...A...S...F...Y...N...Y...H...V...E...L...L...O...M...L...A...G...G...I...S...S...L...M...E...H...Y...K...E...K...P...Y...K...T...T...D...D...E...A...I...K...G...	963
mSkl	V...SDTF...L...S...L...A...S...F...Y...N...Y...H...V...E...L...L...O...M...L...A...G...G...I...S...S...L...M...E...H...Y...K...E...K...P...Y...K...T...T...D...D...E...A...I...K...G...	974
mSkl	V...SDTF...L...S...L...A...S...F...Y...N...Y...H...V...E...L...L...O...M...L...A...G...G...I...S...S...L...M...E...H...Y...K...E...K...P...Y...K...T...T...D...D...E...A...I...K...G...	1054
mSkl	RT...CKL...GL...L...S...L...D...O...T...V...L...S...G...I...N...P...R...K...T...F...G...O...L...G...S...D...N...F...I...L...C...V...L...A...R...M...I...D...E...Z...E...D...S...O...Z...H...H...	1020
mSkl	RT...CKL...GL...L...S...L...D...O...T...V...L...S...G...I...N...P...R...K...T...F...G...O...L...G...S...D...N...F...I...L...C...V...L...A...R...M...I...D...E...Z...E...D...S...O...Z...H...H...	1024
mSkl	RT...CKL...GL...L...S...L...D...O...T...V...L...S...G...I...N...P...R...K...T...F...G...O...L...G...S...D...N...F...I...L...C...V...L...A...R...M...I...D...E...Z...E...D...S...O...Z...H...H...	1113
mSkl	F...V...I...R...P...S...N...C...H...L...S...D...S...D...G...A...I...P...N...T...T...C...K...S...D...S...F...F...N...F...R...L...K...I...T...L...	1064
mSkl	F...V...I...R...P...S...N...C...H...L...S...D...S...D...G...A...I...P...N...T...T...C...K...S...D...S...F...F...N...F...R...L...K...I...T...L...	1094
mSkl	F...V...I...R...P...S...N...C...H...L...S...D...S...D...G...A...I...P...N...T...T...C...K...S...D...S...F...F...N...F...R...L...K...I...T...L...	1172
mSkl	QTRRRHW...P...G...R...I...S...I...R...T...M...P...I...S...P...I...E...T...O...S...T...R...E...R...G...H...L...S...I...T...T...P...E...S...L...W...	1110
mSkl	QTRRRHW...P...G...R...I...S...I...R...T...M...P...I...S...P...I...E...T...O...S...T...R...E...R...G...H...L...S...I...T...T...P...E...S...L...W...	1151
mSkl	QTRRRHW...P...G...R...I...S...I...R...T...M...P...I...S...P...I...E...T...O...S...T...R...E...R...G...H...L...S...I...T...T...P...E...S...L...W...	1223
mSkl	T...Q...L...F...C...G...S...L...D...N...G...I...C...V...G...D...Y...R...M...I...D...F...C...L...O...F...D...H...N...A...G...Q...S...R...A...S...L...S...H...S...H...S...S...Q...S...S...	1134
mSkl	T...Q...L...F...C...G...S...L...D...N...G...I...C...V...G...D...Y...R...M...I...D...F...C...L...O...F...D...H...N...A...G...Q...S...R...A...S...L...S...H...S...H...S...S...Q...S...S...	1205
mSkl	T...Q...L...F...C...G...S...L...D...N...G...I...C...V...G...D...Y...R...M...I...D...F...C...L...O...F...D...H...N...A...G...Q...S...R...A...S...L...S...H...S...H...S...S...Q...S...S...	1261
mSkl	...K...S...S...V...H...S...I...F...S...T...A...N...R...P...N...R...P...K...S...R...E...S...R...D...K...Q...N...A...T...	1134
mSkl	...K...S...S...V...H...S...I...F...S...T...A...N...R...P...N...R...P...K...S...R...E...S...R...D...K...Q...N...A...T...	1234

Figure 1b







Figures 3A-3C Varying pH at +80mV




Figure 3B Reversibility of pH Effect




Figure 3C Varying Voltage at pH 7.6




Figure 3D Macroscopic patch current




Figure 4A

a

nd96

nd96 +  $\text{HCO}_3^-$

nd96 +  $\text{NH}_4^+$




Figure 4B

b




Figure 4C

c





Figure 4D

d



## DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **A PH SENSITIVE POTSSSIUM CHANNEL IN SPERMATOCYTES** the specification of which \_\_\_\_ is attached hereto or X was filed on 10/21/98 as Application No. 09/176,664 and was amended on \_\_\_\_\_ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

Thereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:




Application No.	Filing Date
60,063,138	10/22/97
60,076,172	02/27/98

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status

Full Name of Inventor 1:	Last Name: <b>SALKOFF</b>	First Name: <b>LAWRENCE</b>	Middle Name or Initial:	
Residence & Citizenship:	City: <b>Clayton</b>	State/Foreign Country: <b>Missouri</b>	Country of Citizenship: <b>USA</b>	
Post Office Address:	Post Office Address: <b>6327 Alamo Avenue</b>	City: <b>Clayton</b>	State/Country: <b>Missouri</b>	Postal Code: <b>63105</b>
Full Name of Inventor 2:	Last Name: <b>SCHREIBER</b>	First Name: <b>MATTHEW</b>	Middle Name or Initial:	
Residence & Citizenship:	City: <b>Clayton</b>	State/Foreign Country: <b>Missouri</b>	Country of Citizenship: <b>USA</b>	
Post Office Address:	Post Office Address: <b>7561 York Drive</b>	City: <b>Clayton</b>	State/Country: <b>Missouri</b>	Postal Code: <b>63105</b>
Full Name of Inventor 3:	Last Name: <b>SILVIA</b>	State/Foreign Country: <b>CHRIS</b>	Middle Name or Initial:	
Residence & Citizenship:	City: <b>Durham</b>	State/Foreign Country: <b>North Carolina</b>	Country of Citizenship: <b>USA</b>	
Post Office Address:	Post Office Address: <b>3105 Broomsedge Way</b>	City: <b>Durham</b>	State/Country: <b>North Carolina</b>	Postal Code: <b>27712</b>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  <b>LAWRENCE SALKOFF</b>	Signature of Inventor 2  <b>MATTHEW SCHREIBER</b>	Signature of Inventor  <b>CHRIS SILVIA</b>
Date <b>1-15-99</b>	Date <b>1-15-99</b>	

## DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **A PH SENSITIVE POTSSIUM CHANNEL IN SPERMATOCYTES** the specification of which \_\_\_\_ is attached hereto or X was filed on 10/21/98 as Application No. 09/176,664 and was amended on \_\_\_\_\_ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

Thereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:


Application No.	Filing Date
60,063,138	10/22/97
60,076,172	02/27/98

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status

Full Name of Inventor 1:	Last Name: <b>SALKOFF</b>	First Name: <b>LAWRENCE</b>	Middle Name or Initial:	
Residence & Citizenship:	City: <b>Clayton</b>	State/Foreign Country: <b>Missouri</b>	Country of Citizenship: <b>USA</b>	
Post Office Address:	Post Office Address: <b>6327 Alamo Avenue</b>	City: <b>Clayton</b>	State/Country: <b>Missouri</b>	Postal Code: <b>63105</b>
Full Name of Inventor 2:	Last Name: <b>SCHREIBER</b>	First Name: <b>MATTHEW</b>	Middle Name or Initial:	
Residence & Citizenship:	City: <b>Clayton</b>	State/Foreign Country: <b>Missouri</b>	Country of Citizenship: <b>USA</b>	
Post Office Address:	Post Office Address: <b>7561 York Drive</b>	City: <b>Clayton</b>	State/Country: <b>Missouri</b>	Postal Code: <b>63105</b>
Full Name of Inventor 3:	Last Name: <b>SILVIA</b>	State/Foreign Country: <b>CHRIS</b>	Middle Name or Initial:	
Residence & Citizenship:	City: <b>Durham</b>	State/Foreign Country: <b>North Carolina</b>	Country of Citizenship: <b>USA</b>	
Post Office Address:	Post Office Address: <b>3105 Broomsedge Way</b>	City: <b>Durham</b>	State/Country: <b>North Carolina</b>	Postal Code: <b>27712</b>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  _____ <b>LAWRENCE SALKOFF</b>	Signature of Inventor 2  _____ <b>MATTHEW SCHREIBER</b>	Signature of Inventor   _____ <b>CHRIS SILVIA</b>
Date	Date	Date <b>Dec 15 1998</b>

POWER OF ATTORNEY BY ASSIGNEE

The Washington University is the Assignee of the invention entitled: PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES, the specification of which     is attached hereto or X was filed on October 21, 1998 as Application Serial No. 09/176,664.

Assignee hereby appoints the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Annette S. Parent, Reg. No. 42,058  
Kenneth A. Weber, Reg. No. 31,677  
Eugenia Garrett-Wackowski, Reg. No. 37,330  
Jonathan Alan Quine, Reg. No. 41,261

Send Correspondence to:

Annette S. Parent  
TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94111-3834

Direct Telephone Calls to:

(Name, reg. no., tele. no.)

Annette S. Parent  
Reg. No.: 42,058  
(415) 576-0200

Date:

1/22/99

The Washington University

By:

  
(Signature)

Andrew Neighbour, Ph.D.  
Associate Vice Chancellor  
For Technology Management



POWER OF ATTORNEY BY ASSIGNEE

ICAgen, Incorporated is the Assignee of the invention entitled: PH SENSITIVE POTASSIUM CHANNEL IN SPERMATOCYTES, the specification of which \_\_\_ is attached hereto or X was filed on October 21, 1998 as Application Serial No. 09/176,664.


Assignee hereby appoints the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Annette S. Parent, Reg. No. 42,058  
Kenneth A. Weber, Reg. No. 31,677  
Eugenia Garrett-Wackowski, Reg. No. 37,330  
Jonathan Alan Quine, Reg. No. 41,261

Send Correspondence to: Annette S. Parent TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8 <sup>th</sup> Floor San Francisco, CA 94111-3834	Direct Telephone Calls to: (Name, reg. no., tele. no.)  Annette S. Parent Reg. No.: 42,058 (415) 576-0200
---	--

ICAgen, Incorporated

Date: 12/16/98

By:   
(Signature)

Name: ROBERT J JAKOBS

Title: ASSISTANT SECRETARY

Date:

~~Lawrence Salkoff~~

SIGNATURE WITNESSED BY:

(1) Date:

Signature of Witness 1

(2) Date:

Signature of Witness 2

Date:

Matthew Schreiber

SIGNATURE WITNESSED BY:

(1) Date:

Signature of Witness 1

(2) Date:

Signature of Witness 2

# SEQUENCE LISTING

<110> Salkoff, Lawrence  
Schreiber, Matthew  
Silvia, Chris  
The Washington University  
ICAgene Inc.

<120> A pH Sensitive Potassium Channel in Spermatocytes

<130> 018512-000120US

<140> 09/176,664

<141> 1998-10-21

<150> US 60/063,138

<151> 1997-10-22

<150> US 60/076,172

<151> 1998-02-27

<160> 53

<170> PatentIn Ver. 2.0

<210> 1

<211> 1112

<212> PRT

<213> Mus musculus

<220>

<223> mouse Slo3 (mSlo3)

<220>

<221> VARIANT

<222> (5)

<223> polymorphic variant #2 Leu -> Ile

<220>

<221> VARIANT

<222> (21)

<223> polymorphic variant #1 Ile -> Val

<220>

<221> VARIANT

<222> (25)

<223> polymorphic variant #3 Ala -> Ser

<400> 1

Met	Ser	Gln	Thr	Leu	Leu	Asp	Ser	Leu	Asn	Gln	Lys	Glu	Leu	Thr	Glu
1				5					10					15	

Thr	Ser	Cys	Thr	Ile	Glu	Ile	Gln	Ala	Ala	Phe	Ile	Leu	Ser	Ser	Leu
			20					25					30		

Ala	Thr	Phe	Phe	Gly	Gly	Leu	Ile	Ile	Leu	Phe	Leu	Phe	Arg	Ile	Ala
		35				40						45			

Leu	Lys	Ser	Ser	Arg	Ser	Trp	Lys	Tyr	Val	Lys	Gly	Pro	Arg	Gly	Leu
	50					55					60				

Leu Glu Leu Phe Ser Ser Arg Arg Ile Glu Ala Asn Pro Leu Arg Lys  
 65 70 75 80  
 Leu Tyr Phe His Gly Val Phe Arg Gln Arg Ile Glu Met Leu Leu Ser  
 85 90 95  
 Ala Gln Thr Val Val Gly Gln Val Leu Val Ile Leu Val Phe Val Leu  
 100 105 110  
 Ser Ile Gly Ser Leu Val Ile Tyr Phe Ile Asn Ser Met Asp Pro Val  
 115 120 125  
 Arg Arg Cys Ser Ser Tyr Glu Asp Lys Ile Val His Gly Asp Leu Ser  
 130 135 140  
 Phe Asn Ala Phe Phe Ser Phe Tyr Phe Gly Leu Arg Phe Trp Ala Ala  
 145 150 155 160  
 Glu Asp Lys Ile Lys Phe Trp Leu Glu Met Asn Ser Ile Val Asp Ile  
 165 170 175  
 Phe Thr Ile Pro Pro Thr Phe Ile Ser Tyr Tyr Leu Lys Ser Asn Trp  
 180 185 190  
 Leu Gly Leu Arg Phe Leu Arg Ala Leu Arg Leu Leu Glu Leu Pro Lys  
 195 200 205  
 Ile Leu Gln Ile Leu Gln Val Ile Lys Thr Ser Asn Ser Val Lys Leu  
 210 215 220  
 Ser Lys Leu Leu Ser Ile Val Ile Ser Thr Trp Phe Thr Ala Ala Gly  
 225 230 235 240  
 Phe Leu His Leu Val Glu Asn Ser Gly Asp Pro Trp Leu Asn Gly Arg  
 245 250 255  
 Asn Ser Gln Thr Met Ser Tyr Phe Glu Ser Ile Tyr Leu Val Thr Ala  
 260 265 270  
 Thr Met Ser Thr Val Gly Phe Gly Asp Val Val Ala Lys Thr Ser Leu  
 275 280 285  
 Gly Arg Ile Phe Ile Val Phe Phe Thr Leu Gly Ser Leu Ile Leu Phe  
 290 295 300  
 Ala Asn Tyr Ile Pro Glu Met Val Glu Leu Phe Ser Thr Arg Lys Lys  
 305 310 315 320  
 Tyr Thr Lys Pro Tyr Glu Ala Val Lys Gly Lys Lys Phe Ile Val Val  
 325 330 335  
 Cys Gly Asn Ile Thr Val Asp Ser Val Thr Ala Phe Leu Arg Asn Phe  
 340 345 350  
 Leu His Trp Lys Ser Gly Glu Ile Asn Ile Glu Ile Val Phe Leu Gly  
 355 360 365  
 Glu Thr Leu Pro Cys Leu Glu Leu Glu Thr Leu Leu Lys Cys His Thr  
 370 375 380

1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094

Val 705	Val	Leu	Lys	Arg	Ser 710	Glu	Lys	Ala	Lys	His 715	Glu	Phe	Gln	Asn	His 720
Ile	Val	Val	Cys	Val 725	Phe	Gly	Asp	Ala	Gln 730	Cys	Thr	Leu	Val	Gly 735	Leu
Arg	Asn	Phe	Val 740	Met	Pro	Leu	Arg	Ala 745	Ser	Asn	Tyr	Thr	Arg 750	Gln	Glu
Leu	Lys	Asp 755	Ile	Val	Phe	Ile	Gly 760	Ser	Leu	Glu	Tyr	Phe 765	Gln	Arg	Glu
Trp	Arg 770	Phe	Leu	Arg	Asn	Phe	Pro 775	Lys	Ile	His	Ile 780	Met	Pro	Gly	Ser
Ala 785	Leu	Tyr	Met	Gly 790	Asp	Leu	Ile	Ala	Val 795	Asn	Val	Glu	Gln	Cys	Ser 800
Met	Cys	Val	Ile 805	Leu	Ala	Thr	Pro	Tyr	Lys 810	Ala	Leu	Ser	Ser	Gln 815	Ile
Leu	Val	Asp	Thr 820	Glu	Ala	Ile	Met	Ala 825	Thr	Leu	Asn	Ile	Gln 830	Ser	Leu
Arg	Ile 835	Thr	Ser	Pro	Thr	Pro	Gly 840	Ser	Ser	Lys	Ser	Glu 845	Val	Lys	Pro
Ser 850	Ser	Ala	Phe	Asp	Ser	Lys 855	Glu	Arg	Lys	Gln	Arg 860	Tyr	Lys	Gln	Ile
Pro 865	Ile	Leu	Thr	Glu	Leu 870	Lys	Asn	Pro	Ser	Asn 875	Ile	His	Phe	Ile	Glu 880
Gln	Met	Gly	Gly 885	Leu	Asp	Gly	Met	Leu	Lys 890	Gly	Thr	Ser	Leu	His 895	Leu
Ser	Thr	Ser	Phe 900	Ser	Thr	Gly	Ala	Val 905	Phe	Ser	Asp	Thr	Phe 910	Leu	Asp
Ser	Leu	Leu 915	Ala	Thr	Ser	Phe	Tyr 920	Asn	Tyr	His	Val	Val 925	Glu	Leu	Leu
Gln 930	Met	Leu	Val	Thr	Gly	Gly 935	Ile	Ser	Ser	Glu	Met 940	Glu	His	Tyr	Leu
Val 945	Lys	Glu	Lys	Pro	Tyr 950	Lys	Thr	Thr	Asp	Asp 955	Tyr	Glu	Ala	Ile	Lys 960
Ser	Gly	Arg	Thr 965	Arg	Cys	Lys	Leu	Gly	Leu 970	Leu	Ser	Leu	Asp	Gln 975	Thr
Val	Leu	Ser	Gly 980	Ile	Asn	Pro	Arg	Lys 985	Thr	Phe	Gly	Gln	Leu 990	Phe	Cys
Gly	Ser	Leu 995	Asp	Asn	Phe	Gly	Ile 1000	Leu	Cys	Val	Gly	Leu 1005	Tyr	Arg	Met
Ile 1010	Asp	Glu	Glu	Glu	Pro	Ser	Gln 1015	Glu	His	Lys	Arg 1020	Phe	Val	Ile	Thr

Arg Pro Ser Asn Glu Cys His Leu Leu Pro Ser Asp Leu Val Phe Cys  
1025 1030 1035 1040

Ala Ile Pro Phe Asn Thr Thr Cys Gly Lys Ser Asp Ser Ser Pro Phe  
1045 1050 1055

Asn Phe Arg Leu Lys Thr Thr Leu Gln Thr Arg Arg Arg His Trp Pro  
1060 1065 1070

Arg Gly Arg Ile Ser Ser Ile Arg Thr Met Pro Thr Ser Pro Thr Ile  
1075 1080 1085

Phe Thr Gln Ser Thr Thr Arg Glu Arg Gly Gly Leu Ser Thr Thr Thr  
1090 1095 1100

Pro Glu Ser Ile Leu Trp Thr Arg  
1105 1110

<210> 2

<211> 3339

<212> DNA

<213> Mus musculus

<220>

<223> mouse Slo3 (mSlo3)

<400> 2

atgtctcaaa	cattgctaga	cagtttaaat	cagaaggagt	tgacggaaac	gtcatgtaca	60
atcgaaatcc	aggcagcggt	cattctttcc	tccttggcga	ctttcttcgg	gggactcatc	120
atcttattcc	ttttcagaat	agccttgaaa	agctcaagaa	gttggaataa	cgtaacgggg	180
ccaagaggac	totttgaact	attctcatca	cgtagaatcg	aggctaatac	tttgaggaaa	240
ctttactttc	atggagtatt	tcgtcagcgc	atcgaaatgc	tgctttctgc	acagaccgtc	300
gtggggcaag	tggttggtgat	ccttgtcttt	gtactaagca	tcgggtctct	tgtgatctat	360
ttcatcaatt	caatggatcc	tgttcgaagg	tgttcttcat	atgaagacaa	aattgtccat	420
ggggatttga	gtttcaacgc	ttcttttagc	ttctattttg	ggttgagggt	ttgggcagct	480
gaagacaaga	tcaagttctg	gttgagatg	aattcaattg	tagacatttt	taccatcccg	540
ccaaccttta	tttcttatta	tttgaagagt	aattggctag	gtttgagatt	tctaagagct	600
ctgcggttgc	tcgaactccc	taaaatctta	cagatcctac	aagtcatcaa	gaccagcaat	660
tcagtgaagc	tttccaaact	gttgtaata	gttatcagta	cctggttcac	ggcagcagga	720
ttccttcacc	ttggtgaaaa	ttctgggtgac	ccttggtcca	acggaagaaa	ctcacagact	780
atgtcatact	ttgagtctat	ttatctggtg	acagcaacaa	tgtcaactgt	tggctttggg	840
gacgtggtgg	ccaagacatc	cctaggacgg	atcttcattg	ttttcttcac	ccttgggagt	900
ttgatactat	ttgcaaacta	cattccagaa	atggtggagc	tcctttctac	caggaagaaa	960
tacaccaagc	cctacgaagc	agtcaaagga	aaaaagttca	tcgtggtctg	tggaacatc	1020
acagttgaca	gtgttactgc	tttctgagg	aattttctcc	actggaagtc	cggggaaatc	1080
aatattgaga	tcgtattcct	tggagagact	ctcccttgct	tggaactgga	gaccttactg	1140
aagtgccaca	catcctgtac	caacttcgta	tgcggcaccg	cactgaagtt	cgaggatctg	1200
aagcgagttg	cagtgagaaa	ctcggaggcg	tgccctgattc	tagccaacca	tttctgtagt	1260
gactttacatg	acgaagacaa	ctcaaacatt	atgagggtgc	tctcgatcaa	gaactattat	1320
ccacagacca	gagtcatcat	tcagatactt	cagtctcaaa	acaaggtttt	cctgtcaaaa	1380
atccccaact	gggactggag	tgctggagac	aatatcctct	gctttgcaga	gctaaagctc	1440
ggatttatcg	cccaaggctg	cttgggtgcc	gggctgtgca	cctttctcac	gactctgttc	1500
attgaacaaa	acaaaagggt	ttttcctaaa	catccctggc	aaaaacattt	cttgaatggc	1560
ttgaagaaca	agattctgac	acagcgcttc	tctaacgact	tcgtggggat	gacatttccc	1620
caggtctccc	ggctctgctt	tgtgaagcta	aatctcatgc	tgatcgccat	ccaacacaag	1680
cccttctttc	acagttgttg	cactctgata	ctaaaccocat	catcccaagt	gaggctgaat	1740
aaggacacct	tagggttctt	cattgcggtg	tcctccaaag	ccgtcaaaaag	ggctttcttt	1800
tactgttcca	actgtcacag	cgatgtgtgc	aatcctgagc	taattggaaa	gtgtaactgt	1860
aaaatcaaga	gccgacaaca	actcatagca	ccgaccatca	tggtgatgaa	aagcagcttg	1920
accgatttca	ccacttcttc	acacatccac	gcttctatgt	caacagaaat	tcacacttgt	1980





<210> 4  
 <211> 416  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> human Slo3 (hSlo3)

<400> 4  
 ggcttggcag cgctcattct ttcctccttt gtgacctct tcagtggact catcagcctg 60  
 ttgatcttca ggctgatctg gagayctgtt aaaaaatggc aaatcatcaa gggaacagga 120  
 attatcttgg aactgttcac atcaggtacc atcgctagga gccatgtaag aagcctccac 180  
 ttccagggac aatttcgtga tcatatagaa atgttgcttt cagcccagac ctttgtgggg 240  
 caagtgttgg tgatccttgt ctttgtacta agcattgggt ctcttataat ctatttcac 300  
 aattcwgctg accctgttgg aacgctgttc atcatatgaa gacaaaacca ttctattga 360  
 tttggttttc aatgctttct ttagtttcta ttttgggttg aggttttggc aaagcc 416

<210> 5  
 <211> 4  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> PEPTIDE  
 <222> (1)..(4)  
 <223> mSlo3 peptide starting with amino acid 687

<400> 5  
 Met Leu Asp Ser  
 1

<210> 6  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> human Slo3-b (hSlo3-b)

<220>  
 <221> MOD\_RES  
 <222> (29)  
 <223> Xaa = any amino acid

<400> 6  
 Gly Leu Ala Ala Leu Ile Leu Ser Ser Phe Val Thr Leu Phe Thr Gly  
 1 5 10 15  
 Leu Ile Ser Leu Leu Ile Phe Arg Leu Ile Trp Arg Xaa Val Lys Lys  
 20 25 30  
 Trp Gln Ile Ile Lys Gly Thr Gly Ile Ile Leu Glu Leu Phe Thr Ser  
 35 40 45  
 Gly Thr Ile Ala Arg Ser His Val Arg Ser Leu His Phe Gln Gly Gln  
 50 55 60  
 Phe Arg Asp His Ile Glu Met Leu Leu Ser Ala Gln Thr Phe Val Gly  
 65 70 75 80

Gln Val Leu Val Ile Leu Val Phe Val Leu Ser Ile Gly Ser Leu Ile  
85 90 95

Ile Tyr Phe Ile Asn Ser Ala Asp Pro Val Gly Thr Leu Phe Ile Ile  
100 105 110

<210> 7  
<211> 112  
<212> PRT  
<213> Homo sapiens

<220>  
<223> human Slo3-c (hSLO3-c)

<220>  
<221> MOD\_RES  
<222> (29)  
<223> Xaa = any amino acid

<400> 7  
Gly Leu Ala Ala Leu Ile Leu Ser Ser Phe Val Thr Leu Phe Ser Gly  
1 5 10 15

Leu Ile Ser Leu Leu Ile Phe Arg Leu Ile Trp Arg Xaa Val Lys Lys  
20 25 30

Trp Gln Ile Ile Lys Gly Thr Gly Ile Ile Leu Glu Leu Phe Thr Ser  
35 40 45

Gly Thr Ile Ala Arg Ser His Val Arg Ser Leu His Phe Gln Gly Gln  
50 55 60

Phe Arg Asp His Ile Glu Met Leu Leu Ser Ala Gln Thr Phe Val Gly  
65 70 75 80

Gln Val Leu Val Ile Leu Val Phe Val Leu Ser Ile Gly Ser Leu Ile  
85 90 95

Ile Tyr Phe Ile Asn Ser Met Asp Pro Val Gly Thr Leu Phe Ile Ile  
100 105 110

<210> 8  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:mSlo3 primer

<400> 8  
ctcgaactcc ctaaaatctt acagat

26

<210> 9  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:mSlo3 primer  
 <400> 9  
 ttccgttgag ccaggggtca ccagaatt 28

<210> 10  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:mSlo3 primer  
 <400> 10  
 tctgctttgt gaagctaaat ct 22

<210> 11  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:mSlo3 primer  
 <400> 11  
 tttcaaagcc tctttagcgg taa 23

<210> 12  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:mSlo3 primer  
 <400> 12  
 ttatgcctgg atctgcactc tacatg 26

<210> 13  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:mSlo3 primer  
 <400> 13  
 atagtttccg tctactaccg aaa 23

<210> 14  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence







Pro	Leu	Arg	Ala	Ser	Asn	Tyr	Thr	Arg	Lys	Glu	Leu	Lys	Asp	Ile	Val	
			740						745						750	
Phe	Ile	Gly	Ser	Leu	Asp	Tyr	Leu	Gln	Arg	Glu	Trp	Arg	Phe	Leu	Arg	
		755					760					765				
Asn	Phe	Pro	Gln	Ile	Tyr	Ile	Leu	Pro	Gly	Cys	Ala	Leu	Tyr	Ser	Gly	
	770					775					780					
Asp	Leu	His	Ala	Ala	Asn	Ile	Glu	Gln	Cys	Ser	Met	Cys	Ala	Val	Leu	
785					790					795					800	
Ser	Pro	Pro	Pro	Gln	Pro	Ser	Ser	Asn	Gln	Thr	Leu	Val	Asp	Thr	Glu	
				805					810					815		
Ala	Ile	Met	Ala	Thr	Leu	Thr	Ile	Gly	Ser	Leu	Gln	Ile	Asp	Ser	Ser	
			820					825					830			
Ser	Asp	Pro	Ser	Pro	Ser	Val	Ser	Glu	Glu	Thr	Pro	Gly	Tyr	Thr	Asn	
		835					840					845				
Gly	His	Asn	Glu	Lys	Ser	Asn	Cys	Arg	Lys	Val	Pro	Ile	Leu	Thr	Glu	
	850					855					860					
Leu	Lys	Asn	Pro	Ser	Asn	Ile	His	Phe	Ile	Glu	Gln	Leu	Gly	Gly	Leu	
865					870					875					880	
Glu	Gly	Ser	Leu	Gln	Glu	Thr	Asn	Leu	His	Leu	Ser	Thr	Ala	Phe	Ser	
				885					890					895		
Thr	Gly	Thr	Val	Phe	Ser	Ser	Ser	Phe	Leu	Asp	Ser	Leu	Leu	Ala	Thr	
			900					905					910			
Ala	Phe	Tyr	Asn	Tyr	His	Val	Leu	Glu	Leu	Leu	Gln	Met	Leu	Val	Thr	
		915					920					925				
Gly	Gly	Val	Ser	Ser	Gln	Leu	Glu	Gln	His	Leu	Asp	Lys	Asp	Lys	Val	
	930					935					940					
Tyr	Gly	Val	Ala	Asp	Ser	Cys	Thr	Ser	Leu	Leu	Ser	Gly	Arg	Asn	Arg	
945					950					955					960	
Cys	Lys	Leu	Gly	Leu	Leu	Ser	Leu	His	Glu	Thr	Ile	Leu	Ser	Asp	Val	
				965					970					975		
Asn	Pro	Arg	Asn	Thr	Phe	Gly	Gln	Leu	Phe	Cys	Gly	Ser	Leu	Asp	Leu	
			980					985					990			
Phe	Gly	Ile	Leu	Cys	Val	Gly	Leu	Tyr	Arg	Ile	Ile	Asp	Glu	Glu	Glu	
		995					1000					1005				
Leu	Asn	Pro	Glu	Asn	Lys	Arg	Phe	Val	Ile	Thr	Arg	Pro	Ala	Asn	Glu	
	1010					1015					1020					
Phe	Lys	Leu	Leu	Pro	Ser	Asp	Leu	Val	Phe	Cys	Ala	Ile	Pro	Phe	Ser	
1025					1030					1035					1040	
Thr	Ala	Cys	Tyr	Lys	Arg	Asn	Glu	Glu	Phe	Ser	Leu	Gln	Lys	Ser	Tyr	
				1045					1050					1055		

Glu Ile Val Asn Lys Ala Ser Gln Thr Thr Glu Asp Thr Phe Arg His  
 1060 1065 1070

Lys Leu Ser Ser His Pro Leu Ile Gln Leu Leu Arg His Cys Ile His  
 1075 1080 1085

Gln Ser Ile Leu Thr Ser Arg Glu Leu Thr Pro Ser Leu Phe Leu Ser  
 1090 1095 1100

Lys  
 1105

<210> 17  
 <211> 3319  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> human Slo3-1 (hSlo3-1)

<400> 17

```

atgtttcaga ctaagctacg aaatgaaact tgggaagact tgccaaaaat gtcctgcaca 60
actgagatcc aagcagcatt cattctctct tcctttgtga ccttcttcag tggactcatc 120
atcctgttga tcttcaggct gatctggaga tctgttaaaa aatggcaaat catcaaggga 180
acaggaatta tcttggaact gttcacatca ggtaccatcg ctaggagcca tgtaagaagc 240
ctccacttcc agggacaatt tctgtatcat atagaaatgt tgctttcagc ccagaccttt 300
gtggggcaag tgttggtgat ccttgtcttt gtactaagca ttgggtctct tataatctat 360
ttcatcaatt ctgctgaccc tgttggaagc tgttcatcat atgaagaca aaccattcct 420
attgatttgg ttttcaatgc tttctttagt ttctattttg gattgaggtt tatggcagct 480
gatgacaaga tcaagtctcg gctggagatg aattcaatcg tagacatctt taccatccca 540
ccaaccttta tttcttatta tttgaagagc aattggctag gtttaagggt cctaagagcc 600
ttgcgcctgc tagaactccc tcaaactctg caaattctac gagccatcaa gaccagtaac 660
tcaagtgaag tttccaaact gctgtcaata attctcagta cctgggttcac agctgcgagg 720
ttcattcacc tgggtggaaa ttctgggtgat ccctggctca aaggtagaaa ttcacagaat 780
atatcatatt ttgagtcaat ttacctggtc atggcaacaa cgtcaacogt tggatttggg 840
gatgtggtag ccaagacatc cttaggacgg accttcatca tgttcttcac actggggagt 900
ttgatattat ttgcgaacta tatacctgaa atgggtggaac tgtttgctaa caagaggaaa 960
tacaccagtt cmtatgaagc actcaaagga aagaagttta ttgtggtctg tggaaacatc 1020
actgtggaca gtgtgaccgc tttcctgagg aatttcctcc gcgacaagtc aggagagatc 1080
aacactgaaa ttgttttctt gggagaaaacc cctccttctt tggaaacttga aaccatattt 1140
aaatgctact tggcctacac aacgttcatt tctggatctg caatgaagtg ggaggatctg 1200
aggcgagttg cgggtggaatc tgcagaggca tgacctgatta tagccaatcc tttgtgcagt 1260
gattcccatg ctgaagatat ttccaaactt atgagggtgc tctctatcaa gaactatgat 1320
totaccacca gaatcatcat acagatactg caatcccata acaaggttta tctgccaaag 1380
attcccatgct ggaactggga caccggagac aacatcatct gctttgctga attaaaactt 1440
ggattttatcg cccaaggctg tttggtgcca ggcttgtgta ccttcctaac atctctattt 1500
gtggagcaaa acaaaaaggt tatgcctaaa cagacctgga agaaacactt cttgaatagc 1560
atgaaaaaca aaattctgac ccaacgtctc tctgatgact ttgctggaat gagctttcct 1620
gaagttgccc ggctctgctt tctgaagatg tacctcctgt tgatagccat cgaatacaag 1680
tccctcttta cggatggttt ctgtggtctg atactaaatc cacctccaca agtgaggata 1740
cgtaagaaca cattagggtt ctttattgct gaaactccaa aggacgtcag aagagccttg 1800
ttttactgtt cagtctgtca tgatgatgtg ttcatctctg agctaattac aaactgtggc 1860
tgcaaaagca gaagccggca gcacatcaca gtgccatcgg taaagagaat gaaaaaatgt 1920
ctgaagggaa tctcctctcg tatatcaggg caggattctc cgccaagggt atctgcaagc 1980
acttcgagca tatcaaactt caccaccagg actcttcaac atgatgtaga acaagattct 2040
gaccagcttg atagcagtgg gatgtttcac tggtgcaaac caacctctt ggacaagggtg 2100
actctgaaac gaactggcaa gtcaaagtat aagtttcgga accatattgt agcatgtgta 2160
tttgagatg cccactcagc cccgatgggg ctctcggaact ttgtaatgcc cttgagagcc 2220
agcaactata ccaggaagga gctgaaggac atagtgttca ttgggtctct ggactatcta 2280
cagagagaat ggcgatttct ccggaatttt cccagatat acattctgcc tggatgtgca 2340

```







Thr	Ser	Leu	Phe	Val	Glu	Gln	Asn	Lys	Lys	Val	Met	Pro	Lys	Gln	Thr	500	505	510
Trp	Lys	Lys	His	Phe	Leu	Asn	Ser	Met	Lys	Asn	Lys	Ile	Leu	Thr	Gln	515	520	525
Arg	Leu	Ser	Asp	Asp	Phe	Ala	Gly	Met	Ser	Phe	Pro	Glu	Val	Ala	Arg	530	535	540
Gly	Leu	Ile	Leu	Asn	Pro	Pro	Pro	Gln	Val	Arg	Ile	Arg	Lys	Asn	Thr	545	550	555
Leu	Gly	Phe	Phe	Ile	Ala	Glu	Thr	Pro	Lys	Asp	Val	Arg	Arg	Ala	Leu	565	570	575
Phe	Tyr	Cys	Ser	Val	Cys	His	Asp	Asp	Val	Phe	Ile	Pro	Glu	Leu	Ile	580	585	590
Thr	Asn	Cys	Gly	Cys	Lys	Ser	Arg	Ser	Arg	Gln	His	Ile	Thr	Val	Pro	595	600	605
Ser	Val	Lys	Arg	Met	Lys	Lys	Cys	Leu	Lys	Gly	Ile	Ser	Ser	Arg	Ile	610	615	620
Ser	Gly	Gln	Asp	Ser	Pro	Pro	Arg	Val	Ser	Ala	Ser	Thr	Ser	Ser	Ile	625	630	635
Ser	Asn	Phe	Thr	Thr	Arg	Thr	Leu	Gln	His	Asp	Val	Glu	Gln	Asp	Ser	645	650	655
Asp	Gln	Leu	Asp	Ser	Ser	Gly	Met	Phe	His	Trp	Cys	Lys	Pro	Thr	Ser	660	665	670
Leu	Asp	Lys	Val	Thr	Leu	Lys	Arg	Thr	Gly	Lys	Ser	Lys	Tyr	Lys	Phe	675	680	685
Arg	Asn	His	Ile	Val	Ala	Cys	Val	Phe	Gly	Asp	Ala	His	Ser	Ala	Pro	690	695	700
Met	Gly	Leu	Arg	Asn	Phe	Val	Met	Pro	Leu	Arg	Ala	Ser	Asn	Tyr	Thr	705	710	715
Arg	Lys	Glu	Leu	Lys	Asp	Ile	Val	Phe	Ile	Gly	Ser	Leu	Asp	Tyr	Leu	725	730	735
Gln	Arg	Glu	Trp	Arg	Phe	Leu	Arg	Asn	Phe	Pro	Gln	Ile	Tyr	Ile	Leu	740	745	750
Pro	Gly	Cys	Ala	Leu	Tyr	Ser	Gly	Asp	Leu	His	Ala	Ala	Asn	Ile	Glu	755	760	765
Gln	Cys	Ser	Met	Cys	Ala	Val	Leu	Ser	Pro	Pro	Pro	Gln	Pro	Ser	Ser	770	775	780
Asn	Gln	Thr	Leu	Val	Asp	Thr	Glu	Ala	Ile	Met	Ala	Thr	Leu	Thr	Ile	785	790	795
Gly	Ser	Leu	Gln	Ile	Asp	Ser	Ser	Ser	Asp	Pro	Ser	Pro	Ser	Val	Ser	805	810	815

Glu Glu Thr Pro Gly Tyr Thr Asn Gly His Asn Glu Lys Ser Asn Cys  
 820 825 830  
 Arg Lys Val Pro Ile Leu Thr Glu Leu Lys Asn Pro Ser Asn Ile His  
 835 840 845  
 Phe Ile Glu Gln Leu Gly Gly Leu Glu Gly Ser Leu Gln Glu Thr Asn  
 850 855 860  
 Leu His Leu Ser Thr Ala Phe Ser Thr Gly Thr Val Phe Ser Ser Ser  
 865 870 875 880  
 Phe Leu Asp Ser Leu Leu Ala Thr Ala Phe Tyr Asn Tyr His Val Leu  
 885 890 895  
 Glu Leu Leu Gln Met Leu Val Thr Gly Gly Val Ser Ser Gln Leu Glu  
 900 905 910  
 Gln His Leu Asp Lys Asp Lys Val Tyr Gly Val Ala Asp Ser Cys Thr  
 915 920 925  
 Ser Leu Leu Ser Gly Arg Asn Arg Cys Lys Leu Gly Leu Leu Ser Leu  
 930 935 940  
 His Glu Thr Ile Leu Ser Asp Val Asn Pro Arg Asn Thr Phe Gly Gln  
 945 950 955 960  
 Leu Phe Cys Gly Ser Leu Asp Leu Phe Gly Ile Leu Cys Val Gly Leu  
 965 970 975  
 Tyr Arg Ile Ile Asp Glu Glu Glu Leu Asn Pro Glu Asn Lys Arg Phe  
 980 985 990  
 Val Ile Thr Arg Pro Ala Asn Glu Phe Lys Leu Leu Pro Ser Asp Leu  
 995 1000 1005  
 Val Phe Cys Ala Ile Pro Phe Ser Thr Ala Cys Tyr Lys Arg Asn Glu  
 1010 1015 1020  
 Glu Phe Ser Leu Gln Lys Ser Tyr Glu Ile Val Asn Lys Ala Ser Gln  
 1025 1030 1035 1040  
 Thr Thr Glu Asp Thr Phe Arg His Lys Leu Ser Ser His Pro Leu Ile  
 1045 1050 1055  
 Gln Leu Leu Arg His Cys Ile His Gln Ser Ile Leu Thr Ser Arg Glu  
 1060 1065 1070  
 Leu Thr Pro Ser Leu Phe Leu Ser Lys  
 1075 1080

<210> 19  
 <211> 3247  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> human Slo3-2 (hSlo3-2)

<400> 19

atgtttcaga	ctaagctacg	aaatgaaact	tggaagact	tgccaaaaat	gtcctgcaca	60
actgagatcc	aagcagcatt	cattctctct	tcctttgtga	ccttcttcag	tggaactcatc	120
atcctgttga	tcttcaggct	gatctggaga	tctgttaaaa	aatggcaaat	catcaaggga	180
acaggaatta	tcttggaact	gttcacatca	ggtaccatcg	ctaggagcca	tgtaagaagc	240
ctccacttcc	agggacaatt	tcgtgatcat	atagaaatgt	tgctttcagc	ccagaccttt	300
gtggggcaag	tggttggtgat	ccttgtcttt	gtactaagca	ttgggtctct	tataatctat	360
ttcatcaatt	ctgctgaccc	tggtggaagc	tggtcatcat	atgaagacaa	aaccattcct	420
attgatttgg	ttttcaatgc	tttctttagt	ttctattttg	gattgaggtt	tatggcagct	480
gatgacaaga	tcaagttctg	gctggagatg	aattcaatcg	tagacatctt	taccatccca	540
ccaaccttta	tttcttatta	tttgaagagc	aattggctag	gtttaagggtt	cctaagagcc	600
ttgcgccctgc	tagaactccc	tcaaatcttg	caaattctac	gagccatcaa	gaccagtaac	660
tcagtgaagt	tttccaaaact	gctgtcaata	attctcagta	cctgggtcac	agctgcggga	720
ttcattcacc	tggttgaaaa	ttctggtgat	ccctggctca	aaggtagaaa	ttcacagaat	780
atatcatatt	ttgagtcaat	ttacctggct	atggcaacaa	cgtcaaccgt	tggttttggg	840
gatgtggtag	ccaagacatc	cttaggacgg	accttcacat	tggtcttcac	actggggagt	900
ttgatattat	ttgcgaaact	tatacctgaa	atggtggaac	tggttgctaa	caagaggaaa	960
tacaccagtt	cmtatgaagc	actcaaagga	aagaagttta	ttgtggtctg	tggaaacatc	1020
actgtggaca	gtgtgaccgc	tttctgagg	aatttctctc	gcgacaagtc	aggagagatc	1080
aacactgaaa	ttgttttctc	gggagaaaacc	cctccttctt	tggaacttga	aaccatattt	1140
aaatgctact	tggcctacac	aacgttcatt	tctggatctg	caatgaagtg	ggaggatctg	1200
aggcgagttg	cggttggaatc	tgagaggcca	tgccctgatta	tagccaatcc	tttgtgcagt	1260
gattcccatg	ctgaagatat	ttccaacatt	atgaggggtg	tctctatcaa	gaactatgat	1320
tctaccacca	gaatcatcat	acagatactg	caatcccata	acaaggttta	tctgccaaag	1380
attcccagct	ggaactggga	caccggagac	aacatcatct	gctttgctga	attaaaactt	1440
ggatttatcg	cccaaggctg	tttggtgcca	ggcttgtgta	ccttcctaac	atctctattt	1500
gtggagcaaaa	acaaaaagggt	tatgcctaaa	cagacctgga	agaaacactt	cttgaatagc	1560
atgaaaaaca	aaattctgac	ccaacgtctc	tctgatgact	ttgctggaat	gagctttcct	1620
gaagttgccc	gtggtctgat	actaaatcca	cctccacaag	tgaggatacg	taagaacaca	1680
ttagggttct	ttattgctga	aactccaaag	gacgtcagaa	gagccttggt	ttactgttca	1740
gtctgtcatg	atgatgtgtt	cattcctgag	ctaattacaa	actgtggctg	caaaagcaga	1800
agccggcgagc	acatcacagt	gccatcggta	aagagaatga	aaaaatgtct	gaagggaatc	1860
tcctctcgtg	tatcagggca	ggattctccg	ccaagggtat	ctgcaagcac	ttcgagcata	1920
tcaaacttca	ccaccaggac	tcttcaacat	gatgtagaac	aagattctga	ccagcttgat	1980
agcagtggga	tgtttctactg	gtgcaaacca	acctctttgg	acaagggtgac	tctgaaacga	2040
actggcaagt	caaaagtataa	gtttcggaac	catattgtag	catgtgtatt	tggaagtacc	2100
cactcagccc	cgatggggct	tcggaacttt	gtaatgcctt	tgagagccag	caactatacc	2160
aggaaggagc	tgaaggacat	agtgttcatt	gggtctctgg	actatctaca	gagagaatgg	2220
cgatttctcc	ggaattttcc	ccagatatac	attctgcctg	gatgtgcaat	ttattctgga	2280
gacctccatg	cggccaacat	agagcaatgc	tccatgtgtg	ctgtcttgct	ccccccaccc	2340
cagccatcaa	gcaaccagac	tttggttagac	acagaagcca	tcatggcaac	cctcaccatc	2400
ggatccttgc	aaattgactc	ctcctctgac	ccgtcaccct	cagtgtcaga	ggagactcca	2460
ggttacacaa	atggacataa	tgagaaatca	aactgccgaa	aagtccttat	ccttactgaa	2520
ctgaaaaaatc	cttccaacat	tcactttatt	gaacagcttg	gtggactgga	agggtccctc	2580
caagaaacaa	atctgcatct	cagcactgcc	ttttctacgg	gcaactgttt	ttccagcagc	2640
ttcttggatt	ctctgctggc	cacggccttc	tacaattatc	atgtcctgga	attgcttcag	2700
atgctggtga	caggaggagt	aagttctcag	ctggaacaac	atttagataa	ggataaagtc	2760
tatggtgtgg	cagatagctg	cacgtogctc	ttgtctggaa	gaaaccgggtg	taagctgggg	2820
cttctgtcct	tacacgaaac	catttttatca	gacgttaatc	caagaaacac	ctttggacaa	2880
ctgttctgtg	gctcattaga	tcttttttga	atcctgtgtg	ttggcttata	ccgaataatt	2940
gatgaagagg	agctcaaccc	agaaaaacaa	aggtttgtga	tcacccggcc	agccaatgag	3000
ttcaagctgc	tgcttccaga	tcttgtgttt	tgtgccatac	ccttcagcac	tgcttgttat	3060
aaaagggaatg	aagagttctc	attgcaaaag	tcatatgaaa	ttgtaaataa	agcatcacag	3120
acaacagagg	acacattcag	acacaaattg	tcctccacc	cattgattca	gttactgaga	3180
cattgtattc	accagtctat	tcttaccagc	cgagaactaa	ctccctctct	tttccctaagc	3240
aaatagt						3247

<210> 20  
 <211> 1134  
 <212> PRT  
 <213> Mus musculus

<220>  
 <223> mouse Slo3 (mSlo3)

<400> 20  
 Met Ser Gln Thr Leu Leu Asp Ser Leu Asn Gln Lys Glu Leu Thr Glu  
   1                  5                  10                  15  
 Thr Ser Cys Thr Ile Glu Ile Gln Ala Ala Phe Ile Leu Ser Ser Leu  
                   20                  25                  30  
 Ala Thr Phe Phe Gly Gly Leu Ile Ile Leu Phe Leu Phe Arg Ile Ala  
           35                  40                  45  
 Leu Lys Ser Ser Arg Ser Trp Lys Tyr Val Lys Gly Pro Arg Gly Leu  
       50                  55                  60  
 Leu Glu Leu Phe Ser Ser Arg Arg Ile Glu Ala Asn Pro Leu Arg Lys  
       65                  70                  75                  80  
 Leu Tyr Phe His Gly Val Phe Arg Gln Arg Ile Glu Met Leu Leu Ser  
                   85                  90                  95  
 Ala Gln Thr Val Val Gly Gln Val Leu Val Ile Leu Val Phe Val Leu  
                   100                  105                  110  
 Ser Ile Gly Ser Leu Val Ile Tyr Phe Ile Asn Ser Met Asp Pro Val  
       115                  120                  125  
 Arg Arg Cys Ser Ser Tyr Glu Asp Lys Ile Val His Gly Asp Leu Ser  
       130                  135                  140  
 Phe Asn Ala Phe Phe Ser Phe Tyr Phe Gly Leu Arg Phe Trp Ala Ala  
       145                  150                  155                  160  
 Glu Asp Lys Ile Lys Phe Trp Leu Glu Met Asn Ser Ile Val Asp Ile  
                   165                  170                  175  
 Phe Thr Ile Pro Pro Thr Phe Ile Ser Tyr Tyr Leu Lys Ser Asn Trp  
                   180                  185                  190  
 Leu Gly Leu Arg Phe Leu Arg Ala Leu Arg Leu Leu Glu Leu Pro Lys  
       195                  200                  205  
 Ile Leu Gln Ile Leu Gln Val Ile Lys Thr Ser Asn Ser Val Lys Leu  
       210                  215                  220  
 Ser Lys Leu Leu Ser Ile Val Ile Ser Thr Trp Phe Thr Ala Ala Gly  
       225                  230                  235                  240  
 Phe Leu His Leu Val Glu Asn Ser Gly Asp Pro Trp Leu Asn Gly Arg  
                   245                  250                  255  
 Asn Ser Gln Thr Met Ser Tyr Phe Glu Ser Ile Tyr Leu Val Thr Ala  
                   260                  265                  270

Thr	Met	Ser	Thr	Val	Gly	Phe	Gly	Asp	Val	Val	Ala	Lys	Thr	Ser	Leu	275	280	285
Gly	Arg	Ile	Phe	Ile	Val	Phe	Phe	Thr	Leu	Gly	Ser	Leu	Ile	Leu	Phe	290	295	300
Ala	Asn	Tyr	Ile	Pro	Glu	Met	Val	Glu	Leu	Phe	Ser	Thr	Arg	Lys	Lys	305	310	315
Tyr	Thr	Lys	Pro	Tyr	Glu	Ala	Val	Lys	Gly	Lys	Lys	Phe	Ile	Val	Val	325	330	335
Cys	Gly	Asn	Ile	Thr	Val	Asp	Ser	Val	Thr	Ala	Phe	Leu	Arg	Asn	Phe	340	345	350
Leu	His	Trp	Lys	Ser	Gly	Glu	Ile	Asn	Ile	Glu	Ile	Val	Phe	Leu	Gly	355	360	365
Glu	Thr	Leu	Pro	Cys	Leu	Glu	Leu	Glu	Thr	Leu	Leu	Lys	Cys	His	Thr	370	375	380
Ser	Cys	Thr	Asn	Phe	Val	Cys	Gly	Thr	Ala	Leu	Lys	Phe	Glu	Asp	Leu	385	390	395
Lys	Arg	Val	Ala	Val	Glu	Asn	Ser	Glu	Ala	Cys	Leu	Ile	Leu	Ala	Asn	405	410	415
His	Phe	Cys	Ser	Asp	Leu	His	Asp	Glu	Asp	Asn	Ser	Asn	Ile	Met	Arg	420	425	430
Val	Leu	Ser	Ile	Lys	Asn	Tyr	Tyr	Pro	Gln	Thr	Arg	Val	Ile	Ile	Gln	435	440	445
Ile	Leu	Gln	Ser	Gln	Asn	Lys	Val	Phe	Leu	Ser	Lys	Ile	Pro	Asn	Trp	450	455	460
Asp	Trp	Ser	Ala	Gly	Asp	Asn	Ile	Leu	Cys	Phe	Ala	Glu	Leu	Lys	Leu	465	470	475
Gly	Phe	Ile	Ala	Gln	Gly	Cys	Leu	Val	Pro	Gly	Leu	Cys	Thr	Phe	Leu	485	490	495
Thr	Thr	Leu	Phe	Ile	Glu	Gln	Asn	Gln	Lys	Val	Phe	Pro	Lys	His	Pro	500	505	510
Trp	Gln	Lys	His	Phe	Leu	Asn	Gly	Leu	Lys	Asn	Lys	Ile	Leu	Thr	Gln	515	520	525
Arg	Leu	Ser	Asn	Asp	Phe	Val	Gly	Met	Thr	Phe	Pro	Gln	Val	Ser	Arg	530	535	540
Leu	Cys	Phe	Val	Lys	Leu	Asn	Leu	Met	Leu	Ile	Ala	Ile	Gln	His	Lys	545	550	555
Pro	Phe	Phe	His	Ser	Cys	Cys	Thr	Leu	Ile	Leu	Asn	Pro	Ser	Ser	Gln	565	570	575
Val	Arg	Leu	Asn	Lys	Asp	Thr	Leu	Gly	Phe	Phe	Ile	Ala	Asp	Ser	Ser	580	585	590

Lys	Ala	Val	Lys	Arg	Ala	Phe	Phe	Tyr	Cys	Ser	Asn	Cys	His	Ser	Asp
		595					600					605			
Val	Cys	Asn	Pro	Glu	Leu	Ile	Gly	Lys	Cys	Asn	Cys	Lys	Ile	Lys	Ser
	610					615					620				
Arg	Gln	Gln	Leu	Ile	Ala	Pro	Thr	Ile	Met	Val	Met	Lys	Ser	Ser	Leu
625					630					635					640
Thr	Asp	Phe	Thr	Thr	Ser	Ser	His	Ile	His	Ala	Ser	Met	Ser	Thr	Glu
				645					650					655	
Ile	His	Thr	Cys	Phe	Ser	Arg	Glu	Gln	Pro	Ser	Leu	Ile	Thr	Ile	Thr
			660					665					670		
Thr	Asn	Arg	Pro	Thr	Thr	Asn	Asp	Thr	Val	Asp	Asp	Thr	Asp	Met	Leu
		675					680					685			
Asp	Ser	Ser	Gly	Met	Phe	His	Trp	Cys	Arg	Ala	Met	Pro	Leu	Asp	Lys
	690					695					700				
Val	Val	Leu	Lys	Arg	Ser	Glu	Lys	Ala	Lys	His	Glu	Phe	Gln	Asn	His
705					710					715					720
Ile	Val	Val	Cys	Val	Phe	Gly	Asp	Ala	Gln	Cys	Thr	Leu	Val	Gly	Leu
				725					730					735	
Arg	Asn	Phe	Val	Met	Pro	Leu	Arg	Ala	Ser	Asn	Tyr	Thr	Arg	Gln	Glu
			740					745					750		
Leu	Lys	Asp	Ile	Val	Phe	Ile	Gly	Ser	Leu	Glu	Tyr	Phe	Gln	Arg	Glu
		755					760					765			
Trp	Arg	Phe	Leu	Arg	Asn	Phe	Pro	Lys	Ile	His	Ile	Met	Pro	Gly	Ser
	770					775					780				
Ala	Leu	Tyr	Met	Gly	Asp	Leu	Ile	Ala	Val	Asn	Val	Glu	Gln	Cys	Ser
785					790					795					800
Met	Cys	Val	Ile	Leu	Ala	Thr	Pro	Tyr	Lys	Ala	Leu	Ser	Ser	Gln	Ile
				805					810					815	
Leu	Val	Asp	Thr	Glu	Ala	Ile	Met	Ala	Thr	Leu	Asn	Ile	Gln	Ser	Leu
			820					825					830		
Arg	Ile	Thr	Ser	Pro	Thr	Pro	Gly	Ser	Ser	Lys	Ser	Glu	Val	Lys	Pro
		835					840					845			
Ser	Ser	Ala	Phe	Asp	Ser	Lys	Glu	Arg	Lys	Gln	Arg	Tyr	Lys	Gln	Ile
		850				855					860				
Pro	Ile	Leu	Thr	Glu	Leu	Lys	Asn	Pro	Ser	Asn	Ile	His	Phe	Ile	Glu
865					870					875					880
Gln	Met	Gly	Gly	Leu	Asp	Gly	Met	Leu	Lys	Gly	Thr	Ser	Leu	His	Leu
				885					890					895	
Ser	Thr	Ser	Phe	Ser	Thr	Gly	Ala	Val	Phe	Ser	Asp	Thr	Phe	Leu	Asp
			900					905					910		





Leu	Trp	Thr	Val	Cys	Cys	His	Cys	Gly	Gly	Lys	Thr	Lys	Glu	Ala	Gln
50						55					60				
Lys	Ile	Asn	Asn	Gly	Ser	Ser	Gln	Ala	Asp	Gly	Thr	Leu	Lys	Pro	Val
65					70					75					80
Asp	Glu	Lys	Glu	Glu	Val	Val	Ala	Ala	Glu	Val	Gly	Trp	Met	Thr	Ser
				85					90					95	
Val	Lys	Asp	Trp	Ala	Gly	Val	Met	Ile	Ser	Ala	Gln	Thr	Leu	Thr	Gly
			100					105					110		
Arg	Val	Leu	Val	Val	Leu	Val	Phe	Ala	Leu	Ser	Ile	Gly	Ala	Leu	Val
		115					120					125			
Ile	Tyr	Phe	Ile	Asp	Ser	Ser	Asn	Pro	Ile	Glu	Ser	Cys	Gln	Asn	Phe
	130					135					140				
Tyr	Lys	Asp	Phe	Thr	Leu	Gln	Ile	Asp	Met	Ala	Phe	Asn	Val	Phe	Phe
145					150					155					160
Leu	Leu	Tyr	Phe	Gly	Leu	Arg	Phe	Ile	Ala	Ala	Asn	Asp	Lys	Leu	Trp
				165					170					175	
Phe	Trp	Leu	Glu	Val	Asn	Ser	Val	Val	Asp	Phe	Phe	Thr	Val	Pro	Pro
			180					185					190		
Val	Phe	Val	Ser	Val	Tyr	Leu	Asn	Arg	Ser	Trp	Leu	Gly	Leu	Arg	Phe
		195					200					205			
Leu	Arg	Ala	Leu	Arg	Leu	Ile	Gln	Phe	Ser	Glu	Ile	Leu	Gln	Phe	Leu
	210					215					220				
Asn	Ile	Leu	Lys	Thr	Ser	Asn	Ser	Ile	Lys	Leu	Val	Asn	Leu	Leu	Ser
225					230					235					240
Ile	Phe	Ile	Ser	Thr	Trp	Leu	Thr	Ala	Ala	Gly	Phe	Ile	His	Leu	Val
				245					250					255	
Glu	Asn	Ser	Gly	Asp	Pro	Trp	Glu	Asn	Phe	Gln	Asn	Asn	Gln	Ala	Leu
			260					265					270		
Thr	Tyr	Trp	Glu	Cys	Val	Tyr	Leu	Leu	Met	Val	Thr	Met	Ser	Thr	Val
		275					280					285			
Gly	Tyr	Gly	Asp	Val	Tyr	Ala	Lys	Thr	Thr	Leu	Gly	Arg	Leu	Phe	Met
	290					295					300				
Val	Phe	Phe	Ile	Leu	Gly	Gly	Leu	Ala	Met	Phe	Ala	Ser	Tyr	Val	Pro
305					310					315					320
Glu	Ile	Ile	Glu	Leu	Ile	Gly	Asn	Arg	Lys	Lys	Tyr	Gly	Gly	Ser	Tyr
				325					330					335	
Ser	Ala	Val	Ser	Gly	Arg	Lys	His	Ile	Val	Val	Cys	Gly	His	Ile	Thr
			340					345					350		
Leu	Glu	Ser	Val	Ser	Asn	Phe	Leu	Lys	Asp	Phe	Leu	His	Lys	Asp	Arg
		355					360					365			

Asp	Asp	Val	Asn	Val	Glu	Ile	Val	Phe	Leu	His	Asn	Ile	Ser	Pro	Asn	
370						375					380					
Leu	Glu	Leu	Glu	Ala	Leu	Phe	Lys	Arg	His	Phe	Thr	Gln	Val	Glu	Phe	
385					390					395					400	
Tyr	Gln	Gly	Ser	Val	Leu	Asn	Pro	His	Asp	Leu	Ala	Arg	Val	Lys	Ile	
				405					410					415		
Glu	Ser	Ala	Asp	Ala	Cys	Leu	Ile	Leu	Ala	Asn	Lys	Tyr	Cys	Ala	Asp	
			420					425					430			
Pro	Asp	Ala	Glu	Asp	Ala	Ser	Asn	Ile	Met	Arg	Val	Ile	Ser	Ile	Lys	
		435					440					445				
Asn	Tyr	His	Pro	Lys	Ile	Arg	Ile	Ile	Thr	Gln	Met	Leu	Gln	Tyr	His	
450						455					460					
Asn	Lys	Ala	His	Leu	Leu	Asn	Ile	Pro	Ser	Trp	Asn	Trp	Lys	Glu	Gly	
465					470					475					480	
Asp	Asp	Ala	Ile	Cys	Leu	Ala	Glu	Leu	Lys	Leu	Gly	Phe	Ile	Ala	Gln	
				485					490					495		
Ser	Cys	Leu	Ala	Gln	Gly	Leu	Ser	Thr	Met	Leu	Ala	Asn	Leu	Phe	Ser	
			500					505					510			
Met	Arg	Ser	Phe	Ile	Lys	Ile	Glu	Glu	Asp	Thr	Trp	Gln	Lys	Tyr	Tyr	
		515					520					525				
Leu	Glu	Gly	Val	Ser	Asn	Glu	Met	Tyr	Thr	Glu	Tyr	Leu	Ser	Ser	Ala	
		530				535					540					
Phe	Val	Gly	Leu	Ser	Phe	Pro	Thr	Val	Cys	Glu	Leu	Cys	Phe	Val	Lys	
545					550					555					560	
Leu	Lys	Leu	Leu	Met	Ile	Ala	Ile	Glu	Tyr	Lys	Ser	Ala	Asn	Arg	Glu	
				565					570					575		
Ser	Arg	Ile	Leu	Ile	Asn	Pro	Gly	Asn	His	Leu	Lys	Ile	Gln	Glu	Gly	
			580					585					590			
Thr	Leu	Gly	Phe	Phe	Ile	Ala	Ser	Asp	Ala	Lys	Glu	Val	Lys	Arg	Ala	
		595					600					605				
Phe	Phe	Tyr	Cys	Lys	Ala	Cys	His	Asp	Asp	Val	Thr	Asp	Pro	Lys	Arg	
610						615					620					
Ile	Lys	Lys	Cys	Gly	Cys	Arg	Arg	Leu	Ile	Tyr	Phe	Glu	Asp	Glu	Gln	
625					630					635					640	
Pro	Pro	Thr	Leu	Ser	Pro	Lys	Lys	Lys	Gln	Arg	Asn	Gly	Gly	Met	Arg	
				645					650					655		
Asn	Ser	Pro	Asn	Thr	Ser	Pro	Lys	Leu	Met	Arg	His	Asp	Pro	Leu	Leu	
			660					665					670			
Ile	Pro	Gly	Asn	Asp	Gln	Ile	Asp	Asn	Met	Asp	Ser	Asn	Val	Lys	Lys	
		675					680					685				

Tyr 690	Asp	Ser	Thr	Gly	Met	Phe 695	His	Trp	Cys	Ala	Pro 700	Lys	Glu	Ile	Glu
Lys 705	Val	Ile	Leu	Thr	Arg 710	Ser	Glu	Ala	Ala	Met 715	Thr	Val	Leu	Ser	Gly 720
His	Val	Val	Val	Cys 725	Ile	Phe	Gly	Asp	Val 730	Ser	Ser	Ala	Leu	Ile 735	Gly
Leu	Arg	Asn	Leu 740	Val	Met	Pro	Leu	Arg 745	Ala	Ser	Asn	Phe	His 750	Tyr	His
Glu	Leu	Lys 755	His	Ile	Val	Phe	Val 760	Gly	Ser	Ile	Glu	Tyr 765	Leu	Lys	Arg
Glu 770	Trp	Glu	Thr	Leu	His	Asn 775	Phe	Pro	Lys	Val	Ser 780	Ile	Leu	Pro	Gly
Thr 785	Pro	Leu	Ser	Arg	Ala 790	Asp	Leu	Arg	Ala	Val 795	Asn	Ile	Asn	Leu	Cys 800
Asp	Met	Cys	Val 805	Ile	Leu	Ser	Ala	Asn	Gln 810	Asn	Asn	Ile	Asp	Asp 815	Thr
Ser	Leu	Gln	Asp 820	Lys	Glu	Cys	Ile	Leu	Ala	Ser	Leu	Asn 830	Ile	Lys	Ser
Met	Gln	Phe 835	Asp	Asp	Ser	Ile	Gly 840	Val	Leu	Gln	Ala	Asn 845	Ser	Gln	Gly
Phe 850	Thr	Pro	Pro	Gly	Met	Asp 855	Arg	Ser	Ser	Pro	Asp 860	Asn	Ser	Pro	Val
His 865	Gly	Met	Leu	Arg	Gln 870	Pro	Ser	Ile	Thr	Thr 875	Gly	Val	Asn	Ile	Pro 880
Ile	Ile	Thr	Glu 885	Leu	Val	Asn	Asp	Thr	Asn 890	Val	Gln	Phe	Leu	Asp 895	Gln
Asp	Asp	Asp	Asp 900	Asp	Pro	Asp	Thr	Glu 905	Leu	Tyr	Leu	Thr	Gln 910	Pro	Phe
Ala	Cys	Gly 915	Thr	Ala	Phe	Ala	Val 920	Ser	Val	Leu	Asp	Ser 925	Leu	Met	Ser
Ala 930	Thr	Tyr	Phe	Asn	Asp	Asn 935	Ile	Leu	Thr	Leu	Ile 940	Arg	Thr	Leu	Val
Thr 945	Gly	Gly	Ala	Thr	Pro 950	Glu	Leu	Glu	Ala	Leu 955	Ile	Ala	Glu	Glu	Asn 960
Ala	Leu	Arg	Gly 965	Gly	Tyr	Ser	Thr	Pro	Gln 970	Thr	Leu	Ala	Asn	Arg 975	Asp
Arg	Cys	Arg	Val 980	Ala	Gln	Leu	Ala	Leu 985	Leu	Asp	Gly	Pro	Phe 990	Ala	Asp
Leu	Gly	Asp 995	Gly	Gly	Cys	Tyr 1000	Gly	Asp	Leu	Phe	Cys 1005	Lys	Ala	Leu	Lys

Thr Tyr Asn Met Leu Cys Phe Gly Ile Tyr Arg Leu Arg Asp Ala His  
1010 1015 1020

Leu Ser Thr Pro Ser Gln Cys Thr Lys Arg Tyr Val Ile Thr Asn Pro  
1025 1030 1035 1040

Pro Tyr Glu Phe Glu Leu Val Pro Thr Asp Leu Ile Phe Cys Leu Met  
1045 1050 1055

Gln Phe Asp His Asn Ala Gly Gln Ser Arg Ala Ser Leu Ser His Ser  
1060 1065 1070

Ser His Ser Ser Gln Ser Ser Ser Lys Lys Ser Ser Ser Val His Ser  
1075 1080 1085

Ile Pro Ser Thr Ala Asn Arg Pro Asn Arg Pro Lys Ser Arg Glu Ser  
1090 1095 1100

Arg Asp Lys Gln Asn Ala Thr Arg Met Thr Arg Met Gly Gln Ala Glu  
1105 1110 1115 1120

Lys Lys Trp Phe Thr Asp Glu Pro Asp Asn Ala Tyr Pro Arg Asn Ile  
1125 1130 1135

Gln Ile Lys Pro Met Ser Thr His Met Ala Asn Gln Ile Asn Gln Tyr  
1140 1145 1150

Lys Ser Thr Ser Ser Leu Ile Pro Pro Ile Arg Glu Val Glu Asp Glu  
1155 1160 1165

Cys Glu Leu Val Pro Thr Asp Leu Ile Phe Cys Leu Met Gln Phe Asp  
1170 1175 1180

His Asn Ala Gly Gln Ser Arg Ala Ser Leu Ser His Ser Ser His Ser  
1185 1190 1195 1200

Ser Gln Ser Ser Ser Lys Lys Ser Ser Ser Val His Ser Ile Pro Ser  
1205 1210 1215

Thr Ala Asn Arg Pro Asn Arg Pro Lys Ser Arg Glu Ser Arg Asp Lys  
1220 1225 1230

Gln Asn Ala Thr  
1235

<210> 22

<211> 1262

<212> PRT

<213> Drosophila sp.

<220>

<223> Drosophila Slol (dSlol)

<400> 22

Met Ala Ser Gly Leu Ile Asp Thr Asn Phe Ser Ser Thr Leu Ala Asn  
1 5 10 15

Gly Met Ser Gly Cys Asp Gln Ser Thr Val Glu Pro Leu Ala Asp Asp  
20 25 30

Pro	Thr	Asp	Ser	Pro	Phe	Asp	Ala	Asp	Asp	Cys	Leu	Lys	Val	Arg	Lys
		35					40					45			
Tyr	Trp	Cys	Phe	Leu	Leu	Ser	Ser	Ile	Phe	Thr	Phe	Leu	Ala	Gly	Leu
	50					55					60				
Leu	Val	Val	Leu	Leu	Trp	Arg	Ala	Phe	Ala	Phe	Val	Ser	Cys	Arg	Lys
	65				70					75					80
Glu	Pro	Asp	Leu	Gly	Pro	Asn	Asp	Pro	Lys	Gln	Lys	Glu	Gln	Lys	Ala
				85					90					95	
Ser	Arg	Asn	Lys	Gln	Glu	Phe	Glu	Gly	Thr	Phe	Met	Thr	Glu	Ala	Lys
			100					105					110		
Asp	Trp	Ala	Gly	Glu	Leu	Ile	Ser	Gly	Gln	Thr	Thr	Thr	Gly	Arg	Ile
		115					120					125			
Leu	Val	Val	Leu	Val	Phe	Ile	Leu	Ser	Ile	Ala	Ser	Leu	Ile	Ile	Tyr
	130					135					140				
Phe	Val	Asp	Ala	Ser	Ser	Glu	Glu	Val	Glu	Arg	Cys	Gln	Lys	Trp	Ser
145					150					155					160
Asn	Asn	Ile	Thr	Gln	Gln	Ile	Asp	Leu	Ala	Phe	Asn	Ile	Phe	Phe	Met
				165					170					175	
Val	Tyr	Phe	Phe	Ile	Arg	Phe	Ile	Ala	Ala	Ser	Asp	Lys	Leu	Trp	Phe
			180					185					190		
Met	Leu	Glu	Met	Tyr	Ser	Phe	Val	Asp	Tyr	Phe	Thr	Ile	Pro	Pro	Ser
		195					200					205			
Phe	Val	Ser	Ile	Tyr	Leu	Asp	Arg	Thr	Trp	Ile	Gly	Leu	Arg	Phe	Leu
	210					215					220				
Arg	Ala	Leu	Arg	Leu	Met	Thr	Val	Pro	Asp	Ile	Leu	Gln	Tyr	Leu	Asn
225					230					235					240
Val	Leu	Lys	Thr	Ser	Ser	Ser	Ile	Arg	Leu	Ala	Gln	Leu	Val	Ser	Ile
				245					250					255	
Phe	Ile	Ser	Val	Trp	Leu	Thr	Ala	Ala	Gly	Ile	Ile	His	Leu	Leu	Glu
			260					265					270		
Asn	Ser	Gly	Asp	Pro	Leu	Asp	Phe	Asn	Asn	Ala	His	Arg	Leu	Ser	Tyr
		275					280					285			
Trp	Thr	Cys	Val	Tyr	Phe	Leu	Ile	Val	Thr	Met	Ser	Thr	Val	Gly	Tyr
	290					295					300				
Gly	Asp	Val	Tyr	Cys	Glu	Thr	Val	Leu	Gly	Arg	Thr	Phe	Leu	Val	Phe
305					310					315					320
Phe	Leu	Leu	Val	Gly	Leu	Ala	Val	Phe	Ala	Ser	Trp	Ile	Pro	Glu	Ile
				325					330					335	
Thr	Glu	Leu	Ala	Ala	Gln	Arg	Ser	Lys	Tyr	Gly	Gly	Thr	Tyr	Ser	Lys
			340					345					350		

Asp	Pro	Arg	Lys	Arg	His	Ile	Val	Val	Cys	Gly	His	Ile	Thr	Tyr	Glu
355		360						365							
Ser	Val	Ser	His	Phe	Leu	Lys	Asp	Phe	Leu	His	Glu	Asp	Arg	Glu	Asp
370		375						380							
Val	Asp	Val	Glu	Val	Val	Phe	Leu	His	Arg	Lys	Pro	Pro	Asp	Leu	Glu
385		390						395				400			
Leu	Glu	Gly	Leu	Phe	Lys	Arg	His	Phe	Thr	Thr	Val	Glu	Phe	Phe	Gln
		405						410				415			
Gly	Thr	Ile	Met	Asn	Pro	Ile	Asp	Leu	Gln	Arg	Val	Lys	Val	His	Glu
		420						425				430			
Ala	Asp	Ala	Cys	Leu	Val	Leu	Ala	Asn	Lys	Tyr	Cys	Gln	Asp	Pro	Asp
		435						440				445			
Ala	Glu	Asp	Ala	Ala	Asn	Ile	Met	Arg	Val	Ile	Ser	Ile	Lys	Asn	Tyr
450		455						460							
Ser	Asp	Asp	Ile	Arg	Val	Ile	Ile	Gln	Leu	Met	Gln	Tyr	His	Asn	Lys
465		470						475				480			
Ala	Tyr	Leu	Leu	Asn	Ile	Pro	Ser	Trp	Asp	Trp	Lys	Gln	Gly	Asp	Asp
		485						490				495			
Val	Ile	Cys	Leu	Ala	Glu	Leu	Lys	Leu	Gly	Phe	Ile	Ala	Gln	Ser	Cys
		500						505				510			
Leu	Ala	Pro	Gly	Phe	Ser	Thr	Met	Met	Ala	Asn	Leu	Phe	Ala	Met	Arg
		515						520				525			
Ser	Phe	Lys	Thr	Ser	Pro	Asp	Met	Gln	Ser	Trp	Thr	Asn	Asp	Tyr	Leu
530		535						540							
Arg	Gly	Thr	Gly	Met	Glu	Met	Tyr	Thr	Glu	Thr	Leu	Ser	Pro	Thr	Phe
545		550						555				560			
Ile	Gly	Ile	Pro	Phe	Ala	Gln	Ala	Thr	Glu	Leu	Cys	Phe	Ser	Lys	Leu
		565						570				575			
Lys	Leu	Leu	Leu	Leu	Ala	Ile	Glu	Ile	Lys	Gly	Ala	Glu	Glu	Gly	Ala
		580						585				590			
Asp	Ser	Lys	Ile	Ser	Ile	Asn	Pro	Arg	Gly	Ala	Lys	Ile	Gln	Ala	Asn
		595						600				605			
Thr	Gln	Gly	Phe	Phe	Ile	Ala	Gln	Ser	Ala	Asp	Glu	Val	Lys	Arg	Ala
610		615						620							
Trp	Phe	Tyr	Cys	Lys	Ala	Cys	His	Glu	Asp	Ile	Lys	Asp	Glu	Thr	Leu
625		630						635				640			
Ile	Lys	Lys	Cys	Lys	Cys	Lys	Asn	Leu	Thr	Val	Gln	Pro	Arg	Ser	Lys
		645						650				655			
Phe	Asp	Asp	Leu	Gly	Asp	Ile	Thr	Arg	Asp	Arg	Glu	Asp	Thr	Asn	Leu
		660						665				670			

Leu Asn Arg Asn Val Arg Arg Pro Asn Gly Thr Gly Asn Gly Thr Gly  
 675 680 685  
 Gly Met His His Met Asn Ser Thr Arg Ala Ala Ala Ala Ala Ala  
 690 695 700  
 Ala Ala Gly Lys Gln Val Asn Lys Val Lys Pro Thr Val Asn Val Ser  
 705 710 715 720  
 Arg Gln Val Glu Gly Gln Val Ile Ser Pro Ser Gln Tyr Asn Arg Pro  
 725 730 735  
 Thr Ser Arg Ser Ser Gly Thr Gly Thr Gln Asn Gln Asn Gly Gly Val  
 740 745 750  
 Ser Leu Pro Ala Gly Ile Ala Asp Asp Gln Ser Lys Asp Phe Asp Phe  
 755 760 765  
 Glu Lys Thr Glu Met Lys Tyr Asp Ser Thr Gly Met Phe His Trp Ser  
 770 775 780  
 Pro Ala Lys Ser Leu Gln Asp Cys Ile Leu Asp Arg Asn Gln Ala Ala  
 785 790 795 800  
 Met Thr Val Leu Asn Gly His Val Val Val Cys Leu Phe Ala Asp Pro  
 805 810 815  
 Asp Ser Pro Leu Ile Gly Leu Arg Asn Leu Val Met Pro Leu Arg Ala  
 820 825 830  
 Ser Asn Phe His Tyr His Glu Leu Lys His Val Val Ile Val Gly Ser  
 835 840 845  
 Val Asp Tyr Ile Arg Arg Glu Trp Lys Met Leu Gln Asn Leu Pro Lys  
 850 855 860  
 Ile Ser Val Leu Asn Gly Ser Pro Leu Ser Arg Ala Asp Leu Arg Ala  
 865 870 875 880  
 Val Asn Val Asn Leu Cys Asp Met Cys Cys Ile Leu Ser Ala Lys Val  
 885 890 895  
 Pro Ser Asn Asp Asp Pro Thr Leu Ala Asp Lys Glu Ala Ile Leu Ala  
 900 905 910  
 Ser Leu Asn Ile Lys Ala Met Thr Phe Asp Asp Thr Ile Gly Val Leu  
 915 920 925  
 Ser Gln Arg Gly Pro Glu Phe Asp Asn Leu Ser Ala Thr Ala Gly Ser  
 930 935 940  
 Pro Ile Val Leu Gln Arg Arg Gly Ser Val Tyr Gly Ala Asn Val Pro  
 945 950 955 960  
 Met Ile Thr Glu Leu Val Asn Asp Gly Asn Val Gln Phe Leu Asp Gln  
 965 970 975  
 Asp Asp Asp Asp Asp Pro Asp Thr Glu Leu Tyr Leu Thr Gln Pro Phe  
 980 985 990



Ala Cys Gly Thr Ala Phe Ala Val Ser Val Leu Asp Ser Leu Met Ser  
995 1000 1005

Thr Thr Tyr Phe Asn Gln Asn Ala Leu Thr Leu Ile Arg Ser Leu Ile  
1010 1015 1020

Thr Gly Gly Ala Thr Pro Glu Leu Glu Leu Ile Leu Ala Glu Gly Ala  
1025 1030 1035 1040

Gly Leu Arg Gly Gly Tyr Ser Thr Val Glu Ser Leu Ser Asn Arg Asp  
1045 1050 1055

Arg Cys Arg Val Gly Gln Ile Ser Leu Tyr Asp Gly Pro Leu Ala Gln  
1060 1065 1070

Phe Gly Glu Cys Gly Lys Tyr Gly Asp Leu Phe Val Ala Ala Leu Lys  
1075 1080 1085

Ser Tyr Gly Met Leu Cys Ile Gly Leu Tyr Arg Phe Arg Asp Thr Ser  
1090 1095 1100

Ser Ser Cys Asp Ala Ser Ser Lys Arg Tyr Val Ile Thr Asn Pro Pro  
1105 1110 1115 1120

Asp Asp Phe Ser Leu Leu Pro Thr Asp Gln Val Phe Val Leu Met Gln  
1125 1130 1135

Phe Asp Pro Gly Leu Glu Tyr Lys Pro Pro Ala Val Arg Ala Pro Ala  
1140 1145 1150

Gly Gly Arg Gly Thr Asn Thr Gln Gly Ser Gly Val Gly Gly Gly Gly  
1155 1160 1165

Ser Asn Lys Asp Asp Asn Ser Leu Ser Asn Arg Asp Arg Cys Arg Val  
1170 1175 1180

Gly Gln Ile Ser Leu Tyr Asp Gly Pro Leu Ala Gln Phe Gly Glu Cys  
1185 1190 1195 1200

Gly Lys Tyr Gly Asp Leu Phe Val Ala Ala Leu Lys Ser Tyr Gly Met  
1205 1210 1215

Leu Cys Ile Gly Leu Tyr Arg Phe Arg Asp Thr Ser Ser Ser Cys Asp  
1220 1225 1230

Ala Ser Ser Lys Arg Tyr Val Ile Thr Asn Pro Pro Asp Asp Phe Ser  
1235 1240 1245

Leu Leu Pro Thr Asp Gln Val Phe Val Leu Met Gln Phe Asp  
1250 1255 1260

<210> 23  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:sense  
oligonucleotide

<400> 23  
gtggatgata ccgacatgct ggac 24

<210> 24  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:antisense  
oligonucleotide

<400> 24  
gagaccacct ctctcccgtg tcgt 24

<210> 25  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:mSLo3 (S4 to  
S5) sense primer

<400> 25  
ctcgaactcc ctaaaatctt acagat 26

<210> 26  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:mSLo3 (S4 to  
S5) antisense primer

<400> 26  
ttccgttgag ccaggggtca ccagaatt 28

<210> 27  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:mSLo3 (S8 to  
S9) sense primer

<400> 27  
tctgctttgt gaagctaaat ct 22

<210> 28  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:mSlo3 (S8 to S9) antisense primer  
  
 <400> 28  
 tttcaaagcc tcttttagcgg taa 23  
  
 <210> 29  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:mSlo3 (S9 to S10) sense primer  
  
 <400> 29  
 ttatgcctgg atctgcactc tacatg 26  
  
 <210> 30  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:mSlo3 (S9 to S10) antisense primer  
  
 <400> 30  
 atagtttccg tctactaccg aaa 23  
  
 <210> 31  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:control human beta-actin sense primer  
  
 <400> 31  
 gatgatatcg ccgcgctcgt cgtcgac 27  
  
 <210> 32  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:control human beta-actin antisense primer  
  
 <400> 32  
 tcggtccagg tctgcgtcct accgtac 27

<210> 33  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:northern blot  
       sense primer  
  
 <400> 33  
 cggaacgctc atgtacaatc gaaatcca 28  
  
 <210> 34  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:northern blot  
       antisense primer  
  
 <400> 34  
 ttccgttgag ccaggggtca ccagaatt 28  
  
 <210> 35  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:human testis  
       cDNA library primer  
  
 <400> 35  
 ggcagcgctc attctttcct cctt 24  
  
 <210> 36  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:human testis  
       cDNA library primer  
  
 <400> 36  
 tgcccaaaac ctcaacccaa aata 24  
  
 <210> 37  
 <211> 4  
 <212> PRT  
 <213> Mus musculus  
  
 <220>  
 <221> PEPTIDE  
 <222> (1)..(4)  
 <223> mSlo3 Region A peptide starting at amino acid 792

<400> 37  
Ile Ala Val Asn  
1

<210> 38  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region A peptide ending at amino acid 870

<400> 38  
Leu Thr Glu Leu  
1

<210> 39  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region A peptide starting at amino acid 793

<400> 39  
Arg Ala Val Asn  
1

<210> 40  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region A peptide ending at amino acid 885

<400> 40  
Ile Thr Glu Leu  
1

<210> 41  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region B peptide starting at amino acid 871

<400> 41  
Lys Asn Pro Ser  
1

<210> 42  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region B peptide ending at amino acid 906

<400> 42  
Gly Ala Val Phe  
1

<210> 43  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region B peptide starting at amino acid 886

<400> 43  
Val Asn Asp Thr  
1

<210> 44  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region B peptide ending at amino acid 918

<400> 44  
Gly Thr Ala Phe  
1

<210> 45  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:hybrid of mSlo1  
and mSlo3 sequences at C-terminal end of chimera  
Region B fragment

<400> 45  
Gly Ala Ala Phe  
1

<210> 46  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region C peptide starting at amino acid 899

<400> 46  
Ser Thr Ser Phe  
1

<210> 47  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region C peptide ending at amino acid 941

<400> 47  
Ser Glu Met Glu  
1

<210> 48  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region C peptide starting at amino acid 909

<400> 48  
Thr Gln Pro Phe  
1

<210> 49  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region C peptide ending at amino acid 963

<400> 49  
Pro Glu Leu Glu  
1

<210> 50  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region D peptide starting at amino acid 939

<400> 50  
Glu Met Glu His  
1

<210> 51  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo3 Region D peptide ending at amino acid 1034

<400> 51  
His Leu Leu Pro  
1

<210> 52  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region D peptide starting at amino acid 951

<400> 52  
Glu Leu Glu Ala  
1

<210> 53  
<211> 4  
<212> PRT  
<213> Mus musculus

<220>  
<221> PEPTIDE  
<222> (1)..(4)  
<223> mSlo1 Region D peptide ending at amino acid 1048



Variable	1990		1995		2000		2005		2010		2015		2020		2025		2030		2035		2040		2045		2050																																																																																																																																																																																																																																																																																																																															
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD																																																																																																																																																																																																																																																																																																																														
Age	25.5	10.5	26.5	11.5	27.5	12.5	28.5	13.5	29.5	14.5	30.5	15.5	31.5	16.5	32.5	17.5	33.5	34.5	35.5	36.5	37.5	38.5	39.5	40.5	41.5	42.5	43.5	44.5	45.5	46.5	47.5	48.5	49.5	50.5	51.5	52.5	53.5	54.5	55.5	56.5	57.5	58.5	59.5	60.5	61.5	62.5	63.5	64.5	65.5	66.5	67.5	68.5	69.5	70.5	71.5	72.5	73.5	74.5	75.5	76.5	77.5	78.5	79.5	80.5	81.5	82.5	83.5	84.5	85.5	86.5	87.5	88.5	89.5	90.5	91.5	92.5	93.5	94.5	95.5	96.5	97.5	98.5	99.5	100.5	101.5	102.5	103.5	104.5	105.5	106.5	107.5	108.5	109.5	110.5	111.5	112.5	113.5	114.5	115.5	116.5	117.5	118.5	119.5	120.5	121.5	122.5	123.5	124.5	125.5	126.5	127.5	128.5	129.5	130.5	131.5	132.5	133.5	134.5	135.5	136.5	137.5	138.5	139.5	140.5	141.5	142.5	143.5	144.5	145.5	146.5	147.5	148.5	149.5	150.5	151.5	152.5	153.5	154.5	155.5	156.5	157.5	158.5	159.5	160.5	161.5	162.5	163.5	164.5	165.5	166.5	167.5	168.5	169.5	170.5	171.5	172.5	173.5	174.5	175.5	176.5	177.5	178.5	179.5	180.5	181.5	182.5	183.5	184.5	185.5	186.5	187.5	188.5	189.5	190.5	191.5	192.5	193.5	194.5	195.5	196.5	197.5	198.5	199.5	200.5	201.5	202.5	203.5	204.5	205.5	206.5	207.5	208.5	209.5	210.5	211.5	212.5	213.5	214.5	215.5	216.5	217.5	218.5	219.5	220.5	221.5	222.5	223.5	224.5	225.5	226.5	227.5	228.5	229.5	230.5	231.5	232.5	233.5	234.5	235.5	236.5	237.5	238.5	239.5	240.5	241.5	242.5	243.5	244.5	245.5	246.5	247.5	248.5	249.5	250.5	251.5	252.5	253.5	254.5	255.5	256.5	257.5	258.5	259.5	260.5	261.5	262.5	263.5	264.5	265.5	266.5	267.5	268.5	269.5	270.5	271.5	272.5	273.5	274.5	275.5	276.5	277.5	278.5	279.5	280.5	281.5	282.5	283.5	284.5	285.5	286.5	287.5	288.5	289.5	290.5	291.5	292.5	293.5	294.5	295.5	296.5	297.5	298.5	299.5	300.5	301.5	302.5	303.5	304.5	305.5	306.5	307.5	308.5	309.5	310.5	311.5	312.5	313.5	314.5	315.5	316.5	317.5	318.5	319.5	320.5	321.5	322.5	323.5	324.5	325.5	326.5	327.5	328.5	329.5	330.5	331.5	332.5	333.5	334.5	335.5	336.5	337.5	338.5	339.5	340.5	341.5	342.5	343.5	344.5	345.5	346.5	347.5	348.5	349.5	350.5	351.5	352.5	353.5	354.5	355.5	356.5	357.5	358.5	359.5	360